



## WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Friday, April 22, 2005

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L12	= 2001	519
<input type="checkbox"/>	L11	L10 AND L8	937
<input type="checkbox"/>	L10	coronary artery disease	9074
<input type="checkbox"/>	L9	L7 AND L8	158
<input type="checkbox"/>	L8	FGF-1 OR aFGF OR FGF-2 OR bFGF OR VEGF	14483
<input type="checkbox"/>	L7	L6 AND coronary artery disease	467
<input type="checkbox"/>	L6	514/2,8,12,14.CCLS.	15126
<input type="checkbox"/>	L5	Franco.IN.	6857
<input type="checkbox"/>	L4	Franco-W.IN.	4
<input type="checkbox"/>	L3	Franco-Wayne.IN.	0
<input type="checkbox"/>	L2	Franco-W-P.IN.	3
<input type="checkbox"/>	L1	(Franco-Wayne-P.IN.)	7

END OF SEARCH HISTORY



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for coronary artery disease AND FGF-2 Save Search

Limits Preview/Index History Clipboard Details  
 Display Summary Show 500 Sort by Send to

About Entrez

Text Version

All: 38 Review: 7

Items 1 - 38 of 38

One page.

#### Entrez PubMed

Overview  
 Help | FAQ  
 Tutorial  
 New/Noteworthy  
 E-Utilities

#### PubMed Services

Journals Database  
 MeSH Database  
 Single Citation Matcher  
 Batch Citation Matcher  
 Clinical Queries  
 LinkOut  
 My NCBI (Cubby)

#### Related Resources

Order Documents  
 NLM Catalog  
 NLM Gateway  
 TOXNET  
 Consumer Health  
 Clinical Alerts  
 ClinicalTrials.gov  
 PubMed Central

- ☐ 1: [Lambiase PD, Edwards RJ, Anthopoulos P, Rahman S, Meng YG, Bucknall CA, Redwood SR, Pearson JD, Marber MS.](#) Related Articles, Links

Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support.  
 Circulation. 2004 Jun 22;109(24):2986-92. Epub 2004 Jun 7.  
 PMID: 15184289 [PubMed - indexed for MEDLINE]
- ☐ 2: [van Royen N, Voskuil M, Hoefer I, Jost M, de Graaf S, Hedwig F, Andert JP, Wormhoudt TA, Hua J, Hartmann S, Bode C, Buschmann I, Schaper W, van der Neut R, Piek JJ, Pals ST.](#) Related Articles, Links









CD44 regulates arteriogenesis in mice and is differentially expressed in patients with poor and good collateralization.  
 Circulation. 2004 Apr 6;109(13):1647-52. Epub 2004 Mar 15.  
 PMID: 15023889 [PubMed - indexed for MEDLINE]
- ☐ 3: [Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, Hambrecht R.](#) Related Articles, Links










Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia.  
 Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):684-90. Epub 2004 Feb 26.  
 PMID: 14988094 [PubMed - indexed for MEDLINE]
- ☐ 4: [Biswas SS, Hughes GC, Scarborough JE, Domkowski PW, Diodato L, Smith ML, Landolfo C, Lowe JE, Annex BH, Landolfo KP.](#) Related Articles, Links

Intramyocardial and intracoronary basic fibroblast growth factor in porcine hibernating myocardium: a comparative study.  
 J Thorac Cardiovasc Surg. 2004 Jan;127(1):34-43.  
 PMID: 14752410 [PubMed - indexed for MEDLINE]
- ☐ 5: [Aviles RJ, Annex BH, Lederman RJ.](#) Related Articles, Links

Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2).  
 Br J Pharmacol. 2003 Oct;140(4):637-46.  
 PMID: 14534147 [PubMed - indexed for MEDLINE]
- ☐ 6: [Ruel M, Sellke FW.](#) Related Articles, Links

Angiogenic protein therapy.  
 Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):222-35. Review.  
 PMID: 12973700 [PubMed - indexed for MEDLINE]
- ☐ 7: [Ruel M, Wu GF, Khan TA, Voisine P, Bianchi C, Li J, Li J, Laham RJ, Sellke FW.](#) Related Articles, Links

-  **Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model.**  
Circulation. 2003 Sep 9;108 Suppl 1:II335-40.  
PMID: 12970256 [PubMed - indexed for MEDLINE]
- ☐ **8:** Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R. [Related Articles](#), [Links](#)
-  **Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells.**  
Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 7.  
PMID: 12907464 [PubMed - indexed for MEDLINE]
- ☐ **9:** Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Nishimura K, Tabata Y, Komeda M. [Related Articles](#), [Links](#)
-  **Toward surgical angiogenesis using slow-released basic fibroblast growth factor.**  
Eur J Cardiothorac Surg. 2003 Jul;24(1):105-11; discussion 112.  
PMID: 12853053 [PubMed - indexed for MEDLINE]
- ☐ **10:** Sellke FW, Ruel M. [Related Articles](#), [Links](#)
-  **Vascular growth factors and angiogenesis in cardiac surgery.**  
Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.  
PMID: 12607713 [PubMed - indexed for MEDLINE]
- ☐ **11:** Zhang C, Yang J, Feng J, Jennings LK. [Related Articles](#), [Links](#)
-  **Short-term administration of basic fibroblast growth factor enhances coronary collateral development without exacerbating atherosclerosis and balloon injury-induced vasoproliferation in atherosclerotic rabbits with acute myocardial infarction.**  
J Lab Clin Med. 2002 Aug;140(2):119-25.  
PMID: 12228768 [PubMed - indexed for MEDLINE]
- ☐ **12:** Katinioti AA, Tousoulis D, Economou E, Stefanadis C, Trikas A, Tentolouris C, Pitsavos C, Androulakis A, Toutouzas P. [Related Articles](#), [Links](#)
-  **Basic fibroblast growth factor changes in response to coronary angioplasty in patients with stable angina.**  
Int J Cardiol. 2002 Aug;84(2-3):195-9.  
PMID: 12127372 [PubMed - indexed for MEDLINE]
- ☐ **13:** Post MJ, Laham RJ, Kuntz RE, Novicki D, Simons M. [Related Articles](#), [Links](#)
-  **The effect of intracoronary fibroblast growth factor-2 on restenosis after primary angioplasty or stent placement in a pig model of atherosclerosis.**  
Clin Cardiol. 2002 Jun;25(6):271-8.  
PMID: 12058790 [PubMed - indexed for MEDLINE]
- ☐ **14:** Campuzano R, Barrios V, Cuevas B, Asin-Cardiel E, Muela A, Castro JM, Fernandez-Ayerdi A, Cuevas P. [Related Articles](#), [Links](#)
-  **Serum basic fibroblast growth factor levels in exercise-induced myocardial ischemia more likely a marker of endothelial dysfunction than a marker of ischemia?**  
Eur J Med Res. 2002 Mar 28;7(3):93-7.  
PMID: 11953278 [PubMed - indexed for MEDLINE]
- ☐ **15:** Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA. [Related Articles](#), [Links](#)

-  Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial.  
Circulation. 2002 Feb 19;105(7):788-93.  
PMID: 11854116 [PubMed - indexed for MEDLINE]
- ☐ 16: Wilke NM, Zenovich AG, Jerosch-Herold M, Henry TD. [Related Articles, Links](#)  
 Cardiac Magnetic Resonance Imaging for the Assessment of Myocardial Angiogenesis.  
Curr Interv Cardiol Rep. 2001 Aug;3(3):205-212.  
PMID: 11485690 [PubMed - as supplied by publisher]
- ☐ 17: Bush MA, Samara E, Whitehouse MJ, Yoshizawa C, Novicki DL, Pike M, Laham RJ, Simons M, Chronos NA. [Related Articles, Links](#)  
 Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease.  
J Clin Pharmacol. 2001 Apr;41(4):378-85.  
PMID: 11304894 [PubMed - indexed for MEDLINE]
- ☐ 18: Rosengart TK, Hillebrand K. [Related Articles, Links](#)  
 Gene therapy for coronary artery disease.  
Adv Card Surg. 2001;13:107-20. Review. No abstract available.  
PMID: 11209652 [PubMed - indexed for MEDLINE]
- ☐ 19: Lambiase P, Edwards R, Bucknall CA, Marber MS. [Related Articles, Links](#)  
 Physiologically assessed collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.  
Circulation. 2001 Jan 30;103(4):E22. No abstract available.  
PMID: 11157734 [PubMed - indexed for MEDLINE]
- ☐ 20: Schumacher B, Hannekum A, Pecher P. [Related Articles, Links](#)  
 [Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease]  
Z Kardiol. 2000;89 Suppl 7:23-30. German.  
PMID: 11098556 [PubMed - indexed for MEDLINE]
- ☐ 21: Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, Galt JR, Pike M, Yoshizawa C, Simons M. [Related Articles, Links](#)  
 Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease.  
Circulation. 2000 Oct 3;102(14):1605-10.  
PMID: 11015335 [PubMed - indexed for MEDLINE]
- ☐ 22: Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon RO 3rd, Quyyumi AA. [Related Articles, Links](#)  
 Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris.  
Am J Cardiol. 2000 Jun 15;85(12):1414-9.  
PMID: 10856385 [PubMed - indexed for MEDLINE]
- ☐ 23: Lucassen AM, de Waal RM, Verheugt FW. [Related Articles, Links](#)  
 [Therapeutic angiogenesis as a new experimental treatment for vascular disease]  
Ned Tijdschr Geneesk. 2000 Apr 1;144(14):650-5. Review. Dutch.

PMID: 10774292 [PubMed - indexed for MEDLINE]

- ☐ **24:** [Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA.](#) [Related Articles, Links](#)



Expression and function of PPARgamma in rat and human vascular smooth muscle cells.

Circulation. 2000 Mar 21;101(11):1311-8.

PMID: 10725292 [PubMed - indexed for MEDLINE]

- ☐ **25:** [Fleisch M, Billinger M, Eberli FR, Garachemani AR, Meier B, Seiler C.](#) [Related Articles, Links](#)



Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.

Circulation. 1999 Nov 9;100(19):1945-50.

PMID: 10556219 [PubMed - indexed for MEDLINE]

- ☐ **26:** [Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M.](#) [Related Articles, Links](#)



Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.

Clin Chim Acta. 1999 May;283(1-2):171-82.

PMID: 10404741 [PubMed - indexed for MEDLINE]

- ☐ **27:** [Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S.](#) [Related Articles, Links](#)



Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.

Biochem Biophys Res Commun. 1999 Feb 5;255(1):80-7.

PMID: 10082659 [PubMed - indexed for MEDLINE]

- ☐ **28:** [Laham RJ, Simons M, Tofukuji M, Hung D, Sellke FW.](#) [Related Articles, Links](#)



Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: insight into ischemia-induced reduction in endothelium-dependent vasodilatation.

J Thorac Cardiovasc Surg. 1998 Dec;116(6):1022-8.

PMID: 9832695 [PubMed - indexed for MEDLINE]

- ☐ **29:** [Iwakura A, Komeda M, Fujita M.](#) [Related Articles, Links](#)



[Coronary stenosis and mechanisms of collateral vessel growth]

Nippon Rinsho. 1998 Oct;56(10):2504-8. Review. Japanese.

PMID: 9796310 [PubMed - indexed for MEDLINE]

- ☐ **30:** [Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M.](#) [Related Articles, Links](#)



Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results.

Ann Thorac Surg. 1998 Jun;65(6):1540-4.

PMID: 9647055 [PubMed - indexed for MEDLINE]

- ☐ **31:** [Hasdai D, Barak V, Leibovitz E, Herz I, Sclarovsky S, Eldar M, Scheinowitz M.](#) [Related Articles, Links](#)



Serum basic fibroblast growth factor levels in patients with ischemic heart disease.

Int J Cardiol. 1997 Apr 18;59(2):133-8.

PMID: 9158164 [PubMed - indexed for MEDLINE]

- ☐ **32:** [Ito A, Shimokawa H, Fukumoto Y, Kadokami T, Nakaike R, Takayanagi T, Egashira K, Sueishi K, Takeshita A.](#) [Related Articles, Links](#)



The role of fibroblast growth factor-2 in the vascular effects of interleukin-1 beta in porcine coronary arteries in vivo. *Cardiovasc Res.* 1996 Sep;32(3):570-9. PMID: 8881517 [PubMed - indexed for MEDLINE]

- ☐ **33:** [Taylor AJ, Farb AA, Angello DA, Burwell LR, Virmani R.](#) [Related Articles, Links](#)



Proliferative activity in coronary atherectomy tissue. Clinical, histopathologic, and immunohistochemical correlates. *Chest.* 1995 Sep;108(3):815-20. PMID: 7656639 [PubMed - indexed for MEDLINE]

- ☐ **34:** [Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ.](#) [Related Articles, Links](#)



Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? *Circulation.* 1994 Apr;89(4):1511-7. PMID: 7908609 [PubMed - indexed for MEDLINE]

- ☐ **35:** [Wilcox JN.](#) [Related Articles, Links](#)



Molecular biology: insight into the causes and prevention of restenosis after arterial intervention. *Am J Cardiol.* 1993 Oct 18;72(13):88E-95E. Review. PMID: 8213576 [PubMed - indexed for MEDLINE]

- ☐ **36:** [Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK.](#) [Related Articles, Links](#)



A cascade model for restenosis. A special case of atherosclerosis progression. *Circulation.* 1992 Dec;86(6 Suppl):III47-52. Review. PMID: 1424051 [PubMed - indexed for MEDLINE]

- ☐ **37:** [Gordon D.](#) [Related Articles, Links](#)



Growth factors and cell proliferation in human transplant arteriosclerosis. *J Heart Lung Transplant.* 1992 May-Jun;11(3 Pt 2):S7. No abstract available. PMID: 1623005 [PubMed - indexed for MEDLINE]

- ☐ **38:** [Heidemann P, Hofling B, Heimerl J, Emberger C, Meyer G, Kandolf R, Bauriedel G.](#) [Related Articles, Links](#)




[Proliferative response of smooth muscle cells from human arteriosclerosis lesions to PDGF, bFGF and EGF] *Vasa Suppl.* 1992;35:137-9. German. No abstract available. PMID: 1481019 [PubMed - indexed for MEDLINE]

Display

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
 Department of Health & Human Services  
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Apr 18 2005 07:10:12



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for coronary artery disease AND FGF-1 Save Search

Limits Preview/Index History Clipboard Details

Display Summary Show 500 Sort by Send to

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Items 1 - 7 of 7

One page.

☐ 1: Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R.

[Related Articles, Links](#)



Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells.

Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 7.

PMID: 12907464 [PubMed - indexed for MEDLINE]

☐ 2: Ananyeva N, Tjurmin A, Saenko E, Haudenschild C.

[Related Articles, Links](#)



Low density lipoproteins interact with acidic fibroblast growth factor and modify its function.

Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 2003 Mar 6.

PMID: 12692004 [PubMed - indexed for MEDLINE]

☐ 3: Sellke FW, Ruel M.

[Related Articles, Links](#)



Vascular growth factors and angiogenesis in cardiac surgery.

Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.

PMID: 12607713 [PubMed - indexed for MEDLINE]

☐ 4: Schumacher B, Hannekum A, Pecher P.

[Related Articles, Links](#)



[Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease]

Z Kardiol. 2000;89 Suppl 7:23-30. German.

PMID: 11098556 [PubMed - indexed for MEDLINE]

☐ 5: Safi J Jr, DiPaula AF Jr, Riccioni T, Kajstura J, Ambrosio G, Becker LC, Anversa P, Capogrossi MC.

[Related Articles, Links](#)



Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart.

Microvasc Res. 1999 Nov;58(3):238-49.

PMID: 10527767 [PubMed - indexed for MEDLINE]

☐ 6: Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M.

[Related Articles, Links](#)



Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.

Clin Chim Acta. 1999 May;283(1-2):171-82.

PMID: 10404741 [PubMed - indexed for MEDLINE]

☐ 7: Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M.

[Related Articles, Links](#)



Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.

Surgery. 1996 Aug;120(2):182-8.

PMID: 8751581 [PubMed - indexed for MEDLINE]



Display  Show  Sort by  Send to [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Department of Health &amp; Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Apr 18 2005 07:10:12





All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for coronary artery disease AND VEGF Save Search

Limits Preview/Index History Clipboard Details

Display Summary Show 500 Sort by Send to

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Items 1 - 113 of 113

One page.

☐ 1: [Matsunaga T, Chilian WM, March K.](#)[Related Articles, Links](#)

Angiostatin is negatively associated with coronary collateral growth in patients with coronary artery disease.  
Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2042-6.  
PMID: 15840902 [PubMed - in process]

☐ 2: [Urbich C, Dimmeler S.](#)[Related Articles, Links](#)

Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors.  
Kidney Int. 2005 May;67(5):1672-6.  
PMID: 15840010 [PubMed - in process]

☐ 3: [Urbich C, Knau A, Fichtlscherer S, Walter DH, Bruhl T, Potente M, Hofmann WK, de Vos S, Zeiher AM, Dimmeler S.](#)[Related Articles, Links](#)

FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells.  
FASEB J. 2005 Apr 11; [Epub ahead of print]  
PMID: 15824087 [PubMed - as supplied by publisher]

☐ 4: [Gupta K, Zhang J.](#)[Related Articles, Links](#)

Angiogenesis: a curse or cure?  
Postgrad Med J. 2005 Apr;81(954):236-42.  
PMID: 15811887 [PubMed - in process]

☐ 5: [Gounis MJ, Spiga MG, Graham RM, Wilson A, Haliko S, Lieber BB, Wakhloo AK, Webster KA.](#)[Related Articles, Links](#)

Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle.  
Gene Ther. 2005 May;12(9):762-71.  
PMID: 15772688 [PubMed - in process]

☐ 6: [Panoutsopoulos D, Papalambros E, Sigala F, Zafiropoulos A, Arvanitis DL, Spandidos DA.](#)[Related Articles, Links](#)

Protein and mRNA expression levels of VEGF-A and TGF-beta1 in different types of human coronary atherosclerotic lesions.  
Int J Mol Med. 2005 Apr;15(4):603-10.  
PMID: 15754021 [PubMed - in process]

☐ 7: [Alber HF, Frick M, Dulak J, Dorler J, Zwick RH, Dichtl W, Pachinger O, Weidinger F.](#)[Related Articles, Links](#)

Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease.

Heart. 2005 Mar;91(3):365-6. No abstract available.  
PMID: 15710722 [PubMed - indexed for MEDLINE]

☐ **8:** [Czekalski S.](#)

[Related Articles, Links](#)



[What is new in the treatment of diabetes?--The importance of nephro- and cardioprotective management]

Pol Arch Med Wewn. 2004 Oct;112 Spec No:65-9. Polish.  
PMID: 15669203 [PubMed - indexed for MEDLINE]

☐ **9:** [Heesch C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML, Zeiher AM; CAPTURE Study Investigators.](#)

[Related Articles, Links](#)



Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis.

J Am Coll Cardiol. 2005 Jan 18;45(2):229-37.

PMID: 15653020 [PubMed - indexed for MEDLINE]

☐ **10:** [Yoon YS, Johnson IA, Park JS, Diaz L, Losordo DW.](#)

[Related Articles, Links](#)



Therapeutic myocardial angiogenesis with vascular endothelial growth factors.

Mol Cell Biochem. 2004 Sep;264(1-2):63-74. Review.

PMID: 15544036 [PubMed - indexed for MEDLINE]

☐ **11:** [Maulik N.](#)

[Related Articles, Links](#)



Angiogenic signal during cardiac repair.

Mol Cell Biochem. 2004 Sep;264(1-2):13-23. Review.

PMID: 15544031 [PubMed - indexed for MEDLINE]

☐ **12:** [Pawlak J, Klim B, Szkudlarek M, Dzieciol J.](#)

[Related Articles, Links](#)



[The formation of new blood vessels in coronary artery disease: where we are now]

Postepy Hig Med Dosw (Online). 2004 Oct 6;58:358-63. Polish.

PMID: 15536393 [PubMed - in process]

☐ **13:** [Suzuki A, Miyagawa-Tomita S, Komatsu K, Nakazawa M, Fukaya T, Baba K, Yutani C.](#)

[Related Articles, Links](#)



Immunohistochemical study of apparently intact coronary artery in a child after Kawasaki disease.

Pediatr Int. 2004 Oct;46(5):590-6.

PMID: 15491390 [PubMed - indexed for MEDLINE]

☐ **14:** [Crawford SE, Mavroudis C, Backer CL, Huang X, Mu Y, Volpert OV, Stellmach V, Pahl E, Huang L.](#)

[Related Articles, Links](#)



Captopril suppresses post-transplantation angiogenic activity in rat allograft coronary vessels.

J Heart Lung Transplant. 2004 Jun;23(6):666-73.

PMID: 15366425 [PubMed - indexed for MEDLINE]

☐ **15:** [Celec P, Yonemitsu Y.](#)

[Related Articles, Links](#)











Vascular endothelial growth factor - basic science and its clinical implications.










Pathophysiology. 2004 Oct;11(2):69-75.









PMID: 15364116 [PubMed - as supplied by publisher]











☐ **16:** [Tio RA, Tan ES, Jessurun GA, Veeger N, Jager PL, Slart RH, de Jong RM, Pruim J, Hospers GA, Willemsen AT, de Jongste MJ.](#)

[Related Articles, Links](#)









- van Boven AJ, van Veldhuisen DJ, Zijlstra F.  
 PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease.  
J Nucl Med. 2004 Sep;45(9):1437-43.  
PMID: 15347709 [PubMed - indexed for MEDLINE]
- ☐ 17: Kolsut P, Malecki M, Firek B, Teresinska A, Janik P, Religa Z. Related Articles, Links  
 [Gene therapy with phVEGF165 plasmid--preliminary report]  
Kardiol Pol. 2004 Feb;60 Suppl 1:I-82-9. Polish. No abstract available.  
PMID: 15247953 [PubMed - indexed for MEDLINE]
- ☐ 18: Depre C, Kim SJ, John AS, Huang Y, Rimoldi OE, Pepper JR, Dreyfus GD, Gaussin V, Pennell DJ, Vatner DE, Camici PG, Vatner SF. Related Articles, Links  
 Program of cell survival underlying human and experimental hibernating myocardium.  
Circ Res. 2004 Aug 20;95(4):433-40. Epub 2004 Jul 8.  
PMID: 15242971 [PubMed - indexed for MEDLINE]
- ☐ 19: Nakajima K, Tabata S, Yamashita T, Kusuhashi M, Arakawa K, Ohmori R, Yonemura A, Higashi K, Ayaori M, Nakamura H, Ohsuzu F. Related Articles, Links  
 Plasma vascular endothelial growth factor level is elevated in patients with multivessel coronary artery disease.  
Clin Cardiol. 2004 May;27(5):281-6.  
PMID: 15188944 [PubMed - indexed for MEDLINE]
- ☐ 20: Lambiase PD, Edwards RJ, Anthopoulos P, Rahman S, Meng YG, Bucknall CA, Redwood SR, Pearson JD, Marber MS. Related Articles, Links  
 Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support.  
Circulation. 2004 Jun 22;109(24):2986-92. Epub 2004 Jun 7.  
PMID: 15184289 [PubMed - indexed for MEDLINE]
- ☐ 21: Lemstrom KB, Nykanen AI, Tikkanen JM, Krebs R, Sihvola RK, Kallio EA, Olivier R, Koskinen PK. Related Articles, Links  
 Role of angiogenic growth factors in transplant coronary artery disease.  
Ann Med. 2004;36(3):184-93. Review.  
PMID: 15181974 [PubMed - indexed for MEDLINE]
- ☐ 22: Panchal VR, Rehman J, Nguyen AT, Brown JW, Turrentine MW, Mahomed Y, March KL. Related Articles, Links  
 Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease.  
J Am Coll Cardiol. 2004 Apr 21;43(8):1383-7.  
PMID: 15093871 [PubMed - indexed for MEDLINE]
- ☐ 23: Gouni-Berthold I, Sachinidis A. Related Articles, Links  
 Molecular mechanisms explaining the preventive effects of catechins on the development of proliferative diseases.  
Curr Pharm Des. 2004;10(11):1261-71. Review.  
PMID: 15078140 [PubMed - indexed for MEDLINE]
- ☐ 24: Perrin LA, June JE, Rosebury W, Robertson A, Kovesdi I, Bruder JT, Kessler PD, Keiser JA, Gordon D. Related Articles, Links










-  Increased revascularization efficacy after administration of an adenovirus encoding VEGF(121).  
Gene Ther. 2004 Mar;11(6):512-21.  
PMID: 14999223 [PubMed - indexed for MEDLINE]
- ☐ **25:** [Syed IS, Sanborn TA, Rosengart TK.](#) [Related Articles, Links](#)
-  Therapeutic angiogenesis: a biologic bypass.  
Cardiology. 2004;101(1-3):131-43. Review.  
PMID: 14988635 [PubMed - indexed for MEDLINE]
- ☐ **26:** [Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, Hambrecht R.](#) [Related Articles, Links](#)
-  Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia.  
Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):684-90. Epub 2004 Feb 26.  
PMID: 14988094 [PubMed - indexed for MEDLINE]
- ☐ **27:** [Chong AY, Caine GJ, Lip GY.](#) [Related Articles, Links](#)
-  Angiopoietin/tie-2 as mediators of angiogenesis: a role in congestive heart failure?  
Eur J Clin Invest. 2004 Jan;34(1):9-13.  
PMID: 14984432 [PubMed - indexed for MEDLINE]
- ☐ **28:** [Schalch P, Rahman GF, Patejunas G, Goldschmidt RA, Carbray J, Retuerto MA, Kim D, Esser K, Crystal RG, Rosengart TK.](#) [Related Articles, Links](#)
-  Adenoviral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state.  
J Thorac Cardiovasc Surg. 2004 Feb;127(2):535-40.  
PMID: 14762365 [PubMed - indexed for MEDLINE]
- ☐ **29:** [Symes JF.](#) [Related Articles, Links](#)
-  Gene therapy for ischemic heart disease: therapeutic potential.  
Am J Cardiovasc Drugs. 2001;1(3):159-66. Review.  
PMID: 14728030 [PubMed - indexed for MEDLINE]
- ☐ **30:** [Calvi C, Dentelli P, Pagano M, Rosso A, Pegoraro M, Giunti S, Garbarino G, Camussi G, Pegoraro L, Brizzi MF.](#) [Related Articles, Links](#)
-  Angiopoietin 2 induces cell cycle arrest in endothelial cells: a possible mechanism involved in advanced plaque neovascularization.  
Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):511-8. Epub 2004 Jan 15.  
PMID: 14726409 [PubMed - indexed for MEDLINE]
- ☐ **31:** [Laufs U, Werner N, Link A, Endres M, Wassmann S, Jurgens K, Miche E, Bohm M, Nickenig G.](#) [Related Articles, Links](#)
-  Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis.  
Circulation. 2004 Jan 20;109(2):220-6. Epub 2003 Dec 22.  
PMID: 14691039 [PubMed - indexed for MEDLINE]
- ☐ **32:** [Scheubel RJ, Zorn H, Silber RE, Kuss O, Morawietz H, Holtz J, Simm A.](#) [Related Articles, Links](#)
-  Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting.  
J Am Coll Cardiol. 2003 Dec 17;42(12):2073-80.  
PMID: 14680729 [PubMed - indexed for MEDLINE]

- ☐ 33: [Kolsut P, Malecki M, Zelazny P, Teresinska A, Firek B, Janik P, Religa Z.](#) Related Articles, Links  
 Gene therapy of coronary artery disease with phvegfl65--early outcome. *Kardiol Pol.* 2003 Nov;59(11):373-84. English, Polish. PMID: 14668888 [PubMed - indexed for MEDLINE]
- ☐ 34: [Baklanov D, Simons M.](#) Related Articles, Links  
 Arteriogenesis: lessons learned from clinical trials. *Endothelium.* 2003;10(4-5):217-23. Review. PMID: 14660081 [PubMed - indexed for MEDLINE]
- ☐ 35: [Roguin A, Resar JR.](#) Related Articles, Links  
 Genetics and susceptibility of coronary collateral formation. *Circulation.* 2003 Nov 25;108(21):e149; author reply e149. No abstract available. PMID: 14638531 [PubMed - indexed for MEDLINE]
- ☐ 36: [Chung NA, Lydakis C, Belgore F, Li-Saw-Hee FL, Blann AD, Lip GY.](#) Related Articles, Links  
 Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. *Heart.* 2003 Dec;89(12):1411-5. PMID: 14617549 [PubMed - indexed for MEDLINE]
- ☐ 37: [Panutsopoulos D, Zafiropoulos A, Krambovitis E, Kochiadakis GE, Igoumenidis NE, Spandidos DA.](#) Related Articles, Links  
 Peripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expression. *J Transl Med.* 2003 Oct 6;1(1):6. PMID: 14585103 [PubMed - as supplied by publisher]
- ☐ 38: [Juan-Babot JO, Martinez-Gonzalez J, Berrozpe M, Badimon L.](#) Related Articles, Links  
 [Neovascularization in human coronary arteries with lesions of different severity] *Rev Esp Cardiol.* 2003 Oct;56(10):978-86. Spanish. PMID: 14563292 [PubMed - indexed for MEDLINE]
- ☐ 39: [Nishimura S, Zaitsu M, Hara M, Yokota G, Watanabe M, Ueda Y, Imayoshi M, Ishii E, Tasaki H, Hamasaki Y.](#) Related Articles, Links  
 A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease. *J Pediatr.* 2003 Sep;143(3):357-62. PMID: 14517520 [PubMed - indexed for MEDLINE]
- ☐ 40: [Fujita M, Ikemoto M, Tanaka T, Tamaki S, Yamazato A, Sawamura T, Hasegawa K, Kihara Y, Nohara R, Sasayama S.](#) Related Articles, Links  
 Marked elevation of vascular endothelial growth factor and basic fibroblast growth factor in pericardial fluid of patients with angina pectoris. *Angiogenesis.* 1998;2(1):105-8. PMID: 14517380 [PubMed]
- ☐ 41: [Crottogini A, Meckert PC, Vera Janavel G, Lascano E, Negroni J, Del Valle H, Dulbecco E, Werba P, Cuniberti L, Martinez V, De Lorenzi A, Telayna J, Mele A, Fernandez JL, Marangunich L, Criscuolo M, Capogrossi MC, Laguens R.](#) Related Articles, Links

-  Arteriogenesis induced by intramyocardial vascular endothelial growth factor 165 gene transfer in chronically ischemic pigs.  
Hum Gene Ther. 2003 Sep 20;14(14):1307-18.  
PMID: 14503966 [PubMed - indexed for MEDLINE]
- ☐ **42:** [Ruel M, Sellke FW.](#) Related Articles, Links
-  Angiogenic protein therapy.  
Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):222-35. Review.  
PMID: 12973700 [PubMed - indexed for MEDLINE]
- ☐ **43:** [Hedman M, Yla-Herttuala S.](#) Related Articles, Links
-  Gene therapy for the treatment of peripheral vascular disease and coronary artery disease.  
Drugs Today (Barc). 2000 Sep;36(9):609-17.  
PMID: 12847566 [PubMed]
- ☐ **44:** [Chung NA, Makin AJ, Lip GY.](#) Related Articles, Links
-  Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay.  
Eur J Clin Invest. 2003 Jul;33(7):529-35.  
PMID: 12814387 [PubMed - indexed for MEDLINE]
- ☐ **45:** [Kastrup J.](#) Related Articles, Links
-  Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular growth factor protein therapy?  
Curr Gene Ther. 2003 Jun;3(3):197-206. Review.  
PMID: 12762479 [PubMed - indexed for MEDLINE]
- ☐ **46:** [Rasmussen HS, Rasmussen CS, Macko J.](#) Related Articles, Links
-  VEGF gene therapy for coronary artery disease and peripheral vascular disease.  
Cardiovasc Radiat Med. 2002 Apr-Jun;3(2):114-7. Review.  
PMID: 12699842 [PubMed - indexed for MEDLINE]
- ☐ **47:** [Kusumanto YH, Hospers GA, Mulder NH, Tio RA.](#) Related Articles, Links
-  Therapeutic angiogenesis with vascular endothelial growth factor in peripheral and coronary artery disease: a review.  
Int J Cardiovasc Intervent. 2003;5(1):27-34. Review.  
PMID: 12623562 [PubMed - indexed for MEDLINE]
- ☐ **48:** [Sellke FW, Ruel M.](#) Related Articles, Links
-  Vascular growth factors and angiogenesis in cardiac surgery.  
Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.  
PMID: 12607713 [PubMed - indexed for MEDLINE]
- ☐ **49:** [Khan TA, Sellke FW, Laham RJ.](#) Related Articles, Links
-  Therapeutic angiogenesis: protein-based therapy for coronary artery disease.  
Expert Opin Pharmacother. 2003 Feb;4(2):219-26. Review.  
PMID: 12562312 [PubMed - indexed for MEDLINE]
- ☐ **50:** [Sim EK, Zhang L, Shim WS, Lim YL, Ge R.](#) Related Articles, Links
-  Therapeutic angiogenesis for coronary artery disease.  
J Card Surg. 2002 Jul-Aug;17(4):350-4. Review.

PMID: 12546086 [PubMed - indexed for MEDLINE]

- ☐ **51:** [Kutryk MJ, Stewart DJ.](#) Related Articles, Links  
 **Angiogenesis of the heart.**  
Microsc Res Tech. 2003 Feb 1;60(2):138-58. Review.  
PMID: 12539168 [PubMed - indexed for MEDLINE]
- ☐ **52:** [Lenihan DJ, Osman A, Sriram V, Aitsebaomo J, Patterson C.](#) Related Articles, Links  
 **Evidence for association of coronary sinus levels of hepatocyte growth factor and collateralization in human coronary disease.**  
Am J Physiol Heart Circ Physiol. 2003 May;284(5):H1507-12. Epub 2003 Jan 9.  
PMID: 12521946 [PubMed - indexed for MEDLINE]
- ☐ **53:** [Lee CH, Smits PC.](#) Related Articles, Links  
 **Vascular growth factors for coronary angiogenesis.**  
J Interv Cardiol. 2002 Dec;15(6):511-8. Review.  
PMID: 12476656 [PubMed - indexed for MEDLINE]
- ☐ **54:** [Rasmussen HS, Rasmussen CS, Macko J, Yonehiro G.](#) Related Articles, Links  
 **Angiogenic gene therapy strategies for the treatment of cardiovascular disease.**  
Curr Opin Mol Ther. 2002 Oct;4(5):476-81. Review.  
PMID: 12435049 [PubMed - indexed for MEDLINE]
- ☐ **55:** [Ben-Gary H, McKinney RL, Rosengart T, Lesser ML, Crystal RG.](#) Related Articles, Links  
 **Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.**  
Mol Ther. 2002 Aug;6(2):287-97.  
PMID: 12349828 [PubMed - indexed for MEDLINE]
- ☐ **56:** [Freedman SB, Vale P, Kalka C, Kearney M, Pieczek A, Symes J, Losordo D, Isner JM.](#) Related Articles, Links  
 **Plasma vascular endothelial growth factor (VEGF) levels after intramuscular and intramyocardial gene transfer of VEGF-1 plasmid DNA.**  
Hum Gene Ther. 2002 Sep 1;13(13):1595-603.  
PMID: 12228014 [PubMed - indexed for MEDLINE]
- ☐ **57:** [Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GY.](#) Related Articles, Links  
 **Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?**  
Stroke. 2002 Sep;33(9):2187-91.  
PMID: 12215585 [PubMed - indexed for MEDLINE]
- ☐ **58:** [Eppler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, Annex BH, McCluskey ER, Zioncheck TF.](#) Related Articles, Links  
 **A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans.**  
Clin Pharmacol Ther. 2002 Jul;72(1):20-32.  
PMID: 12152001 [PubMed - indexed for MEDLINE]
- ☐ **59:** [Alber HF, Dulak J, Frick M, Dichtl W, Schwarzacher SP, Pachinger O, Weidinger F.](#) Related Articles, Links

-  Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease.  
J Am Coll Cardiol. 2002 Jun 19;39(12):1951-5.  
PMID: 12084593 [PubMed - indexed for MEDLINE]
- ☐ 60: [Cotton JM, Mathur A, Hong Y, Brown AS, Martin JF, Erusalimsky JD.](#) [Related Articles, Links](#)
-  Acute rise of circulating vascular endothelial growth factor-A in patients with coronary artery disease following cardiothoracic surgery.  
Eur Heart J. 2002 Jun;23(12):953-9.  
PMID: 12069450 [PubMed - indexed for MEDLINE]
- ☐ 61: [Vale PR, Isner JM, Rosenfield K.](#) [Related Articles, Links](#)
-  Therapeutic angiogenesis in critical limb and myocardial ischemia.  
J Interv Cardiol. 2001 Oct;14(5):511-28. Review.  
PMID: 12053643 [PubMed - indexed for MEDLINE]
- ☐ 62: [Byzova TV, Goldman CK, Jankau J, Chen J, Cabrera G, Achen MG, Stacker SA, Carnevale KA, Siemionow M, Deitcher SR, DiCorleto PE.](#) [Related Articles, Links](#)
-  Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo.  
Blood. 2002 Jun 15;99(12):4434-42.  
PMID: 12036873 [PubMed - indexed for MEDLINE]
- ☐ 63: [Herrmann J, Best PJ, Ritman EL, Holmes DR, Lerman LO, Lerman A.](#) [Related Articles, Links](#)
-  Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia.  
J Am Coll Cardiol. 2002 May 1;39(9):1555-61.  
PMID: 11985922 [PubMed - indexed for MEDLINE]
- ☐ 64: [Rosen LS.](#) [Related Articles, Links](#)
-  Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.  
Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44. Review.  
PMID: 11965229 [PubMed - indexed for MEDLINE]
- ☐ 65: [Zimmerman MA, Selzman CH, Raeburn CD, Calkins CM, Barsness K, Harken AH.](#) [Related Articles, Links](#)
-  Clinical applications of cardiovascular angiogenesis.  
J Card Surg. 2001 Nov-Dec;16(6):490-7. Review.  
PMID: 11925031 [PubMed - indexed for MEDLINE]
- ☐ 66: [Sarkar N, Ruck A, Kallner G, Y-Hassan S, Blomberg P, Islam KB, van der Linden J, Lindblom D, Nygren AT, Lind B, Brodin LA, Drvota V, Sylven C.](#) [Related Articles, Links](#)
-  Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease--12-month follow-up: angiogenic gene therapy.  
J Intern Med. 2001 Nov;250(5):373-81.  
PMID: 11887971 [PubMed - indexed for MEDLINE]
- ☐ 67: [Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY.](#) [Related Articles, Links](#)
-  Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of



patients with coronary or peripheral atherosclerosis, or Type II diabetes.  
Clin Sci (Lond). 2002 Feb;102(2):187-94.  
PMID: 11834138 [PubMed - indexed for MEDLINE]

- ☐ 68: [Sarkar N](#), [Blomberg P](#), [Wardell E](#), [Eskandarpour M](#), [Sylvén C](#), [Drvota V](#), [Islam KB](#). Related Articles, Links



Nonsurgical direct delivery of plasmid DNA into rat heart: time course, dose response, and the influence of different promoters on gene expression.

J Cardiovasc Pharmacol. 2002 Feb;39(2):215-24.

PMID: 11791007 [PubMed - indexed for MEDLINE]

- ☐ 69: [Crystal RG](#), [Harvey BG](#), [Wisnivesky JP](#), [O'Donoghue KA](#), [Chu KW](#), [Maroni J](#), [Muscat JC](#), [Pippo AL](#), [Wright CE](#), [Kaner RJ](#), [Leopold PL](#), [Kessler PD](#), [Rasmussen HS](#), [Rosengart TK](#), [Hollmann C](#). Related Articles, Links



Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions.

Hum Gene Ther. 2002 Jan 1;13(1):65-100.

PMID: 11779413 [PubMed - indexed for MEDLINE]

- ☐ 70: [Harvey BG](#), [Maroni J](#), [O'Donoghue KA](#), [Chu KW](#), [Muscat JC](#), [Pippo AL](#), [Wright CE](#), [Hollmann C](#), [Wisnivesky JP](#), [Kessler PD](#), [Rasmussen HS](#), [Rosengart TK](#), [Crystal RG](#). Related Articles, Links



Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.

Hum Gene Ther. 2002 Jan 1;13(1):15-63.

PMID: 11779412 [PubMed - indexed for MEDLINE]

- ☐ 71: [Freedman SB](#), [Isner JM](#). Related Articles, Links



Therapeutic angiogenesis for coronary artery disease.

Ann Intern Med. 2002 Jan 1;136(1):54-71. Review.

PMID: 11777364 [PubMed - indexed for MEDLINE]

- ☐ 72: [Dulak J](#), [Jozkowicz A](#), [Frick M](#), [Alber HF](#), [Dichtl W](#), [Schwarzacher SP](#), [Pachinger O](#), [Weidinger F](#). Related Articles, Links



Vascular endothelial growth factor: angiogenesis, atherogenesis or both?

J Am Coll Cardiol. 2001 Dec;38(7):2137-8. No abstract available.

PMID: 11738334 [PubMed - indexed for MEDLINE]

- ☐ 73: [Huwer H](#), [Welter C](#), [Ozbek C](#), [Seifert M](#), [Straub U](#), [Greilach P](#), [Kalweit G](#), [Isringhaus H](#). Related Articles, Links



Simultaneous surgical revascularization and angiogenic gene therapy in diffuse coronary artery disease.

Eur J Cardiothorac Surg. 2001 Dec;20(6):1128-34.

PMID: 11717016 [PubMed - indexed for MEDLINE]

- ☐ 74: [Davda J](#), [Labhasetwar V](#). Related Articles, Links













An update on angiogenesis therapy.










Crit Rev Eukaryot Gene Expr. 2001;11(1-3):1-21. Review.









PMID: 11693956 [PubMed - indexed for MEDLINE]

- ☐ 75: [Henry TD](#), [Rocha-Singh K](#), [Isner JM](#), [Kereiakes DJ](#), [Giordano FJ](#), [Simons M](#), [Losordo DW](#), [Hendel RC](#), [Bonow RO](#), [Eppler SM](#), [Zioncheck TF](#), [Holmgren EB](#), [McCluskey ER](#). Related Articles, Links

Intracoronary administration of recombinant human vascular endothelial

-  growth factor to patients with coronary artery disease.  
Am Heart J. 2001 Nov;142(5):872-80.  
PMID: 11685177 [PubMed - indexed for MEDLINE]
- ☐ **76:** Choukroun G. Related Articles, Links
-  [Prevention and treatment of type 1 diabetes]  
Presse Med. 2001 Sep 1;30(24 Pt 2):21-3. French.  
PMID: 11577580 [PubMed - indexed for MEDLINE]
- ☐ **77:** Basara N. Related Articles, Links
-  AdGVVEGF121.10 (GenVec).  
Curr Opin Investig Drugs. 2001 Jun;2(6):792-5. Review.  
PMID: 11572658 [PubMed - indexed for MEDLINE]
- ☐ **78:** Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM. Related Articles, Links
-  HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway.  
J Clin Invest. 2001 Aug;108(3):391-7.  
PMID: 11489932 [PubMed - indexed for MEDLINE]
- ☐ **79:** Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N. Related Articles, Links
-  Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease.  
Heart Vessels. 2000;15(3):105-11.  
PMID: 11289497 [PubMed - indexed for MEDLINE]
- ☐ **80:** Ray S, Panja M. Related Articles, Links
-  Current understanding of pathogenesis of coronary artery disease and its future implications.  
J Indian Med Assoc. 2000 Nov;98(11):710-1, 714, 718.  
PMID: 11265801 [PubMed - indexed for MEDLINE]
- ☐ **81:** Brizzi MF, Formato L, Bonamini R. Related Articles, Links
-  The molecular mechanisms of angiogenesis: a new approach to cardiovascular diseases.  
Ital Heart J. 2001 Feb;2(2):81-92. Review.  
PMID: 11256548 [PubMed - indexed for MEDLINE]
- ☐ **82:** Morse MA. Related Articles, Links
-  Technology evaluation: VEGF165 gene therapy, Valentis Inc.  
Curr Opin Mol Ther. 2001 Feb;3(1):97-101. Review.  
PMID: 11249737 [PubMed - indexed for MEDLINE]
- ☐ **83:** Rosengart TK, Hillebrand K. Related Articles, Links
-  Gene therapy for coronary artery disease.  
Adv Card Surg. 2001;13:107-20. Review. No abstract available.  
PMID: 11209652 [PubMed - indexed for MEDLINE]
- ☐ **84:** Freedman SB, Isner JM. Related Articles, Links
-  Therapeutic angiogenesis for ischemic cardiovascular disease.  
J Mol Cell Cardiol. 2001 Mar;33(3):379-93. Review.  
PMID: 11181008 [PubMed - indexed for MEDLINE]

- ☐ **85:** Durairaj A, Mehra A, Singh RP, Faxon DP. Related Articles, Links  
 **Therapeutic angiogenesis.**  
Cardiol Rev. 2000 Sep-Oct;8(5):279-87. Review.  
PMID: 11174906 [PubMed - indexed for MEDLINE]
- ☐ **86:** Rutanen J, Rissanen TT, Kivela A, Vajanto I, Yla-Herttuala S. Related Articles, Links  
 **Clinical applications of vascular gene therapy.**  
Curr Cardiol Rep. 2001 Jan;3(1):29-36. Review.  
PMID: 11139796 [PubMed - indexed for MEDLINE]
- ☐ **87:** Lathi KG, Vale PR, Losordo DW, Cespedes RM, Symes JF, Esakof DD, Maysky M, Isner JM. Related Articles, Links  
 **Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results.**  
Anesth Analg. 2001 Jan;92(1):19-25.  
PMID: 11133594 [PubMed - indexed for MEDLINE]
- ☐ **88:** Vale PR, Losordo DW, Milliken CE, Maysky M, Esakof DD, Symes JF, Isner JM. Related Articles, Links  
 **Left ventricular electromechanical mapping to assess efficacy of phVEGF (165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia.**  
Circulation. 2000 Aug 29;102(9):965-74.  
PMID: 10961959 [PubMed - indexed for MEDLINE]
- ☐ **89:** Mukherjee D, Ellis SG. Related Articles, Links  
 **New options for untreatable coronary artery disease: angiogenesis and laser revascularization.**  
Cleve Clin J Med. 2000 Aug;67(8):577-83.  
PMID: 10946453 [PubMed - indexed for MEDLINE]
- ☐ **90:** O'Brien T, Simari RD. Related Articles, Links  
 **Gene therapy for atherosclerotic cardiovascular disease: a time for optimism and caution.**  
Mayo Clin Proc. 2000 Aug;75(8):831-4. Review.  
PMID: 10943238 [PubMed - indexed for MEDLINE]
- ☐ **91:** Lucassen AM, de Waal RM, Verheugt FW. Related Articles, Links  
 **[Therapeutic angiogenesis as a new experimental treatment for vascular disease]**  
Ned Tijdschr Geneesk. 2000 Apr 1;144(14):650-5. Review. Dutch.  
PMID: 10774292 [PubMed - indexed for MEDLINE]
- ☐ **92:** Lazarous DF, Shou M, Stiber JA, Hodge E, Thirumurti V, Goncalves L, Unger EF. Related Articles, Links  
 **Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis.**  
Cardiovasc Res. 1999 Nov;44(2):294-302.  
PMID: 10690306 [PubMed - indexed for MEDLINE]
- ☐ **93:** Chawla PS, Keelan MH, Kipshidze N. Related Articles, Links  
 **Angiogenesis for the treatment of vascular diseases.**  
Int Angiol. 1999 Sep;18(3):185-92. Review.  
PMID: 10688416 [PubMed - indexed for MEDLINE]

- ☐ **94:** [Moussa I, Moses JW.](#) Related Articles, Links  
 Angiogenesis for treatment of ischemic heart disease: should we worry about progression of atherosclerosis?  
Circulation. 1999 Nov 30;100(22):e109. No abstract available.  
PMID: 10578010 [PubMed - indexed for MEDLINE]
- ☐ **95:** [Fleisch M, Billinger M, Eberli FR, Garachemani AR, Meier B, Seiler C.](#) Related Articles, Links  
 Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.  
Circulation. 1999 Nov 9;100(19):1945-50.  
PMID: 10556219 [PubMed - indexed for MEDLINE]
- ☐ **96:** [Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG.](#) Related Articles, Links  
 Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.  
Ann Surg. 1999 Oct;230(4):466-70; discussion 470-2.  
PMID: 10522716 [PubMed - indexed for MEDLINE]
- ☐ **97:** [Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, Isner JM.](#) Related Articles, Links  
 Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.  
Ann Thorac Surg. 1999 Sep;68(3):830-6; discussion 836-7.  
PMID: 10509970 [PubMed - indexed for MEDLINE]
- ☐ **98:** [Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, Lavie P, Roguin A, Levy AP.](#) Related Articles, Links  
 Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation.  
Circulation. 1999 Aug 3;100(5):547-52.  
PMID: 10430770 [PubMed - indexed for MEDLINE]
- ☐ **99:** [Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG.](#) Related Articles, Links  
 Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.  
Circulation. 1999 Aug 3;100(5):468-74.  
PMID: 10430759 [PubMed - indexed for MEDLINE]
- ☐ **100:** [Losordo DW, Vale PR, Isner JM.](#) Related Articles, Links  
 Gene therapy for myocardial angiogenesis.  
Am Heart J. 1999 Aug;138(2 Pt 2):S132-41. Review.  
PMID: 10426872 [PubMed - indexed for MEDLINE]
- ☐ **101:** [Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M.](#) Related Articles, Links  
 Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.

Clin Chim Acta. 1999 May;283(1-2):171-82.  
PMID: 10404741 [PubMed - indexed for MEDLINE]

- ☐ **102:** [Patterson C, Runge MS.](#) Related Articles, Links



Therapeutic angiogenesis: the new electrophysiology?  
Circulation. 1999 May 25;99(20):2614-6. Review. No abstract available.  
PMID: 10338451 [PubMed - indexed for MEDLINE]

- ☐ **103:** [Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S.](#) Related Articles, Links



Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.  
Biochem Biophys Res Commun. 1999 Feb 5;255(1):80-7.  
PMID: 10082659 [PubMed - indexed for MEDLINE]

- ☐ **104:** [Chen YX, Nakashima Y, Tanaka K, Shiraishi S, Nakagawa K, Sueishi K.](#) Related Articles, Links



Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries.  
Arterioscler Thromb Vasc Biol. 1999 Jan;19(1):131-9.  
PMID: 9888875 [PubMed - indexed for MEDLINE]

- ☐ **105:** [Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM.](#) Related Articles, Links



Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.  
Circulation. 1998 Dec 22-29;98(25):2800-4.  
PMID: 9860779 [PubMed - indexed for MEDLINE]

- ☐ **106:** [Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K.](#) Related Articles, Links



Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis.  
Circulation. 1998 Nov 17;98(20):2108-16.  
PMID: 9815864 [PubMed - indexed for MEDLINE]

- ☐ **107:** [Iwakura A, Komeda M, Fujita M.](#) Related Articles, Links



[Coronary stenosis and mechanisms of collateral vessel growth]  
Nippon Rinsho. 1998 Oct;56(10):2504-8. Review. Japanese.  
PMID: 9796310 [PubMed - indexed for MEDLINE]

- ☐ **108:** [Komatsu R, Ueda M.](#) Related Articles, Links



[Plaque progression and destabilization in human coronary arteries]  
Nippon Rinsho. 1998 Oct;56(10):2477-82. Review. Japanese.  
PMID: 9796305 [PubMed - indexed for MEDLINE]

- ☐ **109:** [Goalstone ML, Natarajan R, Standley PR, Walsh MF, Leitner JW, Carel K, Scott S, Nadler J, Sowers JR, Draznin B.](#) Related Articles, Links



Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells.  
Endocrinology. 1998 Oct;139(10):4067-72.  
PMID: 9751484 [PubMed - indexed for MEDLINE]

☐ **110:** [Metais C, Li J, Li J, Simons M, Sellke FW.](#)

[Related Articles](#), [Links](#)



Effects of coronary artery disease on expression and microvascular response to VEGF.

Am J Physiol. 1998 Oct;275(4 Pt 2):H1411-8.

PMID: 9746492 [PubMed - indexed for MEDLINE]

☐ **111:** [Brilla CG, Rybinski L, Gehrke D, Rupp H.](#)

[Related Articles](#), [Links](#)



[Transmyocardial laser revascularization--an innovative pathophysiologic concept]

Herz. 1997 Aug;22(4):183-9. Review. German.

PMID: 9378452 [PubMed - indexed for MEDLINE]

☐ **112:** [Labarrere CA, Faulk WP.](#)

[Related Articles](#), [Links](#)



Antithrombin determinants of coronary artery disease in transplanted human hearts.

Semin Hematol. 1995 Oct;32(4 Suppl 2):61-6. Review. No abstract available.

PMID: 8821212 [PubMed - indexed for MEDLINE]

☐ **113:** [Levy AP, Levy NS, Loscalzo J, Calderone A, Takahashi N, Yeo KT, Koren G, Colucci WS, Goldberg MA.](#) [Related Articles](#), [Links](#)



Regulation of vascular endothelial growth factor in cardiac myocytes.

Circ Res. 1995 May;76(5):758-66.

PMID: 7728992 [PubMed - indexed for MEDLINE]

Display  Show  Sort by  Send to



[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Apr 18 2005 07:10:12



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for coronary artery disease AND aFGF Save Search

Limits Preview/Index History Clipboard Details

Display Summary Show 500 Sort by Send to

About Entrez

Text Version

All: 8 Review: 1

Items 1 - 8 of 8

One page.

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Pawlak J, Klim B, Szkudlarek M, Dzieciol J.

Related Articles, Links



[The formation of new blood vessels in coronary artery disease: where we are now]

Postepy Hig Med Dosw (Online). 2004 Oct 6;58:358-63. Polish.

PMID: 15536393 [PubMed - in process]

2: Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R.

Related Articles, Links



Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells.

Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 7.

PMID: 12907464 [PubMed - indexed for MEDLINE]

3: Ananyeva N, Tjurmin A, Saenko E, Haudenschild C.

Related Articles, Links



Low density lipoproteins interact with acidic fibroblast growth factor and modify its function.

Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 2003 Mar 6.

PMID: 12692004 [PubMed - indexed for MEDLINE]

4: Sellke FW, Ruel M.

Related Articles, Links



Vascular growth factors and angiogenesis in cardiac surgery.

Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.

PMID: 12607713 [PubMed - indexed for MEDLINE]

5: Schumacher B, Hannekum A, Pecher P.

Related Articles, Links



[Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease]

Z Kardiol. 2000;89 Suppl 7:23-30. German.

PMID: 11098556 [PubMed - indexed for MEDLINE]

6: Safi J Jr, DiPaula AF Jr, Riccioni T, Kajstura J, Ambrosio G, Becker LC, Anversa P, Capogrossi MC.

Related Articles, Links



Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart.

Microvasc Res. 1999 Nov;58(3):238-49.

PMID: 10527767 [PubMed - indexed for MEDLINE]

7: Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M.

Related Articles, Links



Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.

Clin Chim Acta. 1999 May;283(1-2):171-82.

PMID: 10404741 [PubMed - indexed for MEDLINE]

☐ **8:** [Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M.](#) [Related Articles, Links](#)



Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.

u Surgery. 1996 Aug;120(2):182-8.

PMID: 8751581 [PubMed - indexed for MEDLINE]

Display  Show  Sort by Send to

[Write to the Help Desk](#)



[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Apr 18 2005 07:10:12





All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for coronary artery disease AND acidic FGF Save Search

Limits Preview/Index History Clipboard Details

Display Summary Show 500 Sort by Send to

About Entrez

Text Version

All: 2 Review: 0

Items 1 - 2 of 2

One page.

#### Entrez PubMed

Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

#### PubMed Services

Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut

My NCBI (Cubby)

#### Related Resources

Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

☐ 1: Ananyeva N, Tjurmin A, Saenko E, Haudenschield C.

[Related Articles, Links](#)



Low density lipoproteins interact with acidic fibroblast growth factor and modify its function.

Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 2003 Mar 6.  
PMID: 12692004 [PubMed - indexed for MEDLINE]

☐ 2: Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M.

[Related Articles, Links](#)



Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.

Surgery. 1996 Aug;120(2):182-8.  
PMID: 8751581 [PubMed - indexed for MEDLINE]



[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Apr 18 2005 07:10:12



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for coronary artery disease AND basic FGF Save Search

Limits Preview/Index History Clipboard Details

Display Summary Show 500 Sort by Send to

About Entrez

Text Version

Entrez PubMed

Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services

Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
My NCBI (Cubby)

Related Resources

Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

Items 1 - 4 of 4

One page.

☐ 1: Aviles RJ, Annex BH, Lederman RJ.

[Related Articles, Links](#)



Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2).

Br J Pharmacol. 2003 Oct;140(4):637-46.

PMID: 14534147 [PubMed - indexed for MEDLINE]

☐ 2: Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Nishimura K, Tabata Y, Komeda M.

[Related Articles, Links](#)



Toward surgical angiogenesis using slow-released basic fibroblast growth factor.

Eur J Cardiothorac Surg. 2003 Jul;24(1):105-11; discussion 112.

PMID: 12853053 [PubMed - indexed for MEDLINE]

☐ 3: Campuzano R, Barrios V, Cuevas B, Asin-Cardiel E, Muela A, Castro JM, Fernandez-Ayerdi A, Cuevas P.

[Related Articles, Links](#)



Serum basic fibroblast growth factor levels in exercise-induced myocardial ischemia more likely a marker of endothelial dysfunction than a marker of ischemia?

Eur J Med Res. 2002 Mar 28;7(3):93-7.

PMID: 11953278 [PubMed - indexed for MEDLINE]

☐ 4: Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ.

[Related Articles, Links](#)



Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis?

Circulation. 1994 Apr;89(4):1511-7.

PMID: 7908609 [PubMed - indexed for MEDLINE]

[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Apr 18 2005 07:10:12

Welcome to STN International! Enter x:x

\* \* \* \* \* Welcome to STN International \* \* \* \* \*  
\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:09:39 ON 22 APR 2005

=> file BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ADISCTI' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 15:09:47 ON 22 APR 2005

FILE 'ANABSTR' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (c) 2005 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT 2005 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 15:09:47 ON 22 APR 2005

Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'CONFSCI' ENTERED AT 15:09:47 ON 22 APR 2005  
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 15:09:47 ON 22 APR 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 15:09:47 ON 22 APR 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 15:09:47 ON 22 APR 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 15:09:47 ON 22 APR 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 15:09:47 ON 22 APR 2005  
COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved

FILE 'DRUGB' ENTERED AT 15:09:47 ON 22 APR 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 15:09:47 ON 22 APR 2005  
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 15:09:47 ON 22 APR 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 15:09:47 ON 22 APR 2005  
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:09:47 ON 22 APR 2005  
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:09:47 ON 22 APR 2005

FILE 'KOSMET' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 International Federation of the Societies of Cosmetics Chemi:

FILE 'LIFESCI' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (c) 2005 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 15:09:47 ON 22 APR 2005

FILE 'NIOSHTIC' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 15:09:47 ON 22 APR 2005

Compiled and distributed by the NTIS, U.S. Department of Commerce.

It contains copyrighted material.

All rights reserved. (2005)

FILE 'NUTRACEUT' ENTERED AT 15:09:47 ON 22 APR 2005

Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 15:09:47 ON 22 APR 2005

Any reproduction or dissemination in part or in full,

by means of any process and on any support whatsoever

is prohibited without the prior written agreement of INIST-CNRS.

COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 WIPO

FILE 'PHAR' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'VETB' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s coronary artery disease OR acute coronary artery disease OR chronic corona

11 FILES SEARCHED...

12 FILES SEARCHED...

22 FILES SEARCHED...

25 FILES SEARCHED...

32 FILES SEARCHED...

45 FILES SEARCHED...

53 FILES SEARCHED...

65 FILES SEARCHED...

L1 323642 CORONARY ARTERY DISEASE OR ACUTE CORONARY ARTERY DISEASE OR  
CHRONIC CORONARY ARTERY DISEASE

=> S FGF-1 OR FGF-2 OR aFGF OR bFGF OR VEGF

14 FILES SEARCHED...

29 FILES SEARCHED...

40 FILES SEARCHED...

53 FILES SEARCHED...

67 FILES SEARCHED...

65 FILES SEARCHED...

71 FILES SEARCHED...

L5 549 L4 AND PY<=2000

=> D L5 1-549

L5 ANSWER 1 OF 549 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on  
STN

AN 2000:14563 ADISCTI

DN 800836302

TI Effects of a single intracoronary injection of basic fibroblast growth  
factor in stable angina pectoris.

ADIS TITLE: Fibroblast growth factor: therapeutic use.

Angina pectoris

Intracoronary administration in patients with \*\*\*coronary\*\*\*  
\*\*\*artery\*\*\* \*\*\*disease\*\*\* .

AU Unger E F; Goncalves L; Epstein S E; Chew E Y; Trapnell C B; et al.

CS National Heart, Lung, and Blood Institute, Rockville, Maryland, USA.

SO American Journal of Cardiology (Jun 15, 2000), Vol. 85, pp. 1414-1419

DT Study

RE Ischaemic Heart Disease

FS Summary

LA English

WC 663

L5 ANSWER 2 OF 549 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on  
STN

AN 2000:3823 ADISCTI

DN 800813542

TI Effect of intracoronary recombinant human vascular endothelial growth  
factor on myocardial perfusion: evidence for a dose-dependent effect.

ADIS TITLE: Vascular endothelial growth factor: pharmacodynamics.

Effect on myocardial perfusion

In patients with \*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\* .

AU Hendel R C; Henry T D; Rocha Singh K; Isner J M; Kereiakes D J; et al.

CS Northwestern University Medical School, Chicago, Illinois, USA.

Coronary disorders

In patients refractory to conventional therapies.

AU Losordo D W; Vale P R; Isner J M.

CS St. Elizabeth's Medical Center, Boston, Massachusetts, USA.

SO American Heart Journal (Aug 1, 1999), Vol. 138, pp. 132-141

DT Study

RE Ischaemic Heart Disease

FS Summary

LA English

WC 450

L5 ANSWER 5 OF 549 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on  
STN

AN 1999:11635 ADISCTI

DN 800742050

TI The stimulation of neoangiogenesis in the ischemic human heart by the  
growth factor FGF: first clinical results.

ADIS TITLE: Fibroblast growth factor: pharmacodynamics.

Stimulation of neoangiogenesis

In patients undergoing coronary artery bypass graft surgery.

AU Schumacher B; Stegmann Th; Pecher P.

CS University of Ulm, Ulm, Germany.

SO Journal of Cardiovascular Surgery (Dec 1, 1998), Vol. 39, pp. 783-789

DT Study

RE Ischaemic Heart Disease

FS Summary

LA English

WC 518

L5 ANSWER 6 OF 549 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on  
STN

AN 1999:2247 ADISCTI

DN 800734037

TI Gene therapy for myocardial angiogenesis: initial clinical results with  
direct myocardial injection of phVEGF165 as sole therapy for myocardial  
ischemia.



SOURCE: INPHARMA \*\*\*21 Sep 2000\*\*\* ISSN: 1173-8324  
DOCUMENT TYPE: (MIX)  
WORD COUNT: 344

L5 ANSWER 9 OF 549 ADISNEWS COPYRIGHT (C) 2005 Adis Data Information BV on  
STN

ACCESSION NUMBER: 2000:197 ED: 8 Aug 2001 UP: 8 Aug 2001  
DOCUMENT NUMBER: 11738324-800763516  
TITLE: Symposia: News from the 49th Annual Scientific Session of  
the American College of Cardiology.  
SOURCE: INPHARMA \*\*\*20 Apr 2000\*\*\* ISSN: 1173-8324  
DOCUMENT TYPE: (MIX)  
WORD COUNT: 1210

L5 ANSWER 10 OF 549 ADISNEWS COPYRIGHT (C) 2005 Adis Data Information BV on  
STN

ACCESSION NUMBER: 1999:2132 ED: 8 Aug 2001 UP: 8 Aug 2001  
DOCUMENT NUMBER: 11738324-800786553  
TITLE: Product news: Gene therapy shows promise in CAD.  
SOURCE: INPHARMA \*\*\*20 Aug 1999\*\*\* ISSN: 1173-8324  
DOCUMENT TYPE: (MIX)  
WORD COUNT: 283

L5 ANSWER 11 OF 549 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation.  
on STN

AN 1998:31898 BIOBUSINESS

DN 0983721

TI \*\*\*FGF\*\*\* - \*\*\*1\*\*\* promotes neoangiogenesis in the ischaemic heart.

AU Anon

SO European Biotechnology Newsletter, ( \*\*\*1998\*\*\* ) No.263, March 11,  
p.10-11.

ISSN: 0765-2046.

DT ARTICLE

FS UNIQUE

LA English

L5 ANSWER 15 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN  
AN 0187890 BIOCOMMERCE FS Abstract  
CO Valentis Inc (51189), USA  
SO Valentis Press Release, 01 JUN 2000  
TC (Company information)

L5 ANSWER 16 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN  
AN 0187333 BIOCOMMERCE FS Abstract  
CO GenVec Inc (28772), USA  
Scios Inc (25945), USA  
SO GenVec Press Release, 26 APR 2000, vol. 2541, Page(s) 22.  
Scrip, 19 MAY 2000  
TC (Company information)

L5 ANSWER 17 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN  
AN 0186685 BIOCOMMERCE FS Abstract  
CO Vascular Genetics Inc (VGI) (44457), USA  
Food and Drug Administration (FDA) (815), USA  
Johnson & Johnson (1565), USA  
SO Clinica, 20 MAR 2000, vol. 900, Page(s) 15.  
TC (Company information)

L5 ANSWER 18 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN  
AN 0186500 BIOCOMMERCE FS Abstract  
CO Chiron Corp (1282), USA  
SO Chiron Press Release, 12 MAR 2000, vol. 2523, Page(s) 10.  
Scrip, 17 MAR 2000  
TC (Company information)

L5 ANSWER 19 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN  
AN 0181030 BIOCOMMERCE FS Abstract  
CO Vascular Genetics Inc (VGI) (44457), USA  
Human Genome Sciences Inc (HGSI) (26897), USA  
SO Human Genome Sciences Press Release, 17 JUN 1999, vol. 2626, Page(s) 28.  
Marketletter, 28 JUN 1999  
TC (Company information)

TC (Company information)

L5 ANSWER 24 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN  
AN 0161264 BIOCOMMERCE FS Abstract  
CO GenVec Inc (28772), USA  
Parke-Davis Co (3379), USA  
SO Scrip, 16 SEP 1997, vol. 2267, Page(s) 9.  
R&D Focus Drug News, 22 SEP 1997, vol. 637, Page(s) 10.  
BioWorld Financial Watch, 29 SEP 1997, vol. 539, Page(s) 8.  
Genetic Technology News, 24 SEP 1997, vol. 1719, Page(s) 3.  
BioVenture View, OCT 1997, vol. 1210, Page(s) 24.  
Scrip, 16 JAN 1998, vol. 2301, Page(s) 17.  
Nature Biotechnology, OCT 1997, vol. 1510, Page(s) 930.  
Genetic Engineering News, 01 OCT 1997, vol. 1717, Page(s) 27.  
Genetic Engineering News, 15 OCT 1997, vol. 1718, Page(s) 45.  
In Vivo, OCT 1997, vol. 159, Page(s) 74-75.  
Business Week International, 24 NOV 1997, vol. 3538868, Page(s) 44.

TC (Company information)

L5 ANSWER 25 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on  
STN  
AN 2001:257278 BIOSIS  
DN PREV200100257278  
TI Rat sponge implant model: A new system for evaluating angiogenic gene  
transfer.  
AU Wang, H. [Reprint author]; Gordon, D.; Olszewski, B.; Song, Y. L.;  
Kovesdi, I.; Keiser, J. A.  
CS Cardiovascular Therapeutics, Parke-Davis Pharmaceutical Research, 2800  
Plymouth Road, Ann Arbor, MI, 48105, USA  
he.wang@wl.com  
SO International Journal of Molecular Medicine, (December, 2000) Vol. 6, No.  
6, pp. 645-653. print.  
ISSN: 1107-3756.  
DT Article  
LA English

2000.

CODEN: ZKRDX. ISSN: 0300-5860.

DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 28 Mar 2001

Last Updated on STN: 15 Feb 2002

L5 ANSWER 28 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on  
STN

AN 2001:150039 BIOSIS

DN PREV200100150039

TI Role of circulating vascular endothelial growth factor and hepatocyte  
growth factor in patients with \*\*\*coronary\*\*\* \*\*\*artery\*\*\*  
\*\*\*disease\*\*\* .

AU Soeki, Takeshi [Reprint author]; Tamura, Yoshiyuki; Shinohara, Hisanori;  
Tanaka, Hideji; Bando, Kanji; Fukuda, Nobuo

CS Department of Cardiology and Clinical Research Institute, National  
Zentsuji Hospital, 2-1-1 Senyu-cho, Zentsuji, Kagawa, 765-8507, Japan  
tsoeki@jun.ncvc.go.jp

SO Heart and Vessels, (2000) Vol. 15, No. 3, pp. 105-111. print.

CODEN: HEVEEO. ISSN: 0910-8327.

DT Article

LA English

ED Entered STN: 28 Mar 2001

Last Updated on STN: 15 Feb 2002

L5 ANSWER 29 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on  
STN

AN 2001:112482 BIOSIS

DN PREV200100112482

TI Shock waves upregulate vascular endothelial growth factor M-RNA in human  
umbilical vascular endothelial cells.

AU Guttersohn, Achim [Reprint author]; Caspari, Guido H. [Reprint author]

CS Univ of Essen, Essen, Germany

SO Circulation, (October 31, 2000) Vol. 102, No. 18 Supplement, pp. II.432.

AN 2001:14963 BIOSIS  
 DN PREV200100014963  
 TI Neoangiogenesis by local gene therapy: A new therapeutic approach in the  
 treatment of \*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\* .  
 Original Title: Neoangiogenese durch lokale Gentherapie: Ein neues  
 therapeutisches Konzept in der Behandlung der koronaren Herzkrankheit.  
 AU Schumacher, B. [Reprint author]; Hannekum, A.; Pecher, P.  
 CS Abt. Chirurgie IV, Herzchirurgie, Universitaetsklinik Ulm, Steinhoevelstr.  
 9, D-89075, Ulm, Germany  
 SO Zeitschrift fuer Kardiologie, (2000) Vol. 89, No. Supplement 7, pp.  
 VII.23-VII.30. print.  
 CODEN: ZKRDX. ISSN: 0300-5860.  
 DT Article  
 LA German  
 ED Entered STN: 27 Dec 2000  
 Last Updated on STN: 27 Dec 2000

L5 ANSWER 32 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on  
 STN

AN 2000:526436 BIOSIS  
 DN PREV200000526436  
 TI Vascular endothelial growth factor ( \*\*\*VEGF\*\*\* ) and soluble Flt-1  
 (sFlt-1) in patients with atherosclerotic vascular disease.  
 AU Belgore, F. M. [Reprint author]; Lip, G. Y. H. [Reprint author]; McCollum,  
 C. N. [Reprint author]; Blann, A. D. [Reprint author]  
 CS Haemostasis, Thrombosis and Vascular Biology Unit, University Department  
 of Medicine, City Hospital, Birmingham, B18 7QH, UK  
 SO Clinical Science (London), (August, 2000) Vol. 99, No. 2, pp. 19P-20P.  
 print.  
 Meeting Info.: Communications for the Spring Meeting of the Medical  
 Research Society. London, England, UK. May 22, 2000.  
 CODEN: CSCIAE. ISSN: 0143-5221.  
 DT Conference; (Meeting)  
 Conference; Abstract; (Meeting Abstract)  
 LA English  
 ED Entered STN: 6 Dec 2000

L5 ANSWER 35 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on  
STN  
AN 2000:415902 BIOSIS  
DN PREV200000415902  
TI Vascular endothelial growth factor ( \*\*\*VEGF\*\*\* ) and its soluble  
receptor (sFlt-1) in peripheral and \*\*\*coronary\*\*\* \*\*\*artery\*\*\*  
\*\*\*disease\*\*\* .  
AU Blann, A. D. [Reprint author]; Belgore, F. M. [Reprint author]; McCollum,  
C. N.; Lip, G. Y. H. [Reprint author]  
CS University Department of Medicine, City Hospital, Birmingham, UK  
SO Haemostasis, (May, 2000) Vol. 30, No. 1-2, pp. 60. print.  
Meeting Info.: 1st North Sea Conference on Thrombosis and Haemostasis.  
Maastrich, Netherlands. June 12-14, 2000.  
CODEN: HMTSB7. ISSN: 0301-0147.  
DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LA English  
ED Entered STN: 27 Sep 2000  
Last Updated on STN: 8 Jan 2002

L5 ANSWER 36 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on  
STN  
AN 2000:385286 BIOSIS  
DN PREV200000385286  
TI Alcohol and catechin increase \*\*\*VEGF\*\*\* expression in cultured human  
endothelial cells.  
AU Benza, R. L. [Reprint author]; Grenett, H. E. [Reprint author]; Tabengwa,  
E. M. [Reprint author]; Barchuc, J. P. [Reprint author]; Wheeler, C. G.  
[Reprint author]; Booyse, F. M. [Reprint author]  
CS University of Alabama at Birmingham, Birmingham, AL, 35294, USA  
SO Alcoholism Clinical and Experimental Research, (May, 2000) Vol. 24, No. 5  
Supplement, pp. 128A. print.  
Meeting Info.: Scientific Meeting of the Research Society on Alcoholism.  
Santa Barbara, California, USA. June 24-29, 2000. Research Society on  
Alcoholism.  
CODEN: ACRSDM. ISSN: 0145-6008.

-  
Meeting Info.: Autumn Meeting of the British Society for Haemostasis and Thrombosis. Cambridge, England, UK. September 22-24, 1999. British Society for Haemostasis and Thrombosis.

CODEN: BLFIE7. ISSN: 0957-5235.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 19 Apr 2000

Last Updated on STN: 4 Jan 2002

L5 ANSWER 39 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 2000:24118 BIOSIS

DN PREV200000024118

TI Adenoviral-mediated gene transfer induces sustained pericardial  
\*\*\*VEGF\*\*\* expression in dogs: Effect on myocardial angiogenesis.

AU Lazarous, Daisy F. [Reprint author]; Shou, Matie; Stiber, Jonathan A.;  
Hodge, Everett; Thirumurti, Venugopal; Goncalves, Lino; Unger, Ellis F.

CS Division of Cardiology, Al East, Johns Hopkins University School of  
Medicine, Johns Hopkins Bayview Medical Center, 4940 Eastern Avenue,  
Baltimore, MD, 21224, USA

SO Cardiovascular Research, (Nov., 1999) Vol. 44, No. 2, pp. 294-302. print.  
CODEN: CVREAU. ISSN: 0008-6363.

DT Article

LA English

ED Entered STN: 29 Dec 1999

...Last Updated on STN: 31 Dec 2001

L5 ANSWER 40 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 2000:17089 BIOSIS

DN PREV200000017089

TI Physiologically assessed coronary collateral flow and intracoronary growth  
factor concentrations in patients with 1- to 3-vessel \*\*\*coronary\*\*\*  
\*\*\*artery\*\*\* \*\*\*disease\*\*\* .

AU Fleisch, Martin; Billinger, Michael; Eberli, Franz R.; Garachemani, Ali

AU Laham, Roger J. [Reprint author]; Sellke, Frank W. [Reprint author]; Ware, J. Anthony [Reprint author]; Pearlman, Justin D. [Reprint author]; Edelman, Elazar R. [Reprint author]; Simons, Michael [Reprint author]  
 CS BIDMC/Harvard Medical School, Boston, MA, USA  
 SO Journal of the American College of Cardiology, (Feb., 1999) Vol. 33, No. 2 SUPPL. A, pp. 383A-384A. print.  
 Meeting Info.: 48th Annual Scientific Session of the American College of Cardiology. New Orleans, Louisiana, USA. March 7-10, 1999. American College of Cardiology.  
 CODEN: JACCDI. ISSN: 0735-1097.  
 DT Conference; (Meeting)  
 Conference; Abstract; (Meeting Abstract)  
 LA English  
 ED Entered STN: 18 Oct 1999  
 Last Updated on STN: 18 Oct 1999  
  
 L5 ANSWER 43 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN  
 AN 1999:406399 BIOSIS  
 DN PREV199900406399  
 TI Interindividual heterogeneity in the hypoxic regulation of \*\*\*VEGF\*\*\* : Significance for the development of the coronary artery collateral circulation.  
 AU Schultz, Aylit; Lavie, Lena; Hochberg, Irit; Beyar, Rafael; Stone, Tzachi; Skorecki, Karl; Lavie, Peretz; Roguin, Ariel; Levy, Andrew P. [Reprint author]  
 CS Rappaport Faculty of Medicine, Bat Galim, Israel  
 SO Circulation, (Aug. 3, 1999) Vol. 100, No. 5, pp. 547-552. print.  
 CODEN: CIRCAZ. ISSN: 0009-7322.  
 DT Article  
 LA English  
 ED Entered STN: 8 Oct 1999  
 Last Updated on STN: 8 Oct 1999  
  
 L5 ANSWER 44 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN



L5 ANSWER 46 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on  
 STN  
 AN 1999:134228 BIOSIS  
 DN PREV199900134228  
 TI Hepatocyte growth factor is a major mediator in heparin-induced  
 angiogenesis.  
 AU Okada, Masaharu; Matsumori, Akira [Reprint author]; Ono, Koh; Miyamoto,  
 Tadashi; Takahashi, Mamoru; Sasayama, Shigetake  
 CS Dep. Cardiovasc. Med., Kyoto Univ., 54 Kawaracho Shogoin, Sakyo-ku, Kyoto  
 606-8397, Japan  
 SO Biochemical and Biophysical Research Communications, (Feb. 5, 1999) Vol.  
 255, No. 1, pp. 80-87. print.  
 CODEN: BBRCA9. ISSN: 0006-291X.  
 DT Article  
 LA English  
 ED Entered STN: 31 Mar 1999  
 Last Updated on STN: 31 Mar 1999

L5 ANSWER 47 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on  
 STN  
 AN 1999:3267 BIOSIS  
 DN PREV199900003267  
 TI Perspectives of gene therapy for the treatment of \*\*\*coronary\*\*\*  
 \*\*\*artery\*\*\* \*\*\*disease\*\*\* .  
 AU Waltenberger, J. [Reprint author]  
 CS Abteilung Innere Med. II, Med. Klinik Poliklinik, Univ. Ulm,  
 Robert-Koch-Str. 8, 89081 Ulm, Germany  
 SO Zeitschrift fuer Kardiologie, (1998) Vol. 87, No. SUPPL. 2, pp. 152-156.  
 print.  
 CODEN: ZKRDAX. ISSN: 0300-5860.  
 DT Article  
 LA German  
 ED Entered STN: 11 Jan 1999  
 Last Updated on STN: 11 Jan 1999

STN

AN 1997:270129 BIOSIS

DN PREV199799561847

TI Serum basic fibroblast growth factor levels in patients with ischemic heart disease.

AU Hasdai, David; Barak, Vivian; Leibovitz, Eyal; Herz, Itzhak; Sclarovsky, Samuel; Eldar, Michael; Scheinowitz, Mickey [Reprint author]

CS Neufeld Cardiac Res. Inst., Sheba Med. Cent., Tel Hashomer 52621, Israel  
SO International Journal of Cardiology, (1997) Vol. 59, No. 2, pp. 133-138.  
CODEN: IJCDD5. ISSN: 0167-5273.

DT Article

LA English

ED Entered STN: 24 Jun 1997

Last Updated on STN: 24 Jun 1997

L5 ANSWER 51 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 1996:321934 BIOSIS

DN PREV199699044290

TI Vascular endothelial growth factor administration in chronic myocardial ischemia.

AU Harada, Kazumasa; Friedman, Menachem; Lopez, John J.; Wang, Steven Y.; Li, Jian; Prasad, Pottumarthi V.; Pearlman, Justin D.; Edelman, Elazer R.; Sellke, Frank W.; Simons, Michael [Reprint author]

CS Cardiovasc. Div., Beth Israel Hosp., 330 Brookline Ave., Boston, MA 02115, USA

SO American Journal of Physiology, (1996) Vol. 270, No. 5 PART 2, pp. H1791-1802.

CODEN: AJPHAP. ISSN: 0002-9513.

DT Article

LA English

ED Entered STN: 11 Jul 1996

Last Updated on STN: 11 Jul 1996

L5 ANSWER 52 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

L5 ANSWER 54 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on  
STN

AN 1995:263157 BIOSIS

DN PREV199598277457

TI Regulation of vascular endothelial growth factor in cardiac myocytes.

AU Levy, Andrew P.; Levy, Nina S.; Loscalzo, Joseph; Calderone, Angelino;  
Takahashi, Nobuyuki; Yeo, Kiang-Teck; Koren, Gideon; Colucci, Wilson S.;  
Goldberg, Mark A. [Reprint author]

CS Brigham and Women's Hosp., 221 Longwood Ave., Boston, MA 02115, USA

SO Circulation Research, (1995) Vol. 76, No. 5, pp. 758-766.

CODEN: CIRUAL. ISSN: 0009-7330.

DT Article

LA English

ED Entered STN: 26 Jun 1995

Last Updated on STN: 26 Jun 1995

L5 ANSWER 55 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on  
STN

AN 1995:8448 BIOSIS

DN PREV199598022748

TI Angiogenic therapy of acute myocardial infarction (AMI) by  
intrapericardial injection of basic fibroblast growth factor ( \*\*\*bFGF\*\*\*  
) and heparan sulfate (HS): An experimental study.

AU Uchida, Yasumi; Yanagisawa-Miwa, Atsuko; Ikuta, Makoto; Makamura,  
Fumitaka; Tomaru, Takanobu; Fujimori, Yoshiharu; Morita, Toshihiro

CS Second Dep. Internal Med., Univ. Tokyo, Tokyo, Japan

SO Circulation, (1994) Vol. 90, No. 4 PART 2, pp. I296.

Meeting Info.: 67th Scientific Sessions of the American Heart Association.  
Dallas, Texas, USA. November 14-17, 1994.

CODEN: CIRCAZ. ISSN: 0009-7322.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 5 Jan 1995

Last Updated on STN: 23 Feb 1995

L5 ANSWER 58 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN  
 AN 2000:32044206 BIOTECHNO  
 TI Gene therapy for \*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\* .  
 Perspectives and limitations of the therapeutic induction of a collateral  
 circulation  
 GENTHERAPIE BEI KORONARER HERZKRANKHEIT: MOGLICHKEITEN UND GRENZEN EINER  
 THERAPEUTISCHEN INDUKTION VON KOLLATERALEN  
 AU Waltenberger J.  
 CS Dr. J. Waltenberger, Universitätsklinikum Ulm, Robert-Koch-Strasse 8,  
 D-89081 Ulm, Germany.  
 E-mail: johannes.waltenberger@medizin.uni-ulm.de  
 SO Hamostaseologie, ( \*\*\*2000\*\*\* ), 20/4 (162-166), 24 reference(s)  
 CODEN: HAEMD2 ISSN: 0720-9355  
 DT Journal; Conference Article  
 CY Germany, Federal Republic of  
 LA German  
 SL English; German

L5 ANSWER 59 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN  
 AN 2000:30812493 BIOTECHNO  
 TI Neoangiogenesis by local gene therapy: A new therapeutic approach in the  
 treatment of \*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\*  
 NEOANGIOGENESE DURCH LOKALE GENTHERAPIE: EIN NEUES THERAPEUTISCHES  
 KONZEPT IN DER BEHANDLUNG DER KORONAREN HERZKRANKHEIT  
 AU Schumacher B.; Hannekum A.; Pecher P.  
 CS Dr. B. Schumacher, Universitätsklinik Ulm, Abt. Chirurgie IV,  
 Herzchirurgie, Steinhovelstr. 9, D-89075 Ulm, Germany.  
 SO Zeitschrift fur Kardiologie, ( \*\*\*2000\*\*\* ), 89/SUPPL. 7 (VII23-VII30),  
 29 reference(s)  
 CODEN: ZKRDAX ISSN: 0300-5860  
 DT Journal; Article  
 CY Germany, Federal Republic of  
 LA German  
 SL English; German

Symes J.F.

CS Dr. J.F. Symes, Division of Cardiothoracic Surgery, St. Elizabeth's  
Medical Center, MOB 306, 11 Nevins St, Boston, MA 02135, United States.  
E-mail: jsymes@semc.org

SO Annals of Thoracic Surgery, ( \*\*\*2000\*\*\* ), 70/3 (829-834), 20  
reference(s)

CODEN: ATHSAK ISSN: 0003-4975

PUI S0003497500016337

DT Journal; Article

CY United States

LA English

SL English

L5 ANSWER 63 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN  
AN 2000:30644583 BIOTECHNO

TI Gene therapy in cardiovascular diseases  
GENTHERAPIE BEI KARDIOVASKULAREN ERKRANKUNGEN

AU Stegmann Th.J.; Hoppert Th.

CS Dr. Th.J. Stegmann, Klinik Thorax Herz-/Gefasschirurgie, Klinikum Fulda,  
Pacelliallee 4, D-36043 Fulda, Germany.  
E-mail: heart.stegmann@klinikum-fulda.de

SO Journal fur Kardiologie, ( \*\*\*2000\*\*\* ), 7/7-8 (292-295), 30  
reference(s)

CODEN: JKARFN ISSN: 1024-0098

DT Journal; (Short Survey)

CY Austria

LA German

SL English; German

L5 ANSWER 64 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN  
AN 2000:30210343 BIOTECHNO

TI Angiogenesis and arteriogenesis - Not yet for prescription

AU Helisch A.; Schaper W.

CS Dr. A. Helisch, Abt. fur Experimentelle Kardiologie, Max-Planck-Inst. fur  
Physiologische, Klinische Forschung, Benekestr. 2, D-61231 Bad Nauheim,  
Germany.

SO Microvascular Research, ( \*\*\*1999\*\*\* ), 58/3 (238-249), 28 reference(s)  
 CODEN: MIVRA6 ISSN: 0026-2862

DT Journal; Article

CY United States

LA English

SL English

L5 ANSWER 67 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN  
 AN 1999:29526847 BIOTECHNO  
 TI Gene therapy with vascular endothelial growth factor for inoperable  
 \*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\*

AU Symes J.F.; Losordo D.W.; Vale P.R.; Lathi K.G.; Esakof D.D.; Mayskiy M.;  
 Isner J.M.; Schaff H.V.; Atkinson A.W.; Vincent C.K.; Pham S.M.;  
 Stanbridge R.D.L.; Horowitz S.; Thomas N.J.

CS Dr. J.F. Symes, 11 Nevins St/306, Boston, MA 02135, United States.  
 E-mail: jsymes@semc.org

SO Annals of Thoracic Surgery, ( \*\*\*1999\*\*\* ), 68/3 (830-837), 21  
 reference(s)  
 CODEN: ATHSAK ISSN: 0003-4975

PUI S0003497599008073

DT Journal; Conference Article

CY United States

LA English

SL English

L5 ANSWER 68 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN  
 AN 1999:29411709 BIOTECHNO  
 TI Role of vascular endothelial growth factor in the regulation of  
 angiogenesis

AU Ferrara N.

CS Dr. N. Ferrara, Dept. of Cardiovascular Research, Genentech Inc., 1 DNA  
 Way, South San Francisco, CA 94080, United States.  
 E-mail: nf@gene.com

SO Kidney International, ( \*\*\*1999\*\*\* ), 56/3 (794-814), 285 reference(s)  
 CODEN: KDYIA5 ISSN: 0085-2538

DT Journal; General Review

gene therapy with adeno- \*\*\*VEGF\*\*\*

AU Rivard A.; Silver M.; Chen D.; Kearney M.; Magner M.; Annex B.; Peters K.; Isner J.M.

CS Dr. J.M. Isner, St. Elizabeth's Medical Center, 736 Cambridge Street, Boston, MA 02135, United States.

E-mail: jisner@opal.tufts.edu

SO American Journal of Pathology, ( \*\*\*1999\*\*\* ), 154/2 (355-363), 50 reference(s)

CODEN: AJPAA4 ISSN: 0002-9440

DT Journal; Article

CY United States

LA English

SL English

L5 ANSWER 72 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN  
AN 1998:29003959 BIOTECHNO

TI Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF.sub.1.sub.6.sub.5 as sole therapy for myocardial ischemia

AU Losordo D.W.; Vale P.R.; Symes J.F.; Dunnington C.H.; Esakof D.D.; Maysky M.; Ashare A.B.; Lathi K.; Isner J.M.

CS Dr. J.M. Isner, St. Elizabeth's Medical Center, 736 Cambridge St., Boston, MA 02135, United States.

SO Circulation, \*(29 DEC 1998)\* , 98/25 (2800-2804), 19 reference(s)  
CODEN: CIRCAZ ISSN: 0009-7322

DT Journal; Article

CY United States

LA English

SL English

L5 ANSWER 73 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN  
AN 1998:28510806 BIOTECHNO

TI Basic fibroblast growth factor: A potential therapeutic agent for the treatment of acute neurodegenerative disorders and vascular insufficiency

AU Moyer J.A.; Wood A.; Zaleska M.M.; Ay I.; Finklestein S.P.; Protter A.A.

CS J.A. Moyer, CNS Disorders Division, Wyeth-Ayerst Research, CN 8000,

CODEN: MIVRA6 ISSN: 0026-2862

DT Journal; Article  
CY United States  
LA English

L5 ANSWER 76 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN  
AN 1997:27418032 BIOTECHNO  
TI Enhanced angiogenesis and unfavorable remodeling in injured porcine  
coronary artery lesions: Effects of local basic fibroblast growth factor  
delivery  
AU Staab M.E.; Simari R.D.; Srivatsa S.S.; Hasdai D.; Pompili V.J.; Holmes  
D.R. Jr.; Schwartz R.S.  
CS Dr. R.S. Schwartz, Division of Cardiovascular Diseases, Mayo Clinic,  
Rochester, MN 55905, United States.  
SO Angiology, ( \*\*\*1997\*\*\* ), 48/9 (753-760), 29 reference(s)  
CODEN: ANGIAB ISSN: 0003-3197

DT Journal; Article  
CY United States  
LA English  
SL English

L5 ANSWER 77 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN  
AN 1996:26349307 BIOTECHNO  
TI Reduction in myocardial infarct size by basic fibroblast growth factor  
after temporary coronary occlusion in a canine model  
AU Horrigan M.C.G.; MacIsaac A.I.; Nicolini F.A.; Vince D.G.; Lee P.; Ellis  
S.G.; Topol E.J.  
CS Department of Cardiology (F-25), Cleveland Clinic Foundation, 9500 Euclid  
Ave, Cleveland, OH 44195, United States.  
SO Circulation, ( \*\*\*1996\*\*\* ), 94/8 (1927-1933)  
CODEN: CIRCAZ ISSN: 0009-7322

DT Journal; Article  
CY United States  
LA English  
SL English



DN 20550038 PubMed ID: 11098556  
 TI [Neoangiogenesis by local gene therapy: a new therapeutic concept in the  
 treatment of coronary disease].  
 Neoangiogenese durch lokale Genthherapie: Ein neues therapeutisches Konzept  
 in der Behandlung der koronaren Herzkrankheit.  
 AU Schumacher B; Hannekum A; Pecher P  
 CS Universitätsklinik Ulm, Abt. Chirurgie IV Herzchirurgie.  
 SO ZEITSCHRIFT FUR KARDIOLOGIE, \*\*\* (2000) \*\*\* 89 Suppl 7 23-30.  
 Journal code: 0360430. ISSN: 0300-5860.  
 CY GERMANY: Germany, Federal Republic of  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LA German  
 FS MEDLINE; Priority Journals  
 OS MEDLINE 2001057653  
 EM 200012  
 ED Entered STN: 20010423  
 Last Updated on STN: 20010423  
  
 L5 ANSWER 81 OF 549 CANCERLIT on STN  
 AN 2000151124 CANCERLIT  
 DN 20151124 PubMed ID: 10688416  
 TI Angiogenesis for the treatment of vascular diseases.  
 AU Chawla P S; Keelan M H; Kipshidze N  
 SO INTERNATIONAL ANGIOLOGY, \*\*\* (1999 Sep) \*\*\* 18 (3) 185-92. Ref: 66  
 Journal code: 8402693. ISSN: 0392-9590. --  
 CY Italy  
 DT Editorial  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS MEDLINE; Priority Journals  
 OS MEDLINE 2000151124  
 EM 200004  
 ED Entered STN: 20000515

L5 ANSWER 84 OF 549 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:175692 CAPLUS

DN 132:227446

TI Angiogenically effective unit dose of fibroblast growth factor-2 and  
method of use

IN Whitehouse, Martha Jo

PA Chiron Corporation, USA

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2000013701	A2	20000316	WO 1999-US19770	19990827 <--
	WO 2000013701	A3	20000803		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9960223	A1	20000327	AU 1999-60223	19990827 <--
	EP 1121142	A2	20010808	EP 1999-968630	19990827
	EP 1121142	B1	20041020		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002524420	T2	20020806	JP 2000-568509	19990827
	AT 279937	E	20041115	AT 1999-968630	19990827
	US 2002165160	A1	20021107	US 2002-131965	20020425
PRAI	US 1998-145743P	P	19980903		
	US 1998-104102P	P	19981013		

AN 1999:641878 CAPLUS  
 DN 131:252631  
 TI Angiogenesis in cardiovascular disease: current status and therapeutic potential  
 AU Sellke, Frank W.; Simons, Michael  
 CS Beth Israel Deaconess Medical Center, Division of Cardiothoracic Surgery and Cardiovascular Division, Harvard Medical School, Boston, MA, USA  
 SO Drugs ( \*\*\*1999\*\*\* ), 58(3), 391-396  
 CODEN: DRUGAY; ISSN: 0012-6667  
 PB Adis International Ltd.  
 DT Journal; General Review  
 LA English  
 RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 88 OF 549 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1999:48639 CAPLUS  
 DN 130:76613  
 TI Novel composition for treating, preventing and/or delaying ischemic cell death using proteins having the function of \*\*\*\*aFGF\*\*\* or activators of stress-activated protein kinases  
 IN Schaper, Wolfgang; Htun, Patrik  
 PA Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V., Germany  
 SO PCT Int. Appl., 51 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9901150	A1	19990114	WO 1998-EP4134	19980703 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HR, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

L5 ANSWER 91 OF 549 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:804532 CAPLUS

DN 123:276007

TI Method for treating diseases mediated by cellular proliferation in  
response to PDGF, EGF, FGF and \*\*\*VEGF\*\*\*

IN Brown, Paul A.; Bursten, Stuart L.; Rice, Glenn C.; Singer, Jack W.

PA Cell Therapeutics, Inc., USA

SO PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9519171	A1	19950720	WO 1995-US520	19950113 <--
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2192470	AA	19950720	CA 1995-2192470	19950113 <--
	AU 9518313	A1	19950801	AU 1995-18313	19950113 <--
	EP 739203	A1	19961030	EP 1995-910088	19950113 <--
	R: AT, DE, ES, FR, GB, IE, IT				
	US 5795898	A	19980818	US 1995-485325	19950607 <--
	US 5859018	A	19990112	US 1995-485322	19950607 <--
	US 5929081	A	19990727	US 1995-485320	19950607 <--
PRAI	US 1994-181947	A	19940114		
	WO 1995-US520	W	19950113		
OS	MARPAT 123:276007				

L5 ANSWER 92 OF 549 CEABA-VTB COPYRIGHT 2005 DECHEMA on STN

AN 1999(06):4967 CEABA-VTB FS B

DN CEABA: 1999:3174891

TI Blood vessel growth factor genes seen as aid for failing hearts

CS St Elizabeth s Medical Center, Cambridge, MA, USA

SO Biotechnol. Newswatch ( \*\*\*1999\*\*\* ), p.4

ISSN: 0275-3685

TI The bottleneck at Vascular Genetics  
 SO BioCentury, 6 Mar 2000 (20000306), 8(11), p. A8. ISSN: 1097-7201; CODEN:  
 BICEFS.  
 LA English

L5 ANSWER 98 OF 549 CIN COPYRIGHT 2005 ACS on STN  
 AN 29(3):2019K CIN  
 TI ACE inhibitor promotes angiogenesis in rabbits  
 SO Emerging Pharm., Aug 1999 (19990800), 8(8), p. 7. ISSN: 1061-6098; CODEN:  
 EMPHFR.  
 LA English

L5 ANSWER 99 OF 549 CIN COPYRIGHT 2005 ACS on STN  
 AN 28(34):34201J CIN  
 TI Clinical results  
 SO BioCentury, 9 Aug 1999 (19990809), 7(48, Pt. 2), p. B8. ISSN: 1097-7201;  
 CODEN: BICEFS.  
 LA English

L5 ANSWER 100 OF 549 CIN COPYRIGHT 2005 ACS on STN  
 AN 28(27):27212K CIN  
 TI Clinical status  
 SO BioCentury, 21 Jun 1999 (19990621), 7(37, Pt. 2), p. B14. ISSN:  
 1097-7201; CODEN: BICEFS.  
 LA English

L5 ANSWER 101 OF 549 CIN COPYRIGHT 2005 ACS on STN  
 AN 28(13):12771T CIN  
 TI Clinical results  
 SO BioCentury, 15 Mar 1999 (19990315), 7(18, Pt. 2), p. B7-B8. ISSN:  
 1097-7201; CODEN: BICEFS.  
 LA English

L5 ANSWER 102 OF 549 CIN COPYRIGHT 2005 ACS on STN  
 AN 28(10):9559Z CIN  
 TI Clinical results

CODEN: BICEFS.

LA English

L5 ANSWER 108 OF 549 CIN COPYRIGHT 2005 ACS on STN

AN 27(4):3316A CIN

TI Clinical status

SO BioCentury, 5 Jan 1998 (19980105), 6(1, Pt. 2), p. B7. CODEN: BICEFS.

LA English

L5 ANSWER 109 OF 549 CIN COPYRIGHT 2005 ACS on STN

AN 26(23):25804Q CIN

TI Companies aim novel therapeutic strategies at dual nature of angiogenesis

SO Genet. Eng. News, 1 May 1997 (970501), 17(9), p. 6, 33. ISSN: 0270-6377;

CODEN: GENNDX.

LA English

L5 ANSWER 110 OF 549 CIN COPYRIGHT 2005 ACS on STN

AN 26(15):17282C CIN

TI Angiogenic factors put to the test in bypassing blocked arteries

SO Biotechnol. News, 27 Mar 1997 (970327), 17(8), p. 7. ISSN: 0273-3226;

CODEN: BINWEY.

LA English

L5 ANSWER 111 OF 549 CIN COPYRIGHT 2005 ACS on STN

AN 25(51):55796K CIN

TI Scios/Wyeth-Ayerst sign fibblast deal

SO Biotechnol. Bus. News, 13 Nov 1996 (961113), 6(137), p. 9. ISSN:

0965-9595; CODEN: BBUNER.

LA English

L5 ANSWER 112 OF 549 CIN COPYRIGHT 2005 ACS on STN

AN 25(28):30596G CIN

TI Scios to patent method of producing human basic fibroblast growth factor

SO Biotech Pat. News, May 1996 (960500), 10(5), p. 5-6. ISSN: 0898-2813;

CODEN: BPANEP.

LA English

LA English  
OS 2001-025162 [03]  
CR N-PSDB: AAC90481  
DESC Human VEGF206.

L5 ANSWER 116 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN  
AN AAB50434 Protein DGENE  
TI Enhancing biological activity of vascular endothelial growth factor by  
replacing a Cys residue, for producing variant useful for treating  
hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis,  
tumor, pneumonia, infections -

IN Pollitt N S; Abraham J A  
PA (SCIO-N) SCIOS INC.

PI \*\*\*WO 2000071713 A1 20001130 62\*\*\*

AI WO 2000-US13536 20000518

PRAI US 1999-135312 19990520

DT Patent

LA English

OS 2001-025162 [03]

CR N-PSDB: AAC90480

DESC Human VEGF189.

L5 ANSWER 117 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN  
AN AAB50433 Protein DGENE  
TI Enhancing biological activity of vascular endothelial growth factor by  
replacing a Cys residue, for producing variant useful for treating  
hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis,  
tumor, pneumonia, infections -

IN Pollitt N S; Abraham J A

PA (SCIO-N) SCIOS INC.

PI \*\*\*WO 2000071713 A1 20001130 62\*\*\*

AI WO 2000-US13536 20000518

PRAI US 1999-135312 19990520

DT Patent

LA English

OS 2001-025162 [03]

L5 ANSWER 120 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN  
 AN AAB50428 Protein DGENE  
 TI Vascular endothelial growth factor dimer, useful for treating essential  
 hypertension, polycystic kidney diseases, microvascular angiopathy and  
 \*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\* , comprising two  
 monomeric subunits -  
 IN Jue R A; Schellenberger U; Stathis P A; Adriaenssens P I; Abraham J A;  
 Baldwin P A; Pollitt N S  
 PA (SCIO-N) SCIOS INC.  
 PI \*\*\*WO 2000071716 A2 20001130 61\*\*\*  
 AI WO 2000-US13636 20000518  
 PRAI US 1999-135312 19990520  
 US 2000-177407 20000120  
 DT Patent  
 LA English  
 OS 2001-041064 [05]  
 CR N-PSDB: AAC90473  
 DESC Mature human vascular endothelial growth factor polypeptide.

L5 ANSWER 121 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN  
 AN AAB50427 Protein DGENE  
 TI Vascular endothelial growth factor dimer, useful for treating essential  
 hypertension, polycystic kidney diseases, microvascular angiopathy and  
 \*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\* , comprising two  
 monomeric subunits -  
 IN Jue R A; Schellenberger U; Stathis P A; Adriaenssens P I; Abraham J A;  
 Baldwin P A; Pollitt N S  
 PA (SCIO-N) SCIOS INC.  
 PI \*\*\*WO 2000071716 A2 20001130 61\*\*\*  
 AI WO 2000-US13636 20000518  
 PRAI US 1999-135312 19990520  
 US 2000-177407 20000120  
 DT Patent  
 LA English  
 OS 2001-041064 [05]



DESC Recombinant bovine \*\*\*FGF\*\*\* - \*\*\*2\*\*\* protein sequence.

L5 ANSWER 124 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN

AN AAY92777 Protein DGENE

TI Viral vascular endothelial growth factor-like proteins useful for stimulating cell proliferation, modulating vascular permeability while antagonists of the proteins are useful for treating pustular dermatitis

IN Wise L M; Mercer A A; Savory L J; Fleming S B; Stacker S A

PA (LUDW-N) LUDWIG INST CANCER RES.

(UYOT-N) UNIV OTAGO.

PI \*\*\*WO 2000025805 A1 20000511 76\*\*\*

AI WO 1999-US25869 19991102

PRAI US 1998-106689 19981102

US 1998-106800 19981103

DT Patent

LA English

OS 2000-365394 [31]

DESC PDGF/ \*\*\*VEGF\*\*\* family characteristic motif.

L5 ANSWER 125 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN

AN AAY92776 Protein DGENE

TI Viral vascular endothelial growth factor-like proteins useful for stimulating cell proliferation, modulating vascular permeability while antagonists of the proteins are useful for treating pustular dermatitis

IN Wise L M; Mercer A A; Savory L J; Fleming S B; Stacker S A

PA (LUDW-N) LUDWIG INST CANCER RES.

(UYOT-N) UNIV OTAGO.

PI \*\*\*WO 2000025805 A1 20000511 76\*\*\*

AI WO 1999-US25869 19991102

PRAI US 1998-106689 19981102

US 1998-106800 19981103

DT Patent

LA English

OS 2000-365394 [31]

DESC Orf virus strain NZ10 vascular endothelial growth factor-like protein.

AN AAY87848 protein DGENE

TI Novel unit dose comprising fibroblast growth factor, its angiogenically active fragment or mutein for inducing cardiac angiogenesis, treating \*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\* and reducing post myocardial infarction injury -

IN Kavanaugh W M

PA (CHIR) CHIRON CORP.  
(WHIT-I) WHITEHOUSE M J.

PI \*\*\*WO 2000021548 A2 20000420 67\*\*\*

AI WO 1999-US22936 19991013

PRAI US 1998-104103 19981013

DT Patent

LA English

OS 2000-317840 [27]

CR N-PSDB: AAA39555

DESC Bovine \*\*\*FGF\*\*\* - \*\*\*2\*\*\* protein.

L5 ANSWER 129 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN

AN AAY87847 protein DGENE

TI Novel unit dose comprising fibroblast growth factor, its angiogenically active fragment or mutein for inducing cardiac angiogenesis, treating \*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\* and reducing post myocardial infarction injury -

IN Kavanaugh W M

PA (CHIR) CHIRON CORP.  
(WHIT-I) WHITEHOUSE M J.

PI \*\*\*WO 2000021548 A2 20000420 67\*\*\*

AI WO 1999-US22936 19991013

PRAI US 1998-104103 19981013

DT Patent

LA English

OS 2000-317840 [27]

DESC Human \*\*\*FGF\*\*\* - \*\*\*2\*\*\* protein.

L5 ANSWER 130 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN

AN AAY87846 protein DGENE

or intestinal disorders

IN Achen M G; Alitalo K; Stacker S A; Wilks A F

PA (LUDW-N) LUDWIG INST CANCER RES.

(UYHE-N) UNIV HELSINKI LICENSING LTD.

PI \*\*\*WO 9807832 A1 19980226 101\*\*\*

AI WO 1997-US14696 19970821

PRAI US 1997-51426 19970701

AU 1996-1825 19960823

US 1996-23751 19960823

AU 1996-3554 19961111

US 1996-31097 19961114

AU 1997-4954 19970205

US 1997-38814 19970210

AU 1997-7435 19970619

DT Patent

LA English

OS 1998-179057 [16]

DESC Homo sapiens vascular endothelial growth factor D ( \*\*\*VEGF\*\*\* -D)  
peptide.

L5 ANSWER 133 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN

AN AAW53243 Protein DGENE

TI New isolated vascular endothelial growth factor-D - used to develop  
products for use in e.g. modifying angiogenesis or treating lung, heart  
or intestinal disorders

IN Achen M G; Alitalo K; Stacker S A; Wilks A F

PA (LUDW-N) LUDWIG INST CANCER RES.

(UYHE-N) UNIV HELSINKI LICENSING LTD.

PI \*\*\*WO 9807832 A1 19980226 101\*\*\*

AI WO 1997-US14696 19970821

PRAI US 1997-51426 19970701

AU 1996-1825 19960823

US 1996-23751 19960823

AU 1996-3554 19961111

US 1996-31097 19961114

AU 1997-4954 19970205

or intestinal disorders

IN Achen M G; Alitalo K; Stacker S A; Wilks A F

PA (LUDW-N) LUDWIG INST CANCER RES.

(UYHE-N) UNIV HELSINKI LICENSING LTD.

PI \*\*\*WO 9807832 A1 19980226 101\*\*\*

AI WO 1997-US14696 19970821

PRAI US 1997-51426 19970701

AU 1996-1825 19960823

US 1996-23751 19960823

AU 1996-3554 19961111

US 1996-31097 19961114

AU 1997-4954 19970205

US 1997-38814 19970210

AU 1997-7435 19970619

DT Patent

LA English

OS 1998-179057 [16]

CR N-PSDB: AAV20807

DESC Homo sapiens vascular endothelial growth factor D ( \*\*\*VEGF\*\*\* -D).

L5 ANSWER 136 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN

AN AAW53240 Protein DGENE

TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders

IN Achen M G; Alitalo K; Stacker S A; Wilks A F

PA (LUDW-N) LUDWIG INST CANCER RES.

(UYHE-N) UNIV HELSINKI LICENSING LTD.

PI \*\*\*WO 9807832 A1 19980226 101\*\*\*

AI WO 1997-US14696 19970821

PRAI US 1997-51426 19970701

AU 1996-1825 19960823

US 1996-23751 19960823

AU 1996-3554 19961111

US 1996-31097 19961114

AU 1997-4954 19970205

LA English  
OS 2001-025162 [03]  
DESC Human VEGF121 gene mutagenic forward primer oligo 1612.

L5 ANSWER 139 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN  
AN AAC90481 DNA DGENE  
TI Enhancing biological activity of vascular endothelial growth factor by  
replacing a Cys residue, for producing variant useful for treating  
hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis,  
tumor, pneumonia, infections -  
IN Pollitt N S; Abraham J A  
PA (SCIO-N) SCIOS INC.  
PI \*\*\*WO 2000071713 A1 20001130 62\*\*\*  
AI WO 2000-US13536 20000518  
PRAI US 1999-135312 19990520  
DT Patent  
LA English  
OS 2001-025162 [03]  
CR P-PSDB: AAB50435  
DESC Human VEGF206 DNA.

L5 ANSWER 140 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN  
AN AAC90480 DNA DGENE  
TI Enhancing biological activity of vascular endothelial growth factor by  
replacing a Cys residue, for producing variant useful for treating  
hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis,  
tumor, pneumonia, infections -  
IN Pollitt N S; Abraham J A  
PA (SCIO-N) SCIOS INC.  
PI \*\*\*WO 2000071713 A1 20001130 62\*\*\*  
AI WO 2000-US13536 20000518  
PRAI US 1999-135312 19990520  
DT Patent  
LA English  
OS 2001-025162 [03]  
CR P-PSDB: AAB50434

L5 ANSWER 143 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN  
 AN AAC90477 DNA DGENE  
 TI Enhancing biological activity of vascular endothelial growth factor by  
 replacing a Cys residue, for producing variant useful for treating  
 hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis,  
 tumor, pneumonia, infections -  
 IN Pollitt N S; Abraham J A  
 PA (SCIO-N) SCIOS INC.  
 PI \*\*\*WO 2000071713 A1 20001130 62\*\*\*  
 AI WO 2000-US13536 20000518  
 PRAI US 1999-135312 19990520  
 DT Patent  
 LA English  
 OS 2001-025162 [03]  
 CR P-PSDB: AAB50431  
 DESC Human VEGF121 DNA.

L5 ANSWER 144 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN  
 AN AAC90473 cDNA DGENE  
 TI Vascular endothelial growth factor dimer, useful for treating essential  
 hypertension, polycystic kidney diseases, microvascular angiopathy and  
 \*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\* , comprising two  
 monomeric subunits -  
 IN Jue R A; Schellenberger U; Stathis P A; Adriaenssens P I; Abraham J A;  
 Baldwin P A; Pollitt N S  
 PA (SCIO-N) SCIOS INC.  
 PI \*\*\*WO 2000071716 A2 20001130 61\*\*\*  
 AI WO 2000-US13636 20000518  
 PRAI US 1999-135312 19990520  
 US 2000-177407 20000120  
 DT Patent  
 LA English  
 OS 2001-041064 [05]  
 CR P-PSDB: AAB50427; AAB50428  
 DESC Human vascular endothelial growth factor cDNA.

L5 ANSWER 147 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN  
 AN AAA28493 DNA DGENE  
 TI Viral vascular endothelial growth factor-like proteins useful for  
 stimulating cell proliferation, modulating vascular permeability while  
 antagonists of the proteins are useful for treating pustular dermatitis  
 IN Wise L M; Mercer A A; Savory L J; Fleming S B; Stacker S A  
 PA (LUDW-N) LUDWIG INST CANCER RES.  
 (UYOT-N) UNIV OTAGO.  
 PI \*\*\*WO 2000025805 A1 20000511 76\*\*\*  
 AI WO 1999-US25869 19991102  
 PRAI US 1998-106689 19981102  
 US 1998-106800 19981103  
 DT Patent  
 LA English  
 OS 2000-365394 [31]  
 CR P-PSDB: AAY92775  
 DESC ORFV2- \*\*\*VEGF\*\*\* coding sequence.

L5 ANSWER 148 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN  
 AN AAA39555 DNA DGENE  
 TI Novel unit dose comprising fibroblast growth factor, its angiogenically  
 active fragment or mutein for inducing cardiac angiogenesis, treating  
 \*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\* and reducing post  
 myocardial infarction injury -  
 IN Kavanaugh W M  
 PA (CHIR) CHIRON CORP.  
 (WHIT-I) WHITEHOUSE M J.  
 PI \*\*\*WO 2000021548 A2 20000420 67\*\*\*  
 AI WO 1999-US22936 19991013  
 PRAI US 1998-104103 19981013  
 DT Patent  
 LA English  
 OS 2000-317840 [27]  
 CR P-PSDB: AAY87848  
 DESC Bovine \*\*\*FGF\*\*\* - \*\*\*2\*\*\* DNA fragment.

	AU 1996-3554	19961111	
	US 1996-31097	19961114	
	AU 1997-4954	19970205	
	US 1997-38814	19970210	
	AU 1997-7435	19970619	
DT	Patent		
LA	English		
OS	1998-179057 [16]		
DESC	Homo sapiens ***VEGF*** -D gene PCR primer.		
L5	ANSWER 151 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN		
AN	AAV20809 cDNA DGENE		
TI	New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders		
IN	Achen M G; Alitalo K; Stacker S A; Wilks A F		
PA	(LUDW-N) LUDWIG INST CANCER RES.		
	(UYHE-N) UNIV HELSINKI LICENSING LTD.		
PI	***WO 9807832	A1 19980226	101***
AI	WO 1997-US14696	19970821	
PRAI	US 1997-51426	19970701	
	AU 1996-1825	19960823	
	US 1996-23751	19960823	
	AU 1996-3554	19961111	
	US 1996-31097	19961114	
	AU 1997-4954	19970205	
	US 1997-38814	19970210	
	AU 1997-7435	19970619	
DT	Patent		
LA	English		
OS	1998-179057 [16]		
CR	P-PSDB: AAW53243		
DESC	Mus musculus vascular endothelial growth factor D2 ( ***VEGF*** -D2) gene.		
L5	ANSWER 152 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN		



	US 1996-23751	19960823	
	AU 1996-3554	19961111	
	US 1996-31097	19961114	
	AU 1997-4954	19970205	
	US 1997-38814	19970210	
	AU 1997-7435	19970619	
DT	Patent		
LA	English		
OS	1998-179057 [16]		
CR	P-PSDB: AAW53241		
DESC	Homo sapiens vascular endothelial growth factor D ( ***VEGF*** -D) gene.		
L5	ANSWER 154 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN		
AN	AAV20806 cDNA DGENE		
TI	New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders		
IN	Achen M G; Alitalo K; Stacker S A; Wilks A F		
PA	(LUDW-N) LUDWIG INST CANCER RES. (UYHE-N) UNIV HELSINKI LICENSING LTD.		
PI	***WO 9807832	A1 19980226	101***
AI	WO 1997-US14696	19970821	
PRAI	US 1997-51426	19970701	
	AU 1996-1825	19960823	
	US 1996-23751	19960823	
	AU 1996-3554	19961111	
	US 1996-31097	19961114	
	AU 1997-4954	19970205	
	US 1997-38814	19970210	
	AU 1997-7435	19970619	
DT	Patent		
LA	English		
OS	1998-179057 [16]		
CR	P-PSDB: AAW53240		
DESC	Homo sapiens vascular endothelial growth factor D ( ***VEGF*** -D)		

of a patient

IN Hammond H K; Kelly T L

PA (REGC) UNIV CALIFORNIA.

PI \*\*\*WO 9850079 A2 19981112 87\*\*\*

AI WO 1998-US8848 19980430

PRAI US 1997-852779 19970506

DT Patent

LA English

OS 1998-610127 [51]

DESC PCR primer for \*\*\*FGF\*\*\* - \*\*\*1\*\*\* coding sequence.

L5 ANSWER 158 OF 549 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2000-41526 DRUGU T P B

TI Atorvastatin therapy reduces vascular endothelial growth factor (  
\*\*\*VEGF\*\*\* ) in patients with \*\*\*coronary\*\*\* \*\*\*artery\*\*\*  
\*\*\*disease\*\*\* .

AU Alber H; Dulak J; Schwarzacher S; Pachinger O; Weidinger F

CS Univ.Innsbruck; Univ.Jagiellonian

LO Innsbruck, Austria; Cracow, Pol.

SO Atherosclerosis (151, No. 1, 191, 2000)

CODEN: ATHSBL ISSN: 0021-9150

AV Department of Cardiology, University of Innsbruck, Austria.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L5 ANSWER 159 OF 549 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2000-32505 DRUGU T

TI Phase II, multicenter, double-blind, placebo-controlled, dose-finding  
study for safety, pharmacokinetics, and efficacy of recombinant  
fibroblast growth factor (rFGF-2) in subjects with \*\*\*coronary\*\*\*  
\*\*\*artery\*\*\* \*\*\*disease\*\*\* (CAD): \*\*\*FGF\*\*\* - \*\*\*2\*\*\*  
initiating revascularization support trial (FIRST).

AU Simons M

LO Boston, Mass., USA

LA English  
DT Journal  
FA AB; LA; CT  
FS Literature

L5 ANSWER 162 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS  
RESERVED. on STN  
AN 2001350870 EMBASE  
TI Fate of latissimus dorsi muscle flap in cardiomyoplasty and availability  
of omental flap.  
AU Okada M.; Tsukube T.; Hariu T.; Ootaki Y.; Okita Y.  
CS Dr. M. Okada, 1-1-39-103 Sumiyoshihonomachi, Higashinada-ku, Kobe 658-0051,  
Japan  
SO Journal of Congestive Heart Failure and Circulatory Support, (2000) Vol.  
1, No. 4, pp. 285-289.  
Refs: 8  
ISSN: 1468-3768 CODEN: JCHFAT  
CY United Kingdom  
DT Journal; Conference Article  
FS 018 Cardiovascular Diseases and Cardiovascular Surgery  
029 Clinical Biochemistry  
027 Biophysics, Bioengineering and Medical Instrumentation  
LA English  
SL English  
ED Entered STN: 20011018  
Last Updated on STN: 20011018

L5 ANSWER 163 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS  
RESERVED. on STN  
AN 2001018068 EMBASE  
TI [Clinical results of the treatment of \*\*\*coronary\*\*\* \*\*\*artery\*\*\*  
\*\*\*disease\*\*\* with growth factors].  
KLINISCHE ERGEBNISSE DER BEHANDLUNG DER KORONAREN HERZKRANKHEIT MIT  
WACHSTUMSTAKTOREN.  
AU Hoppert Th.; Ibing R.; Schneider A.; Popp M.; Stegmann Th.J.  
CS Dr. Th. Hoppert, Klin. fur Thorax-, Herz/Gefasschir., Klinikum Fulda,

L5 ANSWER 165 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS  
RESERVED. on STN

AN 1999285095 EMBASE

TI Mechanical endothelial damage results in basic fibroblast growth factor-  
mediated activation of extracellular signal-regulated kinases.

AU Pintucci G.; Steinberg B.M.; Seghezzi G.; Yun J.; Apazidis A.; Baumann  
F.G.; Grossi E.A.; Colvin S.B.; Mignatti P.; Galloway A.C.

CS Dr. B.M. Steinberg, NYU Medical Center, 530 First Ave, New York, NY 10016,  
United States

SO Surgery, (1999) Vol. 126, No. 2, pp. 422-427.  
Refs: 21  
ISSN: 0039-6060 CODEN: SURGAZ

CY United States

DT Journal; Article

FS 018 Cardiovascular Diseases and Cardiovascular Surgery  
026 Immunology, Serology and Transplantation

LA English

SL English

ED Entered STN: 19990826  
Last Updated on STN: 19990826

L5 ANSWER 166 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS  
RESERVED. on STN

AN 1999282282 EMBASE

TI Gene therapy for myocardial angiogenesis.

AU Losordo D.W.; Vale P.R.; Isner J.M.

CS Dr. D.W. Losordo, Department of Medicine, Division of Cardiovascular  
Research, St Elizabeth's Medical Center, 736 Cambridge St, Boston, MA  
02135, United States

SO American Heart Journal, (1999) Vol. 138, No. 2 II, pp. S132-S141.  
Refs: 47  
ISSN: 0002-8703 CODEN: AHJOA2

CY United States

DT Journal; General Review

FS 018 Cardiovascular Diseases and Cardiovascular Surgery

SO Clinical Cardiology, (1999) Vol. 22, No. 1 SUPPL., pp. I10-I16.

Refs: 24

ISSN: 0160-9289 CODEN: CLCADC

CY United States

DT Journal; Conference Article

FS 018 Cardiovascular Diseases and Cardiovascular Surgery

037 Drug Literature Index

039 Pharmacy

LA English

SL English

ED Entered STN: 19990225

Last Updated on STN: 19990225

L5 ANSWER 169 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS  
RESERVED. on STN

AN 1998372756 EMBASE

TI Fibroblast growth factor-mediated angiogenesis for the treatment of  
ischemia. Lessons learned from experimental models and early human  
experience.

AU Goncalves L.M.

CS L.M. Goncalves, Cardiology Branch, National Heart, Lung/Blood Institute,  
National Institutes of Health, 10 Center Drive, Bethesda, MD 20892-1518,  
United States. goncalvl@gwgate.nhlbi.nih.gov

SO Revista Portuguesa de Cardiologia, (1998) Vol. 17, No. SUPPL. 2, pp.  
11-20.

Refs: 103

ISSN: 0304-4750 CODEN: RPCADZ

CY Portugal

DT Journal; General Review

FS 018 Cardiovascular Diseases and Cardiovascular Surgery

030 Pharmacology

037 Drug Literature Index

052 Toxicology

LA English

SL English; Portuguese

ED Entered STN: 19981130

CY United States  
 DT Journal; Article  
 FS 005 General Pathology and Pathological Anatomy  
 018 Cardiovascular Diseases and Cardiovascular Surgery  
 LA English  
 SL English  
 ED Entered STN: 960708  
 Last Updated on STN: 960708

L5 ANSWER 172 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS  
 RESERVED. on STN  
 AN 96035325 EMBASE  
 DN 1996035325  
 TI Antithrombin determinants of \*\*\*coronary\*\*\* \*\*\*artery\*\*\*  
 \*\*\*disease\*\*\* in transplanted human hearts.  
 AU Labarrere C.A.; Faulk W.P.  
 CS Division of Experimental Pathology, Reprod./Transplant. Immunology Ctr.,  
 Methodist Hospital, 1701 N Senate Blvd, Indianapolis, IN 46202, United  
 States  
 SO Seminars in Hematology, (1995) Vol. 32, No. 4 SUPPL. 2, pp. 61-66.  
 ISSN: 0037-1963 CODEN: SEHEA3  
 CY United States  
 DT Journal; Conference Article  
 FS 009 Surgery  
 018 Cardiovascular Diseases and Cardiovascular Surgery  
 025 Hematology  
 LA English  
 SL English  
 ED Entered STN: 960212  
 Last Updated on STN: 960212

L5 ANSWER 173 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS  
 RESERVED. on STN  
 AN 91230395 EMBASE  
 DN 1991230395  
 TI Coronary atherosclerosis: Current therapeutic approaches and future

RESPONSE TO PDGF, EGF, FGF, AND \*\*\*VEGF\*\*\* ; ANTIARTHRITIC AGENTS;  
ANTITUMOR AGENTS; CARDIOVASCULAR DISORDERS

IN Brown Paul A; Bursten Stuart L; Rice Glenn C; Singer Jack W  
PA Cell Therapeutics Inc (32953)  
PI US 5859018 A 19990112 (CITED IN 003 LATER PATENTS)  
AI US 1995-485322 19950607  
RLI US 1994-181947 19940114 DIVISION ABANDONED  
FI US 5859018 19990112  
DT Utility  
FS CHEMICAL  
GRANTED  
CLMN 9  
GI 30 Drawing Sheet(s), 36 Figure(s).

L5 ANSWER 176 OF 549 IFIPAT COPYRIGHT 2005 IFI on STN  
AN 03026608 IFIPAT;IFIUDB;IFICDB  
TI METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN  
RESPONSE TO PDGF,EGF,FGF AND \*\*\*VEGF\*\*\* ; ANTITUMOR, ANTICANCER  
AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS

IN Brown Paul A; Bursten Stuart L; Rice Glenn C; Singer Jack W  
PA Cell Therapeutics Inc (32953)  
PI US 5795898 A 19980818 (CITED IN 004 LATER PATENTS)  
AI US 1995-485325 19950607  
RLI US 1994-181947 19940114 DIVISION ABANDONED  
FI US 5795898 19980818  
DT Utility  
FS CHEMICAL  
GRANTED  
CLMN 9  
GI 30 Drawing Sheet(s), 36 Figure(s).

L5 ANSWER 177 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 2000:2695 IMSDRUGNEWS

TITLE: gene therapy, cardiovascular disease GenVec phase change  
II, USA (peripheral vascular disease)

TITLE: trafermin Scios, Chiron, Orquest, Selective Genetics  
licensing agreement  
SOURCE: R&D Focus Drug News ( \*\*\*15 Nov 1999\*\*\* ).  
WORD COUNT: 130

L5 ANSWER 183 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1999:3161 IMSDRUGNEWS  
TITLE: \*\*\*VEGF\*\*\* 121-based therapy, Scios Scios licensing  
offer, Worldwide  
SOURCE: R&D Focus Drug News ( \*\*\*25 Oct 1999\*\*\* ).  
WORD COUNT: 44

L5 ANSWER 184 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1999:577 IMSDRUGNEWS  
TITLE: telbermin Genentech considers product future  
SOURCE: R&D Focus Drug News ( \*\*\*1 Mar 1999\*\*\* ).  
WORD COUNT: 78

L5 ANSWER 185 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1999:76 IMSDRUGNEWS  
TITLE: gene therapy, \*\*\*VEGF\*\*\* -2, Vascular Genetics Vascular  
Genetics IND allowed  
SOURCE: R&D Focus Drug News ( \*\*\*11 Jan 1999\*\*\* ).  
WORD COUNT: 81

L5 ANSWER 186 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1998:4062 IMSDRUGNEWS  
TITLE: basic fibroblast growth factor Chiron phase change II, USA  
SOURCE: R&D Focus Drug News ( \*\*\*16 Nov 1998\*\*\* ).  
WORD COUNT: 166

L5 ANSWER 187 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN



SOURCE: R&D Focus Drug News ( \*\*\*30 Mar 1998\*\*\* ).  
WORD COUNT: 96

L5 ANSWER 192 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 97:2552 IMSDRUGNEWS  
TITLE: telbermin Genentech phase change I, USA  
SOURCE: R&D Focus Drug News ( \*\*\*18 Aug 1997\*\*\* ).  
WORD COUNT: 26

L5 ANSWER 193 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 97:556 IMSDRUGNEWS  
TITLE: trafermin Scios phase change II, USA ( \*\*\*coronary\*\*\*  
\*\*\*artery\*\*\* \*\*\*disease\*\*\* )  
SOURCE: R&D Focus Drug News ( \*\*\*3 Mar 1997\*\*\* ).  
WORD COUNT: 43

L5 ANSWER 194 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 96:3214 IMSDRUGNEWS  
TITLE: trafermin Scios, Wyeth Ayerst licensing agreement  
SOURCE: R&D Focus Drug News ( \*\*\*4 Nov 1996\*\*\* ).  
WORD COUNT: 93

L5 ANSWER 195 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 96:1488 IMSDRUGNEWS  
TITLE: gene therapy, cardiovascular disease GenVec, Scios  
licensing agreement  
SOURCE: R&D Focus Drug News ( \*\*\*24 Jun 1996\*\*\* ).  
WORD COUNT: 59

L5 ANSWER 196 OF 549 IMSRESEARCH COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1998:1157 IMSRESEARCH

-----+-----+-----  
|Ludwig Institute|United States  
|for Cancer |  
|Research |

L5 ANSWER 198 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 1011012836 JICST-EPlus  
TI Gene Therapy Update in Cardiovascular Disease.  
AU SYMES J F  
CS Tufts Univ. School Of Medicine, Usa  
SO Jpn Circ J, (2000) vol. 64, no. Satellite Seminar Abstracts, pp. 104-105.  
Journal Code: F0908A  
CODEN: NJUGAK; ISSN: 0047-1828  
CY Japan  
DT Journal; Preprint  
LA English  
STA New

L5 ANSWER 199 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 1010449915 JICST-EPlus  
TI Therapeutic Angiogenesis Induced by Hepatocyte Growth Factor: Potential  
Gene Therapy for Ischemic diseases.  
AU AOKI M; MORISHITA R; TANIYAMA Y; KANEDA Y; OGIHARA T  
CS Osaka Univ. Medical School, Osaka, Jpn  
SO J Atheroscler Thromb, (2000) vol. 7, no. 2, pp. 71-76. Journal Code:  
L2187A (Fig. 5, Ref. 29)  
ISSN: 1340-3478  
CY Japan  
DT Journal; Preprint  
LA English  
STA New

L5 ANSWER 200 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 1010355801 JICST-EPlus  
TI Myocardial ischemia enhances the expression of acidic fibroblast growth

CS    Todai Daigakuin'igakukeikenkyuka  
       Yamaguchi Univ., Sch. of Med.

SO    Seibutsu Butsuri Kagaku (Japanese Journal of Electrophoresis), (2000) vol.  
       44, no. 4, pp. 257-259. Journal Code: G0565A (Ref. 13)  
       CODEN: SBBKA4; ISSN: 0031-9082

CY    Japan

DT    Journal; Short Communication

LA    Japanese

STA   New

L5    ANSWER 203 OF 549   JICST-EPlus COPYRIGHT 2005 JST on STN

AN    1000916109   JICST-EPlus

TI    Transplantation and regenerative medicine - present situation of study and  
       prospect.   Heart and blood vessel.

AU    KOIKE HIROMI; MORISHITA RYUICHI; KANEDA YASUFUMI

CS    Osaka Univ., Grad. Sch.

SO    Karento Terapi (Current Therapy), (2000) vol. 18, no. 10, pp. 1847-1851.  
       Journal Code: G0171B (Fig. 1, Tbl. 1, Ref. 14)  
       ISSN: 0287-8445

CY    Japan

DT    Journal; Commentary

LA    Japanese

STA   New

L5    ANSWER 204 OF 549   JICST-EPlus COPYRIGHT 2005 JST on STN

AN    1000846517   JICST-EPlus

TI    Remodeling of Coronary Artery Lesions Due to Kawasaki Disease.

AU    SUZUKI A  
       MIYAGAWA-TOMITA S; NAKAZAWA M  
       YUTANI C

CS    Tokyo Teishin Hospital, Jpn  
       Tokyo Women's Medical Univ., Tokyo, Jpn  
       National Cardiovascular Center, Osaka, Jpn

SO    Jpn Heart J, (2000) vol. 41, no. 3, pp. 245-256. Journal Code: Z0752A  
       (Fig. 4, Ref. 22)  
       ISSN: 0021-4868

TI Gene Therapy for Ischemic Disease.  
 AU KOIKE HIROMI; MORISHITA RYUICHI  
 CS Osaka Univ., Grad. Sch.  
 SO Saibo Kogaku (Cell Technology), (2000) vol. 19, no. 8, pp. 1166-1171.  
 Journal Code: Y0229A (Fig. 3, Ref. 8)  
 ISSN: 0287-3796  
 CY Japan  
 DT Journal; Commentary  
 LA Japanese  
 STA New

L5 ANSWER 208 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
 AN 1000627035 JICST-EPlus  
 TI Pericardial Fluid From Patients With Ischemic Heart Disease Accelerates  
 the Growth of Human Vascular Smooth Muscle Cells.  
 AU YONEDA T; FUJITA M; KIHARA Y; HASEGAWA K; INANAMI M; NOHARA R; SASAYAMA S  
 SAWAMURA T  
 TANAKA T  
 CS Kyoto Univ., Kyoto, Jpn  
 National Cardiovascular Center Res. Inst., Osaka, Jpn  
 Takeda Hospital, Kyoto, Jpn  
 SO Jpn Circ J, (2000) vol. 64, no. 7, pp. 495-498. Journal Code: F0908A (Fig.  
 3, Ref. 13)  
 CODEN: NJUGAK; ISSN: 0047-1828  
 CY Japan  
 DT Journal; Article  
 LA English  
 STA New

L5 ANSWER 209 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
 AN 1000456471 JICST-EPlus  
 TI Basic Fibroblast Growth Factor Inhibits Lipopolysaccharide-induced  
 Apoptosis in Cardiac Myocytes.  
 AU IWAI-KANAI E; HASEGAWA K; ARAKI M; FUJITA M; KAKITA T; MORIMOTO T;  
 SASAYAMA S  
 CS Kyoto Univ., Kyoto, Jpn

TI Gene Therapy for ASO: Toward the clinical trial.  
 AU AOKI MOTOKUNI; MORISHITA RYUICHI  
 CS Osaka Univ., Grad. Sch.  
 SO Idenshi Igaku, (2000) vol. 4, no. 1, pp. 151-155. Journal Code: L3408A  
 (Fig. 6, Ref. 7)  
 ISSN: 1343-0971  
 CY Japan  
 DT Journal; Commentary  
 LA Japanese  
 STA New

L5 ANSWER 213 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
 AN 1000256799 JICST-EPlus  
 TI \*\*\*VEGF\*\*\* and vasculoangiogenesis/vascular remodeling.  
 AU ITO HIROSHI; NAKAO KAZUWA  
 CS Kyoto Univ., Grad. Sch.  
 SO Nippon Rinsho (Japanese Journal of Clinical Medicine), (2000) vol. 58, pp.  
 200-205. Journal Code: Z0679A (Fig. 7, Ref. 20)  
 ISSN: 0047-1852  
 CY Japan  
 DT Journal; General Review  
 LA Japanese  
 STA New

L5 ANSWER 214 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
 AN 1000189138 JICST-EPlus  
 TI Cytokines in pericardial fluid collected at open heart surgery.  
 AU TOMIZAWA YASUKO; ENDO MASAHIRO; NISHIDA HIROSHI; IMAI YASUHARU; ISHIZUKA  
 TSUTOMU; HAYASHI TETSUO; KOYANAGI HITOSHI  
 CS Tokyo Women's Medical College, Heart Inst. of Japan  
 SO Coronary, (1999) vol. 16, no. 4, pp. 288-292. Journal Code: Y0812A (Fig.  
 3, Ref. 13)  
 ISSN: 0910-3031  
 CY Japan  
 DT Journal; Article  
 LA Japanese

TI Gene therapy for cardiovascular diseases.  
AU AOKI MOTOKUNI  
MORISHITA RYUICHI  
CS Osaka Univ., Med. Sch.  
Osaka Univ., Grad. Sch.  
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (2000)  
vol. 192, no. 3, pp. 205-208. Journal Code: Z0649A (Fig. 4, Ref. 3)  
CODEN: IGAYAY; ISSN: 0039-2359  
CY Japan  
DT Journal; Commentary  
LA Japanese  
STA New

L5 ANSWER 218 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 1000189066 JICST-EPlus

TI History and prospect of angiogenic therapy.

AU UCHIDA YASUMI; KANAI MASAHIITO

UCHIDA HARUKO

UCHIDA YUKO

OGAWA MUNHEYUKI

CS Toho Univ. School of Medicine., Sakura Hospital

Univ. of Tokyo, Fac. of Med.

Chiba Univ., Sch. of Med.

Jikei Univ. School of Medicine

SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (2000)

vol. 192, no. 1, pp. 128-133. Journal Code: Z0649A (Fig. 3, Ref. 16)

CODEN: IGAYAY; ISSN: 0039-2359

CY Japan

DT Journal; Commentary

LA Japanese

STA New

L5 ANSWER 219 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 1000189064 JICST-EPlus

TI Gene therapy for restenosis.

AU AOKI MOTOKUNI; MORISHITA RYUICHI

L5 ANSWER 222 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 1000122237 JICST-EPlus  
TI New Development of Genetic Medicine. Gene Therapy for Cardiovascular Diseases.  
AU AOKI MOTOKUNI; MORISHITA RYUICHI; KANEDA YASUFUMI  
CS Osaka Univ.  
SO Saishin Igaku, (2000) vol. 55, no. 1, pp. 38-43. Journal Code: Z0358A  
(Fig. 4, Ref. 7)  
CODEN: SAIGAK; ISSN: 0370-8241  
CY Japan  
DT Journal; Commentary  
LA Japanese  
STA New

L5 ANSWER 223 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 1000055956 JICST-EPlus  
TI The Angiogenesis Therapy using \*\*\*VEGF\*\*\* .  
AU TAKESHITA SATOSHI  
CS Teikyo Univ., Sch. of Med.  
SO Ther Res, (1999) vol. 20, no. 11, pp. 3035-3040. Journal Code: Y0681A  
(Fig. 2, Ref. 22)  
ISSN: 0289-8020  
CY Japan  
DT Journal; Commentary  
LA Japanese  
STA New

L5 ANSWER 224 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 1000050410 JICST-EPlus  
TI Vascular Medicine. Therapeutic angiogenesis.  
AU ASAHARA TAKAYUKI; IWAGURO HIDEKI  
CS St. Elizabeth's Medical Center Cardiovascular Res. And Medicine  
SO Bio Clin, (1999) vol. 14, no. 14, pp. 1254-1260. Journal Code: L0059A  
(Fig. 3, Ref. 19)  
ISSN: 0919-8237

CS Osaka City Univ., Med. Sch.  
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1999)  
vol. 191, no. 5, pp. 505-508. Journal Code: Z0649A (Fig. 3, Ref. 34)  
CODEN: IGAYAY; ISSN: 0039-2359  
CY Japan  
DT Journal; Commentary  
LA Japanese  
STA New

L5 ANSWER 228 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 990991097 JICST-EPlus  
TI Elucidation of intracellular information transfer mechanism in the  
myocardial ischemia reperfusion injury and the establishment of the  
anti-adhesion molecule therapy.  
AU SEKO YOSHINORI  
CS Univ. of Tokyo, Fac. of Med.  
SO Sankyo Seimei Kagaku Kenkyu Shinko Zaidan Kenkyu Hokokushu, (1999) vol.  
14, pp. 99-109. Journal Code: L2409A (Fig. 7, Ref. 8)  
CY Japan  
DT Journal; Commentary  
LA Japanese  
STA New

L5 ANSWER 229 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 990985611 JICST-EPlus  
TI Combination of Physiology and Molecular Biology in Cardiology. Ischemic  
Myocardium Disorders and Treatment.  
AU KITAKAZE MASAFUMI; KUZUYA TSUNEHICO; HORI MASATSUGU  
CS Osaka Univ., Grad. Sch.  
SO Junkanki Senmon'i, (1999) vol. 7, no. 2, pp. 215-223. Journal Code: L1766A  
(Fig. 6, Tbl. 3, Ref. 19)  
ISSN: 0918-9599  
CY Japan  
DT Journal; Commentary  
LA Japanese  
STA New



SO Gekkan Soshiki Baiyo Kogaku (Tissue Culture Engineering), (1999) vol. 25,  
no. 11, pp. 447-451. Journal Code: F0781B (Fig. 5, Ref. 9)  
ISSN: 0386-1791  
CY Japan  
DT Journal; General Review  
LA Japanese  
STA New

L5 ANSWER 233 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 990880725 JICST-EPlus  
TI Ischemic heart disease handbooks. Angina pectoris and asymptomatic  
myocardial ischemia. Present of gene therapy for the angina pectoris.  
AU AOKI MOTOKUNI; MORISHITA RYUICHI  
CS Osaka Univ., Grad. Sch.  
SO Shindan to Chiryo (Diagnosis and Treatment), (1999) vol. 87, no. 9, pp.  
1604-1609. Journal Code: Z0941A (Fig. 3, Tbl. 2, Ref. 6)  
ISSN: 0370-999X  
CY Japan  
DT Journal; Commentary  
LA Japanese  
STA New

L5 ANSWER 234 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 990874402 JICST-EPlus  
TI Co-localized expression of vascular endothelial growth factor( \*\*\*VEGF\*\*\*  
) and its receptor in atherectomy specimens mediates restenosis after  
coronary angioplasty.  
AU SAKOMURA YASUNARI; YAMAGUCHI JUN'ICHI; TSURUMI YUKIO; KAWANA MASATOSHI;  
KASANUKI HIROSHI  
CS Tokyo Women's Medical College, Heart Inst. of Japan  
SO Tokyo Joshi Ika Daigaku Sogo Kenkyujo Kiyo, (1998) vol. 19, pp. 72-73.  
Journal Code: L0631A (Ref. 3)  
ISSN: 0911-4491  
CY Japan  
DT Journal; Short Communication  
LA Japanese

AN 990719527 JICST-EPlus  
TI Rehabilitation of heart failure. Cure. 8-b. Exercise therapy for  
ischemic heart disease with complication. Exercise therapy for angina  
pectoris.  
AU FUJITA MASATOSHI  
CS Kyoto Univ., Coll. of Med. Technol.  
SO Heart View, (1999) vol. 3, no. 8, pp. 867-870. Journal Code: L3359A (Fig.  
3, Ref. 18)  
ISSN: 1342-6591  
CY Japan  
DT Journal; Commentary  
LA Japanese  
STA New

L5 ANSWER 238 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 990709417 JICST-EPlus  
TI Recent topics on common diseases. Circulatory organ. Ischemic heart  
disease.  
AU OGAWA HISAO  
CS Kumamoto Univ., Med. Sch.  
SO Gendai Iryo, (1999) vol. 31, no. 7, pp. 1637-1642. Journal Code: Z0273B  
(Fig. 2, Tbl. 1, Ref. 12)  
ISSN: 0533-7259  
CY Japan  
DT Journal; Commentary  
LA Japanese  
STA New

L5 ANSWER 239 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 990705297 JICST-EPlus  
TI Heart failure carried over from childhood. 11. Blood vessel remodeling  
in distal stage of kawasaki disease coronary artery failure.  
AU SUZUKI JUNKO  
TOMITA SACHIKO; BOKU JINSAN; NAKAZAWA MAKOTO  
CS Tokyo Posts. and Telecommun. Hosp.  
Tokyo Women's Medical College, Heart Inst. of Japan

AN 990550807 JICST-EPlus  
TI Gene therapy for atherosclerosis.  
AU MORISHITA RYUICHI; OGIHARA TOSHIO; KANEDA YASUFUMI  
CS Osaka Univ., Grad. Sch.  
SO Idenshi Igaku, (1999) vol. 3, no. 2, pp. 326-331. Journal Code: L3408A  
(Fig. 3, Tbl. 1, Ref. 25)  
ISSN: 1343-0971  
CY Japan  
DT Journal; Commentary  
LA Japanese  
STA New

L5 ANSWER 243 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 990509421 JICST-EPlus  
TI A Study to Determine if Basic Fibroblast Growth Factor( \*\*\*bFGF\*\*\* )  
Reduces Myocardial Infarct Size in Acute Coronary Arterial Occlusion.  
AU SASAME A; NAKAJIMA H; TAMURA K; MIYAGI M; RAKUE H; USUI M; KATOH T; NAITOH  
Y; IBUKIYAMA C  
CS Tokyo Medical Univ., Tokyo, Jpn  
SO Jpn Heart J, (1999) vol. 40, no. 2, pp. 165-178. Journal Code: Z0752A  
(Fig. 6, Ref. 35)  
ISSN: 0021-4868  
CY Japan  
DT Journal; Article  
LA English  
STA New

L5 ANSWER 244 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 990509187 JICST-EPlus  
TI Therapeutic Angiogenesis for Ischemic Heart Disease.  
AU TAKESHITA SATOSHI  
CS Teikyo Univ., Sch. of Med.  
SO Kokyu to Junkan (Respiration and Circulation), (1999) vol. 47, no. 5, pp.  
449-453. Journal Code: Z0660A (Ref. 18)  
ISSN: 0452-3458  
CY Japan

CS Osaka City Univ., Med. Sch.  
 SO Ther Res, (1999) vol. 20, no. 3, pp. 587-595. Journal Code: Y0681A (Fig. 6, Ref. 19)  
 ISSN: 0289-8020  
 CY Japan  
 DT Journal; Commentary  
 LA Japanese  
 STA New

L5 ANSWER 248 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
 AN 990399674 JICST-EPlus  
 TI Elevated Circulating Levels of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor in Patients With Acute Myocardial Infarction.  
 AU TAMURA K; NAKAJIMA H; RAKUE H; SASAME A; NAITO Y; NAGAI Y; IBUKIYAMA C  
 CS Tokyo Medical Univ., Tokyo, Jpn  
 SO Jpn Circ J, (1999) vol. 63, no. 5, pp. 357-361. Journal Code: F0908A (Fig. 2, Ref. 40)  
 CODEN: NJUGAK; ISSN: 0047-1828  
 CY Japan  
 DT Journal; Article  
 LA English  
 STA New

L5 ANSWER 249 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
 AN 990371647 JICST-EPlus  
 TI Effect of Angiogenic Therapy with Vascular Endothelial Growth Factor for Acute Myocardial Infarction.  
 AU HARA TAKESHI; NAITO YUICHI; NAKAJIMA HITOSHI; TAMURA KEN; IBUKIYAMA CHIHARU  
 CS Tokyo Medical College  
 SO Nippon Rinsho Seiri Gakkai Zasshi (Japanese Journal of Applied Physiology), (1999) vol. 29, no. 1, pp. 5-13. Journal Code: Y0689A (Fig. 7, Ref. 23)  
 ISSN: 0286-7052  
 CY Japan  
 DT Journal; Article

the kawasaki disease remoteness stage. The second report.

AU SUZUKI ATSUKO

TOMITA SACHIKO; NAKAZAWA MAKOTO; KOMATSU KEIKO

CS Tokyo Posts. and Telecommun. Hosp.

Tokyo Women's Medical Coll.

SO Prog Med, (1998) vol. 18, no. 7, pp. 1594-1599. Journal Code: F0664B (Fig. 5, Ref. 11)

ISSN: 0287-3648

CY Japan

DT Journal; Short Communication

LA Japanese

STA New

L5 ANSWER 253 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 980640272 JICST-EPlus

TI Approach to the elucidation of disease state.By what reason multiple risk factor syndrome causes the arteriosclerosis. 3.Mechanism of crisis of arteriosclerosis in hyperlipidemia. Significance of arterialization factor \*\*\*VEGF\*\*\* .

AU ITO YUTAKA; NAKAO KAZUYASU

CS Kyoto Univ., Graduate School

SO Mebio, (1998) vol. 15, pp. 104-110. Journal Code: X0106A (Fig. 9, Tbl. 2, Ref. 7)

ISSN: 0910-0474

CY Japan

DT Journal; Commentary

LA Japanese

STA New

L5 ANSWER 254 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 980612724 JICST-EPlus

TI Molecular-biological approach of cardiovascular disease.From the basic to the clinic.The control using the gene of the restenosis after the PTCA.

AU MATSUSHITA HIDETSUGU; MORISHITA RYUICHI; OGIWARA TOSHIO

CS Osaka Univ., Med. Sch.

SO Junkan Kagaku (Circulation Science), (1998) vol. 18, no. 6, pp. 536-539.

L5 ANSWER 257 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 980325579 JICST-EPlus  
TI Effects of Transient Coronary Occlusion on the Capillary Network in the  
Left Ventricle of Rat.  
AU XIE Z; GAO M; KOYAMA T  
CS Hokkaido Univ., Sapporo, JPN  
SO Jpn J Physiol, (1997) vol. 47, no. 6, pp. 537-543. Journal Code: Z0753A  
(Fig. 5, Tbl. 1, Ref. 17)  
CODEN: JJPHAM; ISSN: 0021-521X  
CY Japan  
DT Journal; Article  
LA English  
STA New

L5 ANSWER 258 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 980264305 JICST-EPlus  
TI Regulation and failure of coronary circulation. Coronary collateral  
circulation.  
AU FUJITA MASATOSHI  
CS Kyoto Univ., Coll. of Med. Technol.  
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1998) pp.  
89-93. Journal Code: Z0649A (Fig. 4, Ref. 18)  
CODEN: IGAYAY; ISSN: 0039-2359  
CY Japan  
DT Journal; Commentary  
LA Japanese  
STA New

L5 ANSWER 259 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 970989373 JICST-EPlus  
TI Experimental study of effects of adenosine on angiogenesis in rat  
myocardial infarction.  
AU KOBAYASHI MASAO; ABE GEN; SHIMIZU HIROSHI; OGAWA YASUHIKO; OMOTO NAOKI;  
MATSUOKA KAZUSHI; KAWAMURA KOICHI; MASUDA HIROTAKE; MIURA MAMORU  
CS Akita Univ., Sch. of Med.  
SO Shinkin no Kozo to Taisha (Cardiac Structure and Metabolism), (1997) vol.

TI Coronary collateral circulation.  
 AU FUJITA MASATOSHI  
 CS Kyoto Univ., Coll. of Med. Technol.  
 SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1996)  
 vol. 179, no. 10, pp. 835-839. Journal Code: Z0649A (Fig. 4, Ref. 18)  
 CODEN: IGAYAY; ISSN: 0039-2359  
 CY Japan  
 DT Journal; Commentary  
 LA Japanese  
 STA New

L5 ANSWER 263 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
 AN 970062755 JICST-EPlus  
 TI Vascular remodeling.  
 AU FUJIKAWA HIDEYUKI; SHIMADA KAZUYUKI  
 CS Jichi Med. Sch.  
 SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1996)  
 vol. 179, no. 10, pp. 809-814. Journal Code: Z0649A (Fig. 3, Tbl. 1, Ref. 24)  
 CODEN: IGAYAY; ISSN: 0039-2359  
 CY Japan  
 DT Journal; Commentary  
 LA Japanese  
 STA New

L5 ANSWER 264 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
 AN 970002451 JICST-EPlus  
 TI Ischemic heart disease. New development of treatment and prevention.  
 Gene therapy for post PTCA restenosis.  
 AU MORISHITA RYUICHI; HIGAKI TSUNEO; OGIWARA TOSHIO  
 CS Osaka Univ., Med. Sch.  
 SO Rinsho Kagaku (Journal of Clinical Science), (1996) vol. 32, no. 11, pp.  
 1419-1425. Journal Code: Z0350B (Fig. 5, Tbl. 3, Ref. 23)  
 ISSN: 0385-0323  
 CY Japan  
 DT Journal; Commentary

infarction.

AU SHINOHARA K; SHINOHARA T; MOCHIZUKI N; MOCHIZUKI Y; SAWA H; KOHYA T;  
FUJITA M; FUJIOKA Y; NAGASHIMA K  
CS Hokkaido Univ. School of Medicine, Sapporo, JPN  
SO Heart Vessels, (1996) vol. 11, no. 3, pp. 113-122. Journal Code: X0101A  
(Fig. 7, Tbl. 2, Ref. 33)  
ISSN: 0910-8327  
CY Japan  
DT Journal; Article  
LA English  
STA New

L5 ANSWER 268 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 960813551 JICST-EPlus  
TI Roles of inflammatory cytokine/growth factor in coronary sclerosis and  
crown twitch.  
AU ITO AKIRA; SHIMOKAWA HIROAKI; FUKUMOTO YOSHIHIRO; KADOKAMI TOSHIAKI;  
FURUZAI TOSHIYUKI; KUWATA KOICHI; YAMAWAKI TOORU; EGASHIRA KENSUKE;  
TAKESHITA AKIRA  
CS Kyushu Univ., Fac. of Med.  
SO Ther Res, (1996) vol. 17, no. 8, pp. 3239-3247. Journal Code: Y0681A (Fig.  
10, Ref. 4)  
ISSN: 0289-8020  
CY Japan  
DT Journal; Article  
LA Japanese  
STA New

L5 ANSWER 269 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 960765728 JICST-EPlus  
TI Therapeutic angiogenesis and its clinical applications.  
AU TAKESHITA SATORU  
CS Teikyo Univ., Sch. of Med.  
SO Jikken Igaku (Experimental Medicine), (1996) vol. 14, no. 15, pp.  
2160-2162. Journal Code: Y0568A (Fig. 2, Ref. 8)  
ISSN: 0288-5514



TI Contralateral arterial bolus injection of 30 micrograms of basic  
 fibroblast growth factor failed to augment myocardial blood flow in  
 infarcted myocardium in dogs.

AU MIYATAKA M; ISHIKAWA K; OGAWA I; KOKA H; NAKAI S; KINO H; INAGAKI M;  
 KIMURA A; KATORI R

CS Kinki Univ. School of Medicine, Osaka, JPN

SO Acta Med Kinki Univ, (1996) vol. 21, no. 1, pp. 53-58. Journal Code:  
 S0990A (Tbl. 3, Ref. 22)  
 ISSN: 0386-6092

CY Japan

DT Journal; Article

LA English

STA New

L5 ANSWER 273 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 960220340 JICST-EPlus

TI \*\*\*Coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\* of dialysis patient.  
 Coronary circulation adjustment and disease state. (2). The control of  
 vascular endothelial cell proliferation.

AU KUZUYA TSUNEHICO; NISHIDA MASASHI; TADA MICHIIHIKO

CS Osaka Univ., Med. Sch.

SO Rinsho Toseki (Japanese Journal of Clinical Dialysis), (1996) vol. 12, no.  
 2, pp. 171-174. Journal Code: X0146A (Fig. 1, Ref. 7)  
 ISSN: 0910-5808

CY Japan

DT Journal; General Review

LA Japanese

STA New

L5 ANSWER 274 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 960101131 JICST-EPlus

TI Elastase and cell matrix interactions in the pathobiology of vascular  
 disease.

AU RABINOVITCH M

CS Univ. Toronto, Ontario, CAN

SO Acta Paediatr Jpn, (1995) vol. 37, no. 6, pp. 657-666. Journal Code:

STA New

L5 ANSWER 277 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 950854178 JICST-EPlus  
TI Effect of Basic Fibroblast Growth Factor(b-FGF) in Expansion and  
Remodeling after Acute Myocardial Infarction.  
AU WANG D Y; NAGAO KEN; WATANABE IKUYOSHI; KANMATSUSE KATSUO  
CS Nihon Univ., Sch. of Med.  
SO Nichidai Igaku Zasshi (Journal of Nihon University Medical Association),  
(1995) vol. 54, no. 5, pp. 304-309. Journal Code: F0911A (Fig. 4, Tbl. 2,  
Ref. 17)  
CODEN: NICHAS; ISSN: 0029-0424  
CY Japan  
DT Journal; Article  
LA Japanese  
STA New

L5 ANSWER 278 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 950758711 JICST-EPlus  
TI Recent view on coronal collateral circulation.  
AU SHINOYAMA SHIGETAKE  
CS Kyoto Univ., Fac. of Med.  
SO Rinsho to Kenkyu (Japanese Journal of Clinical and Experimental Medicine),  
(1995) vol. 72, no. 8, pp. 2025-2035. Journal Code: Z0376B (Fig. 10, Ref.  
35)  
ISSN: 0021-4965  
CY Japan  
DT Journal; Commentary  
LA Japanese  
STA New

L5 ANSWER 279 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 950751806 JICST-EPlus  
TI Q&A for acute myocardial infarction Therapeutic angiogenesis.  
AU TAKESHITA SATOSHI; SATO TOMOHIDE  
CS Teikyo Univ., Sch. of Med.

STA New

L5 ANSWER 282 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 950365635 JICST-EPlus  
TI Angiogenesis by \*\*\*bFGF\*\*\* .  
AU UCHIDA YASUMI; MIWA ATSUKO  
CS Univ. of Tokyo, Fac. of Med.  
SO Coronary, (1995) vol. 12, no. 1, pp. 33-40. Journal Code: Y0812A (Fig. 9, Ref. 26)  
ISSN: 0910-3031  
CY Japan  
DT Journal; Commentary  
LA Japanese  
STA New

L5 ANSWER 283 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 950262206 JICST-EPlus  
TI Coronary collateral vessels and fibroblast growth factor.  
AU UCHIDA YASUMI; MIWA ATSUKO  
CS Univ. of Tokyo, Fac. of Med.  
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1995) vol. 172, no. 9, pp. 594-598. Journal Code: Z0649A (Fig. 4, Ref. 26)  
CODEN: IGAYAY; ISSN: 0039-2359  
CY Japan  
DT Journal; General Review  
LA Japanese  
STA New

L5 ANSWER 284 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 950196851 JICST-EPlus  
TI Current Perspectives on the Problem of Ischemic Heart Disease.  
Angiogenesis and Coronary Collateral Development.  
AU UCHIDA YASUMI; MIWA ATSUKO  
CS Univ. of Tokyo, Fac. of Med.  
SO Saishin Igaku, (1995) vol. 50, no. 2, pp. 218-226. Journal Code: Z0358A (Fig. 9, Ref. 26)

-  
DT Journal; Commentary  
LA English  
STA New

L5 ANSWER 287 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 940756922 JICST-EPlus  
TI The Expression and the Role of Vascular Endothelial Growth Factor(  
\*\*\*VEGF\*\*\* ) in Human Normal and Myocardial Infarcted Heart.  
AU SHINOHARA KAHORU  
CS Hokkaido Univ., Sch. of Med.  
SO Hokkaido Igaku Zasshi (Hokkaido Journal of Medical Science), (1994) vol.  
69, no. 4, pp. 978-989,991,993. Journal Code: Z0749A (Fig. 7, Tbl. 2, Ref.  
20)  
ISSN: 0367-6102

CY Japan  
DT Journal; Article  
LA Japanese  
STA New

L5 ANSWER 288 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN  
AN 940112450 JICST-EPlus  
TI Angiogenic therapy by basic fibroblast growth factor for myocardial  
infarction.  
AU MIWA YANAGISAWA ATSUKO; UCHIDA YASUMI  
ITO HIDEKI  
CS Univ. of Tokyo, Faculty of Medicine  
Tokyotorojin'iryosenta  
SO Rinsho Men'eki (Clinical Immunology), (1994) vol. 26, no. 1, pp. 99-106.  
Journal Code: Z0528B (Fig. 5, Tbl. 2, Ref. 23)  
ISSN: 0386-9695

CY Japan  
DT Journal; General Review  
LA Japanese  
STA New

L5 ANSWER 289 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

HIDEAKI; SUGIMOTO TSUNEAKI

YOSHITAKE YOSHINO

ITO HIDEKI

KAJI KAZUHIKO

CS Univ. of Tokyo, Faculty of Medicine

Tokyotorojin'iryosenta

Tokyo Metrop. Inst. of Gerontology

Kanazawa Medical Univ.

SO Myakkangaku (Journal of Japanese College of Angiology), (1992) vol. 32,  
no. 11, pp. 1229-1234. Journal Code: Z0216B (Fig. 8, Ref. 11)

ISSN: 0387-1126

CY Japan

DT Journal; Article

LA Japanese

STA New

L5 ANSWER 292 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 930074736 JICST-EPlus

TI Hypoxia Induces the Alterations in Endothelial Cell Growth.

AU OGAWA SATOSHI; MATSUMOTO MASAYASU; MAEDA YUSUKE; KAMADA TAKENOBU  
KUWABARA KEISUKE; KOGA SHIN; KOGA YUKI; STERN D

CS Osaka Univ., Medical School

Koronbiadai

SO Myakkangaku (Journal of Japanese College of Angiology), (1992) vol. 32,  
no. 11, pp. 1225-1228. Journal Code: Z0216B (Fig. 4, Ref. 8)

ISSN: 0387-1126

CY Japan

DT Journal; Article

LA Japanese

STA New

L5 ANSWER 293 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 930074735 JICST-EPlus

TI The Role of Basic Fibroblast Growth Factor in the Developemtn of  
Collateral Circulation.

AU CHIBA MICHIO; SUMIDA EMIKO; SUMIDA EIJI; TANAKA MASASHI; OKA NAOKI; KUWANO

ISSN: 0029-0203

CY Japan

DT Journal; Article

LA Japanese

STA New

L5 ANSWER 296 OF 549 MEDLINE on STN

AN 2003455187 MEDLINE

DN PubMed ID: 14517380

TI Marked elevation of vascular endothelial growth factor and basic fibroblast growth factor in pericardial fluid of patients with angina pectoris.

AU Fujita M; Ikemoto M; Tanaka T; Tamaki S; Yamazato A; Sawamura T; Hasegawa K; Kihara Y; Nohara R; Sasayama S

CS College of Medical Technology, Kyoto University, Kyoto 606-01, Japan.

SO Angiogenesis, \*\*\* (1998) \*\*\* 2 (1) 105-8.  
Journal code: 9814575. ISSN: 0969-6970.

CY Netherlands

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS NONMEDLINE; PUBMED-NOT-MEDLINE

EM 200310

ED Entered STN: 20031001  
Last Updated on STN: 20031011  
Entered Medline: 20031010

L5 ANSWER 297 OF 549 PASCAL COPYRIGHT 2005 INIST-CNRS. ALL RIGHTS RESERVED. on STN

AN 2000-0358764 PASCAL

CP Copyright .COPYRG. 2000 INIST-CNRS. All rights reserved.

TIEN Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris

AU UNGER E. F.; GONCALVES L.; EPSTEIN S. E.; CHEW E. Y.; TRAPNELL C. B.; CANNON R. O. III; QUYYUMI A. A.; STINE A.; LOSCALZO F.; STIBER J. A.

CS Cardiology Branch, National Heart, Lung, and Blood Institute, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United

L5 ANSWER 299 OF 549 PASCAL COPYRIGHT 2005 INIST-CNRS. ALL RIGHTS  
 RESERVED. on STN  
 AN 1998-0489871 PASCAL  
 CP Copyright .COPYRGT. 1998 INIST-CNRS. All rights reserved.  
 TIEN Effects of \*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\* on  
 expression and microvascular response to \*\*\*VEGF\*\*\*  
 AU METAIS C.; JIANYI LI; JIAN LI; SIMONS M.; SELLKE F. W.  
 CS Division of Cardiothoracic Surgery, Department of Surgery, of the Beth  
 Israel-Deaconess Medical Center and Harvard Medical School, Boston,  
 Massachusetts 02215, United States; Cardiovascular Division, Department  
 of Medicine of Beth Israel-Deaconess Medical Center and Harvard Medical  
 School, Boston, Massachusetts 02215, United States  
 SO American journal of physiology. Heart and circulatory physiology,  
 \*\*\* (1998) \*\*\* , 44(4), H1411-H1418, 48 refs.  
 ISSN: 0363-6135 CODEN: AJPPDI  
 DT Journal  
 BL Analytic  
 CY United States  
 LA English  
 AV INIST-670D, 354000070093100360

L5 ANSWER 300 OF 549 PASCAL COPYRIGHT 2005 INIST-CNRS. ALL RIGHTS  
 RESERVED. on STN  
 AN 1998-0161236 PASCAL  
 CP Copyright .COPYRGT. 1998 INIST-CNRS. All rights reserved.  
 TIEN Growth factors as a potential new treatment for ischemic heart disease  
 Endothelial dysfunction, the renin-angiotensin system, and nitric oxide:  
 impact on \*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\* and  
 therapeutic interventions  
 AU BAUTERS C.  
 PEPINE Carl J. (ed.)  
 CS Service de Cardiologie B et Hemodynamique, Hopital Cardiologique,  
 Universite de Lille, Lille, France  
 Division of Cardiovascular Medicine, University of Florida College of  
 Medicine, Gainesville, Florida, United States

L5 ANSWER 305 OF 549 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN  
AN 1645746 PHARMAML  
TI Genentech disappointed by Phase II rhVEGF165 data  
SO Marketletter February 22, 1999  
DT Newsletter  
WC 503

L5 ANSWER 306 OF 549 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN  
AN 1641161 PHARMAML  
TI Genentech Starts Trials Of Recombinant \*\*\*VEGF\*\*\*  
SO Marketletter April 3, 1998  
DT Newsletter  
WC 750

L5 ANSWER 307 OF 549 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN  
AN 1640985 PHARMAML  
TI \*\*\*VEGF\*\*\* Gene Therapy For CAD/PAD  
SO Marketletter March 25, 1998  
DT Newsletter  
WC 61

L5 ANSWER 308 OF 549 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN  
AN 1639829 PHARMAML  
TI First Patient Gets Gene Therapy For CAD  
SO Marketletter January 8, 1998  
DT Newsletter  
WC 296

L5 ANSWER 309 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN  
  
AN 2001:138 PHIN  
DN B00689884  
DED 1 Dec 2000  
TI Twisted Genes A passing fashion? By Tim Searle  
SO Bioventure-View ( \*\*\*2000\*\*\* ) No. 1512 p5  
DT Newsletter



DN C00663242  
DED 8 May 2000  
TI Phase II CAD ( \*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\* ) gene  
therapy trials begin  
SO Clinica ( \*\*\*2000\*\*\* ) No. 907 p16  
DT Newsletter  
FS BRIEF

L5 ANSWER 314 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 2000:7020 PHIN  
DN B00659202  
DED 1 Apr 2000  
TI COMPANY SNAPSHOT - Human Genome Sciences Inc. Rockville, MD \* Nasdaq: HGSI  
SO Bioventure-View ( \*\*\*2000\*\*\* ) No. 1504 p12  
DT Newsletter  
FS FULL

L5 ANSWER 315 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 2000:5904 PHIN  
DN C00658114  
DED 20 Mar 2000  
TI Researches say gene therapy trials for heart disease show promising  
results, despite FDA "caution"  
SO Clinica ( \*\*\*2000\*\*\* ) No. 900 p15  
DT Newsletter  
FS FULL

L5 ANSWER 316 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 1999:17149 PHIN  
DN S00638962  
DED 1 Oct 1999  
TI Chiron poised for new growth opportunities  
SO Scrip ( \*\*\*1999\*\*\* ) No. 2477 p9

DN S00600330  
DED 30 Oct 1998  
TI Preclinical research update  
SO Scrip ( \*\*\*1998\*\*\* ) No. 2383 p23  
DT Newsletter  
FS FULL

L5 ANSWER 321 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 97:16345 PHIN  
DN S00551440  
DED 10 Sep 1997  
TI Parke-Davis and GenVec partnership  
SO Scrip ( \*\*\*1997\*\*\* ) No. 2267 p9  
DT Newsletter  
FS FULL

L5 ANSWER 322 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 97:13715 PHIN  
DN S00546366  
DED 3 Jul 1997  
TI Genentech earnings down, sales flat  
SO Scrip ( \*\*\*1997\*\*\* ) No. 2253 p12  
DT Newsletter  
FS FULL

L5 ANSWER 323 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 96:21681 PHIN  
DN S00517376  
DED 29 Nov 1996  
TI Scios' Natrecor moves into Phase III  
SO Scrip ( \*\*\*1996\*\*\* ) No. 2185 p13  
DT Newsletter  
FS FULL

SOURCE: Applied Genetics News, ( \*\*\*Dec 2000\*\*\* ) Vol. 21, No. 5.  
ISSN: 0271-7107.  
PUBLISHER: Business Communications Company, Inc.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 214  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 328 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:1116652 PROMT  
TITLE: Human Genome Sciences Forms Biotech Deals.(Brief Article)  
AUTHOR(S): PAPANIKOLAW, JIM  
SOURCE: Chemical Market Reporter, ( \*\*\*6 Mar 2000\*\*\* ) Vol. 257,  
No. 10, pp. 22.  
ISSN: ISSN: 1092-0110.  
PUBLISHER: Schnell Publishing Company, Inc.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 525  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 329 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:1077662 PROMT  
TITLE: GENVEC RAISES \$38M IN IPO FOR ADENOVECTOR TECHNOLOGY.(Brief  
Article)  
AUTHOR(S): Osborne, Randall  
SOURCE: BIOWORLD Today, ( \*\*\*13 Dec 2000\*\*\* ) Vol. 11, No. 240.  
PUBLISHER: American Health Consultants, Inc.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 371  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 330 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:939684 PROMT  
TITLE: Newly Published Preclinical Study Demonstrates Relaxin  
Selectively Stimulates \*\*\*VEGF\*\*\* and \*\*\*bFGF\*\*\* at  
Ischemic Sites.  
SOURCE: PR Newswire, ( \*\*\*31 Oct 2000\*\*\* ) pp. 6454.  
PUBLISHER: PR Newswire Association, Inc.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 604  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 334 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:869511 PROMT  
TITLE: GENVEC TRIES AGAIN FOR IPO, SEEKS \$50M FOR GENE PRODUCTS.  
AUTHOR(S): Huggett, Brady  
SOURCE: BIOWORLD Today, ( \*\*\*9 Oct 2000\*\*\* ) Vol. 11, No. 195.  
PUBLISHER: American Health Consultants, Inc.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 517  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 335 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:851873 PROMT  
TITLE: Genzyme Surgical Products Initiates Second Cardiovascular  
Gene Therapy Clinical Trial.  
SOURCE: PR Newswire, ( \*\*\*2 Oct 2000\*\*\* ) pp. 7025.  
PUBLISHER: PR Newswire Association, Inc.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 1439  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

LANGUAGE: English

WORD COUNT: 656

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 339 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:665667 PROMT

TITLE: Collateral Announces Expanded Angiogenic Gene Research  
Collaboration With New York University.

SOURCE: PR Newswire, ( \*\*\*2 Aug 2000\*\*\* ) .

PUBLISHER: PR Newswire Association, Inc.

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 703

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 340 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:588546 PROMT

TITLE: Transgene Selects Two Novel Cardiovascular Genes From Human  
Genome Sciences for Gene Therapy Development.

SOURCE: PR Newswire, ( \*\*\*12 Jul 2000\*\*\* ) pp. 6625.

PUBLISHER: PR Newswire Association, Inc.

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 2145

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 341 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:527148 PROMT

TITLE: REPAIR INC. PURSUING ANGIOGENIC THERAPIES BASED ON  
\*\*\*FGF\*\*\* - \*\*\*1\*\*\* , FIBRIN.(Brief Article)

AUTHOR(S): Welch, Mary

SOURCE: BIOWORLD Today, ( \*\*\*21 Jun 2000\*\*\* ) Vol. 11, No. 120.

PUBLISHER: American Health Consultants, Inc.

ACCESSION NUMBER: 2000:390881 PROMT  
TITLE: gene therapy, cardiovascular disease GenVec begins phase II  
trial.(Brief Article)  
SOURCE: R & D Focus Drug News, ( \*\*\*8 May 2000\*\*\* ) .  
ISSN: 1350-1135.  
PUBLISHER: IMS World Publications Ltd.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 142  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 345 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:369841 PROMT  
TITLE: Collateral Therapeutics Appoints John F. Warner Ph.D. Vice  
President Of Technology.  
SOURCE: PR Newswire, ( \*\*\*9 May 2000\*\*\* ) .  
PUBLISHER: PR Newswire Association, Inc.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 787  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 346 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:316730 PROMT  
TITLE: Human Genome Sciences Inc. Rockville, MD \* Nasdaq:  
HGSI.(Brief Article)(Statistical Data Included)  
SOURCE: BioVenture View, ( \*\*\*April 2000\*\*\* ) Vol. 15, No. 4, pp.  
12.  
ISSN: 0892-1903.  
PUBLISHER: BioVenture Publishing  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 660  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 350 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:230890 PROMT  
TITLE: GENE THERAPY: Naked Gene Delivery Service.(Brief Article)  
SOURCE: Applied Genetics News, ( \*\*\*March 2000\*\*\* ) Vol. 20, No. 8.  
ISSN: 0271-7107.  
PUBLISHER: Business Communications Company, Inc.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 269

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 351 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:193460 PROMT  
TITLE: Chiron \*\*\*FGF\*\*\* - \*\*\*2\*\*\* study in CAD disappoints.(Brief Article)  
SOURCE: Marketletter, ( \*\*\*20 Mar 2000\*\*\* ) .  
ISSN: 0951-3175.  
PUBLISHER: Marketletter Publications Ltd.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 375

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 352 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:187473 PROMT  
TITLE: AMERICAN COLLEGE OF CARDIOLOGY'S SCIENTIFIC SESSION  
CHIRON'S \*\*\*FGF\*\*\* - \*\*\*2\*\*\* REDUCES ANGINA, BUT FAILS WITH PRIMARY ENDPOINT.  
AUTHOR(S): Pihl; Carey, Karen  
SOURCE: BIOWORLD Today, ( \*\*\*14 Mar 2000\*\*\* ) Vol. 11, No. 49.

PHARMA.

AUTHOR(S): Pihl; Carey, Karen  
SOURCE: BIOWORLD Today, ( \*\*\*28 Feb 2000\*\*\* ) Vol. 11, No. 37.  
PUBLISHER: American Health Consultants, Inc.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 662  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 356 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:133836 PROMT  
TITLE: Vical, Human Genome Sciences and Vascular Genetics Enter  
Strategic Collaboration.  
SOURCE: Business Wire, ( \*\*\*25 Feb 2000\*\*\* ) pp. 43.  
PUBLISHER: Business Wire  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 765  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 357 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:111745 PROMT  
TITLE: Collateral Therapeutics announces issuance of United States  
patent for angiogenic growth factor gene \*\*\*Vegf\*\*\*  
-145. (Brief Article)  
SOURCE: BIOTECH Patent News, ( \*\*\*Jan 2000\*\*\* ) Vol. 14, No. 1.  
ISSN: 0898-2813.  
PUBLISHER: Biotech Patent News  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 511  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 358 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN



ACCESSION NUMBER: 1999:727610 PROMT  
TITLE: Collateral Therapeutics Creates First Combination FGF/  
\*\*\*VEGF\*\*\* Gene For Non-Surgical Cardiovascular  
Angiogenesis.  
SOURCE: PR Newswire, ( \*\*\*8 Nov 1999\*\*\* ) pp. 8563.  
PUBLISHER: PR Newswire Association, Inc.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 695  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 362 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:654487 PROMT  
TITLE: Scios Announces 1999 Third Quarter Financial Results.  
SOURCE: PR Newswire, ( \*\*\*8 Oct 1999\*\*\* ) pp. 2565.  
PUBLISHER: PR Newswire Association, Inc.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 1696  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 363 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:527351 PROMT  
TITLE: COLLATERAL THERAPEUTICS RAISES \$33.9M IN PRIVATE PLACEMENT.  
AUTHOR(S): Seachrist, Lisa  
SOURCE: BIOWORLD Today, ( \*\*\*13 Aug 1999\*\*\* ) Vol. 10, No. 156.  
PUBLISHER: American Health Consultants, Inc.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 562  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 364 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

L5 ANSWER 367 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:376201 PROMT  
TITLE: Biosense Webster Announces Collaboration with Vascular Genetics Inc. on Catheter Delivery of Gene Therapy to Treat Cardiac Disease.  
SOURCE: PR Newswire, ( \*\*\*10 Jun 1999\*\*\* ) pp. 6525.  
PUBLISHER: PR Newswire Association, Inc.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 448  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 368 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:329291 PROMT  
TITLE: Trimedyne Subsidiary Enters Gene Therapy Collaboration With Endovasc Ltd. Inc.  
SOURCE: Business Wire, ( \*\*\*20 May 1999\*\*\* ) pp. 1125.  
PUBLISHER: Business Wire  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 452  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 369 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

-----  
ACCESSION NUMBER: 1999:273148 PROMT  
TITLE: Megabios Acquires Angiogenesis Gene.  
SOURCE: PR Newswire, ( \*\*\*27 Apr 1999\*\*\* ) pp. 3938.  
PUBLISHER: PR Newswire Association, Inc.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 764  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

ACCESSION NUMBER: 1999:175526 PROMT  
TITLE: Genentech disappointed by Phase II rhVEGF165 data.  
SOURCE: Marketletter, ( \*\*\*1 Mar 1999\*\*\* ) .  
ISSN: 0951-3175.  
PUBLISHER: Marketletter Publications Ltd.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 504  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 374 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:162782 PROMT  
TITLE: Megabios and GeneMedicine Complete Merger.  
SOURCE: PR Newswire, ( \*\*\*19 Mar 1999\*\*\* ) pp. 8437.  
PUBLISHER: PR Newswire Association, Inc.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 636  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 375 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:145715 PROMT  
TITLE: vascular endothelial growth factor Genentech considers  
product future.  
SOURCE: R & D Focus Drug News, ( \*\*\*3 Mar 1999\*\*\* ) .  
ISSN: 1350-1135.  
PUBLISHER: IMSWorld Publications Ltd.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 90  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 376 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

L5 ANSWER 379 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:40475 PROMT  
TITLE: Genzyme General Forms Collaboration to Develop Cell  
Therapies for Cardiovascular Disease.  
SOURCE: PR Newswire, ( \*\*\*21 Jan 1999\*\*\* ) pp. 8640.  
PUBLISHER: PR Newswire Association, Inc.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 2579  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 380 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:21785 PROMT  
TITLE: Gene therapy, \*\*\*VEGF\*\*\* -2, Vascular Genetics Vascular  
Genetics IND allowed.  
SOURCE: R & D Focus Drug News, ( \*\*\*11 Jan 1999\*\*\* ) pp. NA(1).  
ISSN: 1350-1135.  
LANGUAGE: English  
WORD COUNT: 106  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 381 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:687886 PROMT  
TITLE: GENENTECH: Year-end results show growth plan on track  
SOURCE: M2 Presswire, ( \*\*\*26 Jan 1998\*\*\* ) .  
PUBLISHER: M2 Communications Ltd.  
DOCUMENT TYPE: Newsletter  
LANGUAGE: English  
WORD COUNT: 1687  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 382 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

SOURCE: The Lancet, ( \*\*\*14 Nov 1998\*\*\* ) pp. 1603(1).  
ISSN: 0099-5355.  
LANGUAGE: English  
WORD COUNT: 794  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 386 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:567527 PROMT  
TITLE: Angiogenesis May Be Stimulated by EECp(R) Therapy.  
SOURCE: PR Newswire, ( \*\*\*4 Nov 1998\*\*\* ) pp. 5638.  
LANGUAGE: English  
WORD COUNT: 221  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 387 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:553344 PROMT  
TITLE: angiopoietin 1 Regeneron, Procter & Gamble preclinical  
data.  
SOURCE: R & D Focus Drug News, ( \*\*\*2 Nov 1998\*\*\* ) pp. NA(1).  
ISSN: 1350-1135.  
LANGUAGE: English  
WORD COUNT: 233  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 388 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:469943 PROMT  
TITLE: Gene therapy, vascular endothelial growth factor B  
Collateral Therapeutics, Ludwig Institute for Cancer  
Research, AMRAD licensing termination  
SOURCE: R & D Focus Drug News, ( \*\*\*14 Sep 1998\*\*\* ) pp. N/A.  
ISSN: 1350-1135.  
LANGUAGE: English  
WORD COUNT: 171

TITLE: COLLATERAL THERAPEUTICS WINS ANGIOGENESIS GENES PATENT By  
Randall Osborne Staff Writer

SOURCE: BIOWORLD Today, ( \*\*\*12 Aug 1998\*\*\* ) pp. N/A.

LANGUAGE: English

WORD COUNT: 401

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 393 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:398071 PROMT

TITLE: GENVEC WITHDRAWS IPO; BLAMES UNSTABLE MARKET CONDITIONS

SOURCE: BIOWORLD Today, ( \*\*\*4 Aug 1998\*\*\* ) pp. N/A.

LANGUAGE: English

WORD COUNT: 463

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 394 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:232468 PROMT

TITLE: Research Study Indicates That TMR Using The Heart Laser  
System Enhances The Effectiveness Of Gene Therapy For Heart  
Disease

SOURCE: PR Newswire, ( \*\*\*8 May 1998\*\*\* ) pp. 508NEF003.

LANGUAGE: English

WORD COUNT: 574

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 395 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:175708 PROMT

TITLE: DEVELOPMENTS IN BIOTECHNOLOGY :GeneMedicine-Cationic Lipid  
Gene Delivery System In Two Phase II Gene Therapy  
Angioplasty Clinical Trials

SOURCE: BioAccess, ( \*\*\*1 Apr 1998\*\*\* ) pp. N/A.  
ISSN: 1356-3432.

LANGUAGE: English

ACCESSION NUMBER: 1998:64791 PROMT  
TITLE: gene therapy, FGF-4, gene therapy, heart disease,  
Collateral Therapeutics Collateral Therapeutics IND  
submission Schering AG IND submission Schering AG  
Collateral Therapeutics  
SOURCE: R & D Focus Drug News, ( \*\*\*19 Jan 1998\*\*\* ) pp. N/A.  
ISSN: 1350-1135.  
LANGUAGE: English  
WORD COUNT: 209  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 400 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:41293 PROMT  
TITLE: Genentech's Year-End Results Show Growth Plan on Track:  
Earnings Increase Nine Percent on Revenues Exceeding \$1  
Billion.  
SOURCE: Business Wire, ( \*\*\*22 Jan 1998\*\*\* ) pp. 01220134.  
LANGUAGE: English  
WORD COUNT: 2029  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 401 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:32445 PROMT  
TITLE: First Patient Gets Gene Therapy For CAD  
SOURCE: Marketletter, ( \*\*\*19 Jan 1998\*\*\* ) pp. N/A.  
ISSN: 0951-3175.  
LANGUAGE: English  
WORD COUNT: 297  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 402 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:17434 PROMT  
TITLE: Collateral Therapeutics Announces Details of First

WORD COUNT: 675

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 406 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 97:445891 PROMT

TITLE: vascular endothelial growth factor Genentech phase change  
I, USA

Vascular endothelial growth factor for \*\*\*coronary\*\*\*

\*\*\*artery\*\*\* \*\*\*disease\*\*\* enters Phase II trials

SOURCE: R & D Focus Drug News, ( \*\*\*18 Aug 1997\*\*\* ) pp. N/A.

ISSN: 1350-1135.

LANGUAGE: English

WORD COUNT: 40

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 407 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 97:283114 PROMT

TITLE: Companies aim novel therapeutic strategies at dual nature  
of angiogenesis.

Novel therapeutic strategies are being developed by several  
biotechnology companies, based on dual nature of  
angiogenesis

AUTHOR(S): Liszewski, Kathy

SOURCE: Genetic Engineering News, ( \*\*\*1 May 1997\*\*\* ) pp. 6.

ISSN: 0270-6377.

LANGUAGE: English

L5 ANSWER 408 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 97:77299 PROMT

TITLE: The Long and the Short of Business Development

SOURCE: Genesis Report-Rx, ( \*\*\*1 Dec 1996\*\*\* ) pp. N/A.

ISSN: 1061-2270.

LANGUAGE: English



L5 ANSWER 412 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:557916 PROMT

TITLE: Scios and Wyeth-Ayerst Announce Agreement to Develop  
FIBLAST for Neurological and Cardiovascular Disorders

SOURCE: PR Newswire, ( \*\*\*23 Oct 1996\*\*\* ) pp. 1023SFW050.

LANGUAGE: English

WORD COUNT: 952

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 413 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:554482 PROMT

TITLE: Industry News (Licensing) Human iNOS Gene Licensed for Gene  
Transfer Pharmaceutical Applications

SOURCE: Blood Weekly, ( \*\*\*21 Oct 1996\*\*\* ) pp. N/A.

ISSN: 1065-6073.

LANGUAGE: English

WORD COUNT: 562

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 414 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:521824 PROMT

TITLE: GenVec, Inc. Licenses The Human iNOS Gene From The  
University of Pittsburgh For All Gene Transfer  
Pharmaceutical Applications

SOURCE: PR Newswire, ( \*\*\*9 Oct 1996\*\*\* ) pp. 1009NYW003.

LANGUAGE: English

WORD COUNT: 777

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 415 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:388705 PROMT

TITLE: EUROPEAN PATENT OFFICE RULES IN FAVOR OF SCIOS FOR FIBLAST

L5 ANSWER 419 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:285146 PROMT  
TITLE: GENVEC INC. LICENSES GENE FROM SCIOS INC. FOR BIOBYPASS  
PRODUCT IN HEART AND VASCULAR DISEASE  
SOURCE: PR Newswire, ( \*\*\*4 Jun 1996\*\*\* ) pp. 0604NYTU010.  
LANGUAGE: English  
WORD COUNT: 535  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 420 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:282152 PROMT  
TITLE: COMPANY DEVELOPMENTS-Product Developments: SCIOS INC  
SOURCE: Bioventure View, ( \*\*\*Jun 1996\*\*\* ) pp. N/A.  
ISSN: 0892-1903.  
LANGUAGE: English  
WORD COUNT: 36  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 421 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:270947 PROMT  
TITLE: Scios to patent method of producing recombinant human basic  
fibroblast growth factor  
SOURCE: BIOTECH Patent News, ( \*\*\*1 May 1996\*\*\* ) pp. N/A.  
ISSN: 0898-2813.  
LANGUAGE: English  
WORD COUNT: 454  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 422 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:240262 PROMT  
TITLE: SCIOS RECEIVES U.S. PATENT FOR THE RECOMBINANT PRODUCTION

SO KARDIOLOGIYA, ( \*\*\*OCT-DEC 2000\*\*\* ) Vol. 40, No. 12, pp. 82-86.  
 Publisher: IZD VO MEDITSINA, PETROVERIGSKII PER 6-8, K-142 MOSCOW, RUSSIA.  
 ISSN: 0022-9040.

DT General Review; Journal  
 LA Russian  
 REC Reference Count: 43

L5 ANSWER 425 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation  
 on STN  
 AN 2000:779094 SCISEARCH  
 GA The Genuine Article (R) Number: 361YH  
 TI Angiogenesis and vasculogenesis. Therapeutic approaches for stimulation of  
 post-natal neovascularization  
 AU Kalka C (Reprint); Asahara T; Krone W; Isner J M  
 CS TUFTS UNIV, ST ELIZABETHS MED CTR, SCH MED, DEPT MED CARDIOVASC RES, 736  
 CAMBRIDGE ST, BOSTON, MA 02135 (Reprint); UNIV COLOGNE, KLIN & POLIKLIN  
 INNERE MED 2, D-5000 COLOGNE 41, GERMANY  
 CYA USA; GERMANY

SO HERZ, ( \*\*\*SEP 2000\*\*\* ) Vol. 25, No. 6, pp. 611-622.  
 Publisher: URBAN & VOGEL, C/O SPRINGER GMBH & CO AUSLIEFERUNGSGESELLSCHAFT  
 KUNDENSERVICE ZEITSCHRIFTEN, D-69126 HABERSTRASSE 7, GERMANY.  
 ISSN: 0340-9937.

DT Article; Journal  
 FS CLIN  
 LA German  
 REC Reference Count: 90  
 \*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L5 ANSWER 426 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation  
 on STN  
 AN 2000:598823 SCISEARCH  
 GA The Genuine Article (R) Number: 339PB  
 TI Adenovirus-mediated \*\*\*VEGF\*\*\* (121) gene transfer stimulates  
 angiogenesis in normoperfused skeletal muscle and preserves tissue  
 perfusion after induction of ischemia  
 AU Gowdak L H W; Poliakova L; Wang X T; Kovesdi I; Fishbein K W; Zacheo A;

AN 1999:982252 SCISEARCH  
 GA The Genuine Article (R) Number: 265KJ  
 TI Serum level of vascular endothelial growth factor is decreased by hormone replacement therapy in postmenopausal women without hypercholesterolemia  
 AU Sumino H; Nakamura T (Reprint); Ichikawa S; Kanda T; Sakamaki T; Sato K; Kobayashi I; Nagai R  
 CS GUNMA UNIV, SCH MED, DEPT INTERNAL MED 2, 3-39-22 SHOWA, MAEBASHI, GUMMA 3718511, JAPAN (Reprint); GUNMA UNIV, SCH MED, DEPT INTERNAL MED 2, MAEBASHI, GUMMA 3718511, JAPAN; CARDIOVASC HOSP CENT JAPAN, GUNMA 3770061, JAPAN; GUNMA UNIV, SCH MED, DEPT LAB MED, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, SCH MED, DEPT MED INFORMAT & DESIC SCI, MAEBASHI, GUMMA 371, JAPAN  
 CYA JAPAN  
 SO ATHEROSCLEROSIS, ( \*\*\*JAN 2000\*\*\* ) Vol. 148, No. 1, pp. 189-195.  
 Publisher: ELSEVIER SCI IRELAND LTD, CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND.  
 ISSN: 0021-9150.  
 DT Article; Journal  
 FS LIFE; CLIN  
 LA English  
 REC Reference Count: 25  
 \*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L5 ANSWER 429 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN  
 AN 1999:654157 SCISEARCH  
 GA The Genuine Article (R) Number: 227QN  
 TI Increased production of cytokines and growth factors by aortic allografts: A possible explanation for myointimal hyperplasia formation  
 AU Sterpetti A V (Reprint); Cucina A; Randone B; Guglielmi M B; Fragale A; Cavallaro A  
 CS UNIV ROMA LA SAPIENZA, IST CLIN CHIRURG 1, LAB CASTRO LAURENZIANO, VIA A SCARPA 14, I-00161 ROME, ITALY (Reprint); UNIV ROMA LA SAPIENZA, IST ISTOL & EMBRIOL, I-00161 ROME, ITALY  
 CYA ITALY  
 SO EUROPEAN SURGICAL RESEARCH, ( \*\*\*JUL-AUG 1999\*\*\* ) Vol. 31, No. 4, pp.

AN 1998:758407 SCISEARCH  
 GA The Genuine Article (R) Number: 124DT  
 TI Effects of \*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\* on  
 expression and microvascular response to \*\*\*VEGF\*\*\*  
 AU Metais C; Li J Y; Li J; Simons M; Sellke F W (Reprint)  
 CS BETH ISRAEL DEACONESS MED CTR, DEPT SURG, DIV CARDIOTHORAC SURG, EAST  
 CAMPUS, DANA 905, BOSTON, MA 02215 (Reprint); BETH ISRAEL DEACONESS MED  
 CTR, DEPT SURG, DIV CARDIOTHORAC SURG, BOSTON, MA 02215; BETH ISRAEL  
 DEACONESS MED CTR, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02215; HARVARD  
 UNIV, SCH MED, BOSTON, MA 02215  
 CYA USA  
 SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, ( \*\*\*OCT:  
 \*\*\* 1998\*\*\* ) Vol. 44, No. 4, pp. H1411-H1418.  
 Publisher: AMER PHYSIOLOGICAL SOC, 9650 ROCKVILLE PIKE, BETHESDA, MD  
 20814.  
 ISSN: 0363-6135.  
 DT Article; Journal  
 FS LIFE  
 LA English  
 REC Reference Count: 48  
 \*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L5 ANSWER 432 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation  
 on STN  
 AN 1998:300195 SCISEARCH  
 GA The Genuine Article (R) Number: ZG762  
 TI Gene therapy for restenosis  
 AU Steg P G (Reprint); Feldman L  
 CS HOP BICHAT, SERV CARDIOL, INSERM U460, 46 RUE HENRI HUCHARD, F-75877 PARIS  
 18, FRANCE (Reprint)  
 CYA FRANCE  
 SO PATHOLOGIE BIOLOGIE, ( \*\*\*MAR 1998\*\*\* ) Vol. 46, No. 3, pp. 201-204.  
 Publisher: EXPANSION SCI FRANCAISE, 31 BLVD LATOUR MAUBOURG, 75007 PARIS,  
 FRANCE.  
 ISSN: 0369-8114.  
 DT Article; Journal

AU HARADA K; FRIEDMAN M; LOPEZ J J; WANG S Y; LI J; PRASAD P V; PEARLMAN J D;  
EDELMAN E R; SELLKE F W; SIMONS M (Reprint)

CS HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT MED, CARDIOVASC DIV, HARVARD  
THORNDIKE LAB, BOSTON, MA, 02215 (Reprint); HARVARD UNIV, BETH ISRAEL  
HOSP, SCH MED, DEPT MED, CARDIOVASC DIV, HARVARD THORNDIKE LAB, BOSTON,  
MA, 02215; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT SURG, BOSTON, MA,  
02215; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT RADIOLOG, BOSTON, MA,  
02215; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, CHARLES A DANA RES INST,  
VASC BIOL UNIT, BOSTON, MA, 02215; MIT, PROGRAM HLTH SCI & TECHNOL,  
CAMBRIDGE, MA, 02139

CYA USA

SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, ( \*\*\*MAY:  
\*\*\* 1996\*\*\* ) Vol. 39, No. 5, pp. H1791-H1802.  
ISSN: 0363-6135.

DT Article; Journal

FS LIFE

LA ENGLISH

REC Reference Count: 34  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L5 ANSWER 435 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation  
on STN

AN 95:835524 SCISEARCH

GA The Genuine Article (R) Number: TG800

TI EFFECTS OF CYTOMEGALOVIRUS-INFECTION ON GROWTH-FACTOR PRODUCTION IN  
ENDOTHELIAL-CELLS AND FIBROBLASTS

AU GARRETT J S; NARUS J C; BOHNSACK J F; CARLING D E; GRIEVES K G; WALDMAN W  
J; SHADDY R E (Reprint)

CS PRIMARY CHILDRENS MED CTR, DIV CARDIOL, 100 N MED DR, SALT LAKE CITY, UT,  
84113 (Reprint); UNIV UTAH, SCH MED, DEPT PEDIAT, SALT LAKE CITY, UT,  
84132; OHIO STATE UNIV, DEPT PATHOL, COLUMBUS, OH, 43210

CYA USA

SO PEDIATRIC RESEARCH, ( \*\*\*DEC 1995\*\*\* ) Vol. 38, No. 6, pp. 1003-1008.  
ISSN: 0031-3998.

DT Article; Journal

FS LIFE

VANDERBILT TRANSPLANT, DEPT MED, NASHVILLE, TN, 37232; VANDERBILT UNIV,  
SCH MED, DEPT CARDIOTHORAC SURG, NASHVILLE, TN, 37232

CYA USA

SO TRANSPLANTATION, ( \*\*\*27 FEB 1995\*\*\* ) Vol. 59, No. 4, pp. 605-611.  
ISSN: 0041-1337.

DT Article; Journal

FS LIFE

LA ENGLISH

REC Reference Count: 48

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L5 ANSWER 438 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation  
on STN

AN 94:580349 SCISEARCH

GA The Genuine Article (R) Number: PF354

TI MODIFICATION OF ALTERNATIVE MESSENGER-RNA SPLICING OF FIBROBLAST  
GROWTH-FACTOR RECEPTORS IN HUMAN CARDIAC ALLOGRAFTS DURING REJECTION

AU ZHAO X M; FRIST W H; YEOH T K; MILLER G G (Reprint)

CS VANDERBILT UNIV, SCH MED, VANDERBILT TRANSPLANT CTR, A3310 MED CTR N,  
NASHVILLE, TN, 37232 (Reprint); VANDERBILT UNIV, SCH MED, VANDERBILT  
TRANSPLANT CTR, NASHVILLE, TN, 37232; VANDERBILT UNIV, SCH MED, DEPT  
THORAC SURG, NASHVILLE, TN, 37232; VANDERBILT UNIV, SCH MED, DEPT MED,  
NASHVILLE, TN, 37232

CYA USA

SO JOURNAL OF CLINICAL INVESTIGATION, ( \*\*\*SEP 1994\*\*\* ) Vol. 94, No. 3,  
pp. 992-1003.  
ISSN: 0021-9738.

DT Article; Journal

FS LIFE

LA ENGLISH

REC Reference Count: 42

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L5 ANSWER 439 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation  
on STN

AN 94:491287 SCISEARCH

L5 ANSWER 441 OF 549 USPATFULL on STN  
AN 2004:301964 USPATFULL  
TI Compositions and methods for modulating expression within smooth muscle cells  
IN Owens, Gary K., Earlysville, VA, United States  
Mack, Christopher, Chapel Hill, NC, United States  
Blank, Randall, Charlottesville, VA, United States  
PA Setagon, Inc., Charlottesville, VA, United States (U.S. corporation)  
PI US 6825035 B1 20041130  
WO 2000024254 20000504 <--  
AI US 2001-807757 20010417 (9)  
WO 1999-US24972 19991022  
20010417 PCT 371 date  
PRAI US 1998-105330P 19981023 (60)  
DT Utility  
FS GRANTED  
LN.CNT 3217  
INCL INCLM: 435/325.000  
INCLS: 536/024.100; 435/320.100; 800/013.000  
NCL NCLM: 435/325.000  
NCLS: 435/320.100; 536/024.100; 800/013.000  
IC [7]  
ICM: C12N005-10  
ICS: C12N015-63; C07H021-04; A01K067-00  
EXF 536/24.1; 435/320.1; 435/325; 800/13  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 442 OF 549 USPATFULL on STN  
AN 2004:78898 USPATFULL  
TI Detecting genetic predisposition to sight-threatening diabetic retinopathy  
IN Duff, Gordon W., South Yorkshire, UNITED KINGDOM  
Richardson, Patrick R. S., Litton Nr. Buxton, UNITED KINGDOM  
Rennie, Ian G., Newbold, UNITED KINGDOM  
PA Interleukin Genetics, Inc., Waltham, MA, United States (U.S.



INCLS: 514/002.000; 514/008.000; 514/012.000

NCL NCLM: 424/085.100

NCLS: 514/002.000; 514/008.000; 514/012.000

IC [7]

ICM: A61K038-19

EXF 424/85.1; 435/724; 514/12; 514/44; 514/2; 514/8

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 444 OF 549 USPATFULL on STN

AN 2002:340044 USPATFULL

TI Expandable space frame

IN Stevens, Walter J., Mountain View, CA, United States

Springer, George S., Stanford, CA, United States

PA The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)

PI US 6497724 B1 20021224

WO 9955257 19991104

<--

AI US 2000-674185 20001027 (9)

WO 1999-US9383 19990430

20001027 PCT 371 date

RLI Continuation-in-part of Ser. No. US 70476, now abandoned

DT Utility

FS GRANTED

LN.CNT 859

INCL INCLM: 623/001.150

INCLS: 623/001.160; 623/001.220

NCL NCLM: 623/001.150

NCLS: 623/001.160; 623/001.220

IC [7]

ICM: A61F002-06

EXF 623/1.15; 623/1.16; 623/1.2; 623/1.22; 606/213

L5 ANSWER 445 OF 549 USPATFULL on STN

AN 2002:263279 USPATFULL

TI Electrically mediated angiogenesis

IN Conrad-Vlasak, Deena, Eden Prairie, MN, United States

FS GRANTED

LN.CNT 773

INCL INCLM: 604/103.020

NCL NCLM: 604/103.020

IC [7]

ICM: A61M029-00

EXF 606/108; 606/194; 606/192; 604/103.01; 604/103.02; 604/183; 604/191

L5 ANSWER 447 OF 549 USPATFULL on STN

AN 2001:33286 USPATFULL

TI Prevention and treatment of cardiovascular pathologies with tamoxifen analogues

IN Grainger, David J., Cambridge, United Kingdom

Metcalfe, James C., Cambridge, United Kingdom

Kunz, Lawrence L., Redmond, WA, United States

Schroff, Robert W., Edmonds, WA, United States

PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

PI US 6197789 B1 20010306

WO 9640098 19961219 <--

AI US 1997-973570 19971205 (8)

WO 1996-US10211 19960607

19980908 PCT 371 date

19980908 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1995-478936, filed on 7 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-476735, filed on 7 Jun 1995, now patented, Pat. No. US 5595722 Continuation-in-part of Ser. No. US 1995-477393, filed on 7 Jun 1995 Continuation-in-part of Ser. No. US 1995-486334, filed on 7 Jun 1995, now patented, Pat. No. US 5770609

DT Utility

FS Granted

LN.CNT 4577

INCL INCLM: 514/319.000

INCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000;  
514/651.000; 514/866.000

NCL NCLM: 514/319.000

IN Nagler, Arnon, Jerusalem, Israel  
 Hazum, Eli, Rehovot, Israel  
 Geller, Ehud, Herzelia, Israel  
 Slavin, Shimon, Jerusalem, Israel  
 Vlodavsky, Israel, Mevaseret Zion, Israel  
 Pines, Mark, Rehovot, Israel

PA Agricultural Research Org. Ministry of Agriculture (Gov.), Israel  
 (non-U.S. government)  
 HadasitMedical Research Serv. & Devel. Ltd., Israel (non-U.S.  
 government)

PI US 6159488 20001212 <--

AI US 1999-325198 19990603 (9)

RLI Continuation-in-part of Ser. No. US 1999-180498, filed on 29 Mar 1999  
 which is a continuation of Ser. No. WO 1997-US15254, filed on 14 Aug  
 1997

DT Utility

FS Granted

LN.CNT 533

INCL INCLM: 424/423.000  
 INCLS: 424/422.000; 424/424.000; 424/473.000; 514/259.000

NCL NCLM: 424/423.000  
 NCLS: 424/422.000; 424/424.000; 424/473.000; 514/266.220

IC [7]  
 ICM: A61K031-505

EXF 424/422; 424/473; 424/423; 424/424; 514/259

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 450 OF 549 USPATFULL on STN

AN 2000:167245 USPATFULL

TI Methods and apparatus for transvascular muscular revascularization and  
 drug delivery

IN Ruiz, Carlos, 1747 N. Country La., Pasadena, CA, United States 91107

PI US 6159196 20001212 <--

AI US 1998-37590 19980309 (9)

DT Utility

FS Granted

corporation)

PI US 6149641 20001121 <--

AI US 1998-220985 19981223 (9)

RLI Continuation of Ser. No. US 1997-916430, filed on 21 Aug 1997, now patented, Pat. No. US 5866561

DT Utility

FS Granted

LN.CNT 250

INCL INCLM: 604/501.000  
INCLS: 604/507.000; 604/103.010; 604/103.020; 623/001.000

NCL NCLM: 604/501.000  
NCLS: 604/103.010; 604/103.020; 604/507.000

IC [7]  
ICM: A61N001-30

EXF 623/1; 604/21; 604/506-510; 604/501; 604/103.01-103.02

L5 ANSWER 453 OF 549 USPATFULL on STN

AN 2000:145865 USPATFULL

TI Targeted contrast agents for diagnostic and therapeutic use

IN Unger, Evan C., Tucson, AZ, United States  
Fritz, Thomas A., Tucson, AZ, United States  
Gertz, Edward W., Paradise Valley, AZ, United States

PA ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)

PI US 6139819 20001031 <--

AI US 1997-932273 19970917 (8)

RLI Continuation-in-part of Ser. No. US 1996-660032, filed on 6 Jun 1996, now abandoned which is a continuation-in-part of Ser. No. US 1996-640464, filed on 1 May 1996, now abandoned which is a continuation-in-part of Ser. No. US 1995-497684, filed on 7 Jun 1995, now abandoned And a continuation-in-part of Ser. No. US 1996-666129, filed on 19 Jun 1996, now patented, Pat. No. US 6033645

DT Utility

FS Granted

LN.CNT 7523

INCL INCLM: 424/009.520  
INCLS: 424/009.510; 424/450.000

AN 2000:138055 USPATFULL  
 TI Methods and compositions for diagnosis of hyperhomocysteinemia  
 IN Austin, Richard C., Ancaster, Canada  
 Hirsh, Jack, Hamilton, Canada  
 Weitz, Jeffrey I., Hamilton, Canada  
 PA Hamilton Civic Hospitals Research Development Inc., Canada (non-U.S.  
 corporation)  
 PI US 6132965 20001017 <--  
 AI US 1998-16540 19980130 (9)  
 RLI Continuation of Ser. No. US 1996-582261, filed on 3 Jan 1996  
 DT Utility  
 FS Granted  
 LN.CNT 2529  
 INCL INCLM: 435/006.000  
 INCLS: 435/091.200; 536/023.100; 536/024.300; 536/024.330  
 NCL NCLM: 435/006.000  
 NCLS: 435/091.200; 536/023.100; 536/024.300; 536/024.330  
 IC [7]  
 ICM: C07H021-04  
 ICS: C12Q001-68  
 EXF 435/6; 435/91.2; 536/23.1; 536/24.3; 536/24.33  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
  
 L5 ANSWER 456 OF 549 USPATFULL on STN  
 AN 2000:131591 USPATFULL  
 TI Nucleic acid ligands of tissue target  
 IN Stephens, Andrew, Boulder, CO, United States  
 Gold, Larry, Boulder, CO, United States  
 Speck, Ulrich, Berlin, Germany, Federal Republic of  
 PA NeXstar Pharmaceuticals, Inc., Boulder, CO, United States (U.S.  
 corporation)  
 PI US 6127119 20001003 <--  
 AI US 1997-976413 19971121 (8)  
 RLI Continuation-in-part of Ser. No. US 1995-433124, filed on 3 May 1995,  
 now patented, Pat. No. US 5750342 which is a continuation-in-part of  
 Ser. No. US 1991-714131, filed on 10 Jun 1991, now patented, Pat. No. US

LN.CNT 5924

INCL INCLM: 530/350.000

INCLS: 530/324.000; 530/326.000; 536/023.100; 536/023.500; 435/069.100;  
435/320.100; 435/325.000

NCL NCLM: 530/350.000

NCLS: 435/069.100; 435/320.100; 435/325.000; 530/324.000; 530/326.000;  
536/023.100; 536/023.500

IC [7]

ICM: C07K016-00

ICS: C12N015-00

EXF 536/23.1; 536/24.1; 536/24.3; 536/23.5; 435/6; 435/69.1; 435/7.1;  
435/172.3; 435/320.1; 435/325; 935/32; 935/52; 530/350

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 458 OF 549 USPATFULL on STN

AN 2000:125551 USPATFULL

TI MRI imaging method and apparatus

IN Pearlman, Justin D., Brookline, MA, United States

PA Beth Israel Deaconess Medical Center, Inc., Boston, MA, United States  
(U.S. corporation)

PI US 6121775 20000919 <--

AI US 1998-98175 19980616 (9)

DT Utility

FS Granted

LN.CNT 857

INCL INCLM: 324/309.000

INCLS: 324/318.000; 324/300.000; 128/653.000

NCL NCLM: 324/309.000

NCLS: 324/300.000; 324/318.000; 600/419.000

IC [7]

ICM: G01V003-00

EXF 324/309; 324/318; 324/300; 128/653; 600/410

L5 ANSWER 459 OF 549 USPATFULL on STN

AN 2000:125047 USPATFULL

TI Epoxide-containing compounds

US 1997-863877, filed on 27 May 1997, now patented, Pat. No. US 5910150  
And a continuation-in-part of Ser. No. US 1997-863925, filed on 27 May  
1997, now patented, Pat. No. US 5941839

DT Utility

FS Granted

LN.CNT 682

INCL INCLM: 606/170.000

INCLS: 606/159.000; 606/046.000

NCL NCLM: 606/170.000

NCLS: 606/046.000; 606/159.000

IC [7]

ICM: A61B017-00

EXF 606/1; 606/7; 606/14; 606/46; 606/159; 606/170

L5 ANSWER 461 OF 549 USPATFULL on STN

AN 2000:121539 USPATFULL

TI Methods for regulating transcription factors

IN Qabar, Maher N., Redmond, WA, United States

McMillan, Michael K., Bellevue, WA, United States

Kahn, Michael S., Kirkland, WA, United States

Tulinsky, John E., Seattle, WA, United States

Ogbu, Cyprian O., Bellevue, WA, United States

Mathew, Jessymol, Bellevue, WA, United States

PA Molecumetics Ltd., Bellevue, WA, United States (U.S. corporation)

PI US 6117896 20000912 <--

AI US 1998-22934 19980212 (9)

RLI Continuation-in-part of Ser. No. US 1997-797915, filed on 10 Feb 1997, -  
now abandoned And a continuation-in-part of Ser. No. US 692420

PRAI US 1997-47067P 19970519 (60)

DT Utility

FS Granted

LN.CNT 4501

INCL INCLM: 514/384.000

INCLS: 514/248.000; 530/323.000; 530/332.000; 548/263.400

NCL NCLM: 514/384.000

NCLS: 514/248.000; 530/323.000; 530/332.000; 548/263.400

TI Therapeutic compounds containing xanthinyl  
 IN Klein, J. Peter, Vashon, WA, United States  
 Leigh, Alistair J., Brier, WA, United States  
 Underiner, Gail E., Brier, WA, United States  
 Kumar, Anil M., Seattle, WA, United States  
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
 PI US 6100271 20000808 <--  
 AI US 1995-483871 19950607 (8)  
 RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994,  
 now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1986  
 INCL INCLM: 514/263.000  
 INCLS: 514/265.000; 544/268.000; 544/269.000; 544/271.000  
 NCL NCLM: 514/263.200  
 NCLS: 514/210.210; 514/234.200; 514/263.220; 514/263.230; 514/263.240;  
 514/263.350; 544/268.000; 544/269.000; 544/271.000  
 IC [7]  
 ICM: A61K031-522  
 ICS: C07D473-10  
 EXF 544/271; 544/268; 544/269; 514/263; 514/265  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
  
 L5 ANSWER 464 OF 549 USPATFULL on STN  
 AN 2000:102275 USPATFULL  
 TI Gene therapies for enhancing cardiac function  
 IN Hammond, H. Kirk, La Jolla, CA, United States  
 Giordano, Frank J., Del Mar, CA, United States  
 Dillmann, Wolfgang H., Solana Beach, CA, United States4)  
 PA The Regents of the University of California, Oakland, CA, United States  
 (U.S. corporation)  
 PI US 6100242 20000808 <--  
 WO 9626742 19960906 <--  
 AI US 1997-722271 19971229 (8)  
 WO 1996-US2631 19960227



IC [7]  
ICM: A61K031-16  
ICS: A61K031-095; A61K031-105  
EXF 514/599; 514/706; 514/707; 514/851; 514/861; 514/863; 514/866; 514/909;  
514/912  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 466 OF 549 USPATFULL on STN  
AN 2000:91735 USPATFULL  
TI Interferon responsive transcript (IRT-1)  
IN Autieri, Michael V., Blue Bell, PA, United States  
PA Temple University of the Commonwealth System of Higher Education,  
Philadelphia, PA, United States (U.S. corporation)  
PI US 6090580 20000718 <--  
AI US 1998-4171 19980102 (9)  
DT Utility  
FS Granted  
LN.CNT 1142  
INCL INCLM: 435/069.100  
INCLS: 435/252.330; 435/325.000; 435/320.100; 530/350.000; 536/023.100;  
536/023.500  
NCL NCLM: 435/069.100  
NCLS: 435/252.330; 435/320.100; 435/325.000; 530/350.000; 536/023.100;  
536/023.500

IC [7]  
ICM: C12P021-06  
ICS: C07H021-04  
EXF 530/350; 536/23.5; 435/69.1; 435/252.3; 435/252.33; 435/320.1; 435/325  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 467 OF 549 USPATFULL on STN  
AN 2000:37806 USPATFULL  
TI Methods for using therapeutic compounds containing xanthinyl  
IN Klein, J. Peter, Vashon, WA, United States  
Leigh, Alistair J., Brier, WA, United States  
Underiner, Gail E., Brier, WA, United States

INCLS: 435/007.100; 435/325.000; 435/243.000; 435/320.100; 536/023.510;  
530/399.000

NCL NCLM: 435/069.400

NCLS: 435/007.100; 435/243.000; 435/320.100; 435/325.000; 530/399.000;  
536/023.510

IC [7]

ICM: C12N015-18

ICS: C12N015-63; C12N001-21; C12N005-00

EXF 435/69.4; 435/320.1; 435/325; 435/243; 536/23.51; 530/399

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 469 OF 549 USPATFULL on STN

AN 2000:12926 USPATFULL

TI Compositions and methods for the treatment and diagnosis of  
cardiovascular disease using rchd523 as a target

IN Falb, Dean A., Wellesley, MA, United States

Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States

PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.  
corporation)

Brigham and Women's Hospital, Boston, MA, United States (U.S.  
corporation)

PI US 6020463 20000201 <--

AI US 1997-944423 19971006 (8)

RLI Division of Ser. No. US 1996-599654, filed on 9 Feb 1996, now patented,  
Pat. No. US 5882925 which is a continuation-in-part of Ser. No. US  
1995-485573, filed on 7 Jun 1995, now patented, Pat. No. US 5968770  
which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10  
Feb 1995

DT Utility

FS Granted

LN.CNT 5972

INCL INCLM: 530/350.000

INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.100

NCL NCLM: 530/350.000

NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.100

IC [6]

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 6020337 20000201 <--  
AI US 1997-950810 19970916 (8)  
RLI Continuation-in-part of Ser. No. US 1993-42946, filed on 5 Apr 1993, now  
patented, Pat. No. US 5670506 And a continuation-in-part of Ser. No. US  
1997-910579, filed on 26 Jul 1997  
DT Utility  
FS Granted  
LN.CNT 1376  
INCL INCLM: 514/258.000  
INCLS: 514/263.000; 544/267.000; 544/272.000; 544/277.000  
NCL NCLM: 514/263.340  
NCLS: 514/210.210; 514/263.360; 544/267.000; 544/272.000; 544/277.000  
IC [6]  
ICM: A61K031-52  
ICS: C07D473-00  
EXF 514/258; 544/267; 544/272; 544/277  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 472 OF 549 USPATFULL on STN  
AN 2000:10014 USPATFULL  
TI Compositions and methods for the treatment and diagnosis of  
cardiovascular disease using rchd528 as a target  
IN Falb, Dean A., Wellesley, MA, United States  
Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States  
PA Millenium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.  
corporation) ...  
Brigham and Women's Hospital, Boston, MA, United States (U.S.  
corporation)  
PI US 6018025 20000125 <--  
AI US 1997-944868 19971006 (8)  
RLI Division of Ser. No. US 1996-599654, filed on 9 Feb 1996, now patented,  
Pat. No. US 5882925 which is a continuation-in-part of Ser. No. US  
1995-485573, filed on 7 Jun 1995 which is a continuation-in-part of Ser.  
No. US 1995-386844, filed on 10 Feb 1995  
DT Utility

ICM: C07H021-04

ICS: C12N015-11; C12N015-63

EXF 514/44; 435/172.3; 435/320.1; 536/23.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 474 OF 549 USPATFULL on STN

AN 1999:159127 USPATFULL

TI Minimally invasive gene therapy delivery device and method

IN Rosengart, Todd K., Tenafly, NJ, United States

Crystal, Ronald G., Potomac, MD, United States

Hartman, Raymond A., Carlsbad, CA, United States

PA Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S. corporation)

PI US 5997509 19991207 <--

AI US 1998-35892 19980306 (9)

DT Utility

FS Granted

LN.CNT 543

INCL INCLM: 604/164.000

INCLS: 604/116.000; 604/181.000; 604/187.000

NCL NCLM: 604/164.010

NCLS: 604/116.000; 604/181.000; 604/187.000

IC [6]

ICM: A61M005-178

ICS: A61M005-00

EXF 604/1; 604/95; 604/115; 604/116; 604/117; 604/181; 604/188; 604/187;  
604/164; 604/207; 604/208; 604/211; 604/218; 604/246; 604/264; 604/272

L5 ANSWER 475 OF 549 USPATFULL on STN

AN 1999:151195 USPATFULL

TI GATA-6 transcription factor: compositions and methods

IN Walsh, Kenneth, Carlisle, MA, United States

PA St. Elizabeth's Medical Center, Boston, MA, United States (U.S. corporation)

PI US 5990092 19991123 <--

AI US 1997-927394 19970827 (8)

L5 ANSWER 477 OF 549 USPATFULL on STN  
AN 1999:132529 USPATFULL  
TI Fluorescence-based assays for measuring cell proliferation  
IN Parandoosh, Zahra, San Diego, CA, United States  
PA Irori, La Jolla, CA, United States (U.S. corporation)  
PI US 5972639 19991026 <--  
AI US 1997-901229 19970724 (8)  
DT Utility  
FS Granted  
LN.CNT 1358  
INCL INCLM: 435/029.000  
NCL NCLM: 435/029.000  
IC [6]  
ICM: C12Q001-02  
EXF 435/6; 435/7.1; 435/7.4; 435/7.72; 435/21; 435/29; 435/195; 435/196;  
435/375; 935/66; 935/76  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 478 OF 549 USPATFULL on STN  
AN 1999:124900 USPATFULL  
TI Enantiomerically pure hydroxylated xanthine compounds  
IN Bianco, James A., Seattle, WA, United States  
Woodson, Paul, Bothell, WA, United States  
Porubek, David, Edmonds, WA, United States  
Singer, Jack, Seattle, WA, United States  
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 5965564 19991012 <--  
AI US 1998-44976 19980320 (9)  
RLI Continuation of Ser. No. US 1995-457703, filed on 1 Jun 1995, now  
patented, Pat. No. US 5739138 which is a division of Ser. No. US  
1994-343810, filed on 22 Nov 1994, now patented, Pat. No. US 5652243  
which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994,  
now patented, Pat. No. US 5648357 which is a continuation of Ser. No. US  
1993-13977, filed on 4 Feb 1993, now abandoned which is a  
continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992,  
now abandoned which is a continuation-in-part of Ser. No. US

angiogenesis

IN Kaplan, Aaron V., Los Altos, CA, United States  
Simons, Michael, Chestnut Hill, MA, United States

PA Localmed, Inc., Palo Alto, CA, United States (U.S. corporation)  
Beth Israel Deaconess Medical Center, Boston, MA, United States (U.S. corporation)

PI US 5941868 19990824 <--

AI US 1996-753224 19961122 (8)

PRAI US 1995-9086P 19951222 (60)

DT Utility

FS Granted

LN.CNT 544

INCL INCLM: 604/500.000

NCL NCLM: 604/500.000

IC [6]  
ICM: A61M031-00

EXF 604/96; 604/101; 604/99; 604/265; 604/266; 604/890.1; 604/892.1; 604/52;  
604/53; 606/192; 606/194

L5 ANSWER 481 OF 549 USPATFULL on STN

AN 1999:92656 USPATFULL

TI Compositions and methods for modulating growth of a tissue in a mammal

IN Weisz, Paul B., State College, PA, United States

PA Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)

PI US 5935940 19990810 <--

AI US 1997-906500 19970805 (8) ..

RLI Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented, Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned , said Ser. No. US 900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 483 OF 549 USPATFULL on STN  
AN 1999:56471 USPATFULL  
TI Methods of modulating tissue growth and regeneration  
IN Herrmann, Howard C., Bryn Mawr, PA, United States  
Barnathan, Elliot, Havertown, PA, United States  
Weisz, Paul B., State College, PA, United States  
PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)  
PI US 5902799 19990511 <--  
AI US 1997-906501 19970805 (8)  
RLI Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented, Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned , said Ser. No. US 900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809  
DT Utility  
FS Granted  
LN.CNT 1703  
INCL INCLM: 514/058.000  
INCLS: 514/021.000; 530/810.000; 530/813.000; 530/817.000  
NCL NCLM: 514/058.000  
NCLS: 514/021.000; 530/810.000; 530/813.000; 530/817.000  
IC [6]  
ICM: A61K031-715  
ICS: A61K031-735  
EXF 514/58; 514/21; 514/56; 530/810; 530/812; 530/813; 530/817  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 484 OF 549 USPATFULL on STN  
AN 1999:43624 USPATFULL

RLI Continuation of Ser. No. US 1993-149681, filed on 9 Nov 1993, now  
abandoned which is a continuation-in-part of Ser. No. US 1992-973804,  
filed on 9 Nov 1992, now patented, Pat. No. US 5340813

DT Utility

FS Granted

LN.CNT 1351

INCL INCLM: 514/263.000

INCLS: 514/261.000; 544/267.000; 544/264.000; 544/265.000

NCL NCLM: 514/263.350

NCLS: 544/264.000; 544/265.000; 544/267.000

IC [6]

ICM: C07D473-00

ICS: A61K031-52

EXF 544/257; 544/267; 544/263; 544/285; 544/287; 514/263; 514/261

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 486 OF 549 USPATFULL on STN

AN 1999:40187 USPATFULL

TI Endothelial-cell specific promoter

IN Patterson, Winston Campbell, Brighton, MA, United States

Lee, Mu-En, Newton, MA, United States

Haber, Edgar, Salisbury, NH, United States

PA President and Fellows of Harvard College, Cambridge, MA, United States  
(U.S. corporation)

PI US 5888765 19990330

<--

AI US 1995-494282 19950623 (8)

DT Utility

FS Granted

LN.CNT 1003

INCL INCLM: 435/069.100

INCLS: 435/172.300; 435/320.100; 435/325.000; 536/024.100; 536/023.100

NCL NCLM: 435/069.100

NCLS: 435/320.100; 435/325.000; 435/455.000; 536/023.100; 536/024.100

IC [6]

ICM: C12N015-09

ICS: C12N015-11; C12N015-79; C12N015-85



PI US 5882914 19990316 <--  
AI US 1995-480473 19950606 (8)  
DT Utility  
FS Granted  
LN.CNT 2493  
INCL INCLM: 435/252.300  
INCLS: 435/320.100; 435/325.000; 536/023.500  
NCL NCLM: 435/252.300  
NCLS: 435/320.100; 435/325.000; 536/023.500  
IC [6]  
ICM: C12N001-20  
ICS: C12N015-63; C12N005-00; C07H021-04  
EXF 435/325; 435/252.3; 435/320.1; 536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 489 OF 549 USPATFULL on STN  
AN 1999:27739 USPATFULL  
TI Developmentally-regulated endothelial cell locus-1  
IN Quertermous, Thomas, Nashville, TN, United States  
Hogan, Brigid, Brentwood, TN, United States  
Snodgrass, H. Ralph, Powell, OH, United States  
Zupancic, Thomas Joel, Worthington, OH, United States  
PA Progenitor, Inc., Menlo Park, CA, United States (U.S. corporation)  
Vanderbilt University, Nashville, TN, United States (U.S. corporation)  
PI US 5877281 19990302 <--  
AI US 1996-659235 19960605 (8)  
RLI Continuation-in-part of Ser. No. US 1995-480229, filed on 7 Jun 1995.  
DT Utility  
FS Granted  
LN.CNT 2861  
INCL INCLM: 530/350.000  
INCLS: 530/402.000; 530/300.000; 530/383.000; 435/069.700; 536/023.100;  
536/023.400; 536/023.500  
NCL NCLM: 530/350.000  
NCLS: 435/069.700; 530/300.000; 530/383.000; 530/402.000; 536/023.100;  
536/023.400; 536/023.500

TI Compositions and methods for modulating growth of a tissue in a mammal  
 IN Herrmann, Howard C., Bryn Mawr, PA, United States  
 Barnathan, Elliot, Havertown, PA, United States  
 Weisz, Paul B., State College, PA, United States  
 PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United  
 States (U.S. corporation)  
 PI US 5874419 19990223 <--  
 AI US 1997-905612 19970804 (8)  
 RLI Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented,  
 Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592,  
 filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser.  
 No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a  
 continuation-in-part of Ser. No. US 1991-691168, filed on 24 Apr 1991,  
 now abandoned which is a continuation of Ser. No. US 1989-397559, filed  
 on 23 Aug 1989, now abandoned , said Ser. No. US 20 -900592 which is a  
 continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990,  
 now patented, Pat. No. US 5183809, issued on 2 Feb 1993  
 DT Utility  
 FS Granted  
 LN.CNT 1482  
 INCL INCLM: 514/058.000  
 INCLS: 514/021.000; 514/023.000; 514/054.000; 514/060.000; 514/769.000;  
 424/652.000; 424/682.000; 424/617.000; 536/103.000  
 NCL NCLM: 514/058.000  
 NCLS: 424/617.000; 424/652.000; 424/682.000; 514/021.000; 514/023.000;  
 514/054.000; 514/060.000; 514/769.000; 536/103.000  
 IC [6]  
 ICM: A61K031-735  
 ICS: A61K047-02; C08B037-16  
 EXF 514/21; 514/23; 514/54; 514/58; 514/60; 514/769; 536/103; 424/652;  
 424/682; 424/617  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 492 OF 549 USPATFULL on STN  
 AN 1999:15930 USPATFULL  
 TI Epoxide-containing compounds

LN.CNT 229

INCL INCLM: 514/182.000

INCLS: 604/096.000

NCL NCLM: 514/182.000

NCLS: 604/096.010

IC [6]

ICM: A61K031-56

EXF 514/182

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 494 OF 549 USPATFULL on STN

AN 1999:4647 USPATFULL

TI Fas ligand compositions for treatment of proliferative disorders

IN Walsh, Kenneth, Carlisle, MA, United States

PA St. Elizabeth's Medical Center, Boston, MA, United States (U.S.  
corporation)

PI US 5858990 19990112 <--

AI US 1997-810453 19970304 (8)

DT Utility

FS Granted

LN.CNT 3038

INCL INCLM: 514/044.000

INCLS: 435/006.000; 435/172.100; 435/320.100; 435/069.100; 435/375.000;  
435/377.000

NCL NCLM: 514/044.000

NCLS: 435/006.000; 435/069.100; 435/320.100; 435/375.000; 435/377.000

IC [6]

ICM: A61K048-00

ICS: C12N015-11

EXF 435/6; 435/172.1; 435/172.3; 435/320.1; 435/325; 435/69.1; 435/31.1;  
435/375; 435/377; 536/23.1; 536/23.5; 514/2; 514/44

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 495 OF 549 USPATFULL on STN

AN 1998:157185 USPATFULL

TI Compositions and methods for the treatment and diagnosis of

now abandoned

DT Utility

FS Granted

LN.CNT 2429

INCL INCLM: 514/651.000

INCLS: 514/824.000

NCL NCLM: 514/651.000

NCLS: 514/824.000

IC [6]

ICM: A61K031-135

EXF 514/56; 514/651; 514/824

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 497 OF 549 USPATFULL on STN

AN 1998:154038 USPATFULL

TI Methods of determining chemicals that modulate expression of genes  
associated with cardiovascular disease

IN Foulkes, J. Gordon, Huntington Station, NY, United States

Liechtfried, Franz E., Vienna, Austria

Pieler, Christian, Vienna, Austria

Stephenson, John R., Santa Cruz, CA, United States

Case, Casey C., Lynbrook, NY, United States

PA Oncogene Science, Inc., Uniondale, NY, United States (U.S. corporation)

PI US 5846720 19981208 <--

AI US 1996-700757 19960815 (8)

RLI Continuation of Ser. No. US 1992-832905, filed on 7 Feb 1992, now  
patented, Pat. No. US 5580722 which is a continuation-in-part of Ser.  
No. US 1990-555196, filed on 18 Jul 1990, now abandoned which is a  
continuation-in-part of Ser. No. US 1989-382712, filed on 18 Jul 1989,  
now abandoned

DT Utility

FS Granted

LN.CNT 3998

INCL INCLM: 435/006.000

INCLS: 435/069.800; 435/091.500; 435/320.100; 935/077.000; 935/078.000

NCL NCLM: 435/006.000

Klein, J. Peter, Vashon Island, WA, United States

Rice, Glenn C., Seattle, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5837703 19981117 <--

AI US 1993-152650 19931112 (8)

RLI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,  
now abandoned

DT Utility

FS Granted

LN.CNT 2596

INCL INCLM: 514/183.000

INCLS: 514/211.000; 514/228.800; 514/241.000; 514/242.000; 514/249.000;  
514/256.000; 514/259.000; 514/263.000; 514/270.000; 514/274.000;  
514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000;  
514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000;  
540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000;  
544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000;  
546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000;  
548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000

NCL NCLM: 514/183.000

NCLS: 514/211.150; 514/228.800; 514/241.000; 514/242.000; 514/249.000;  
514/256.000; 514/266.200; 514/266.300; 514/270.000; 514/274.000;  
514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000;  
514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000;  
540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000;  
544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000;  
546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000;  
548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000

IC [6]

ICM: A61K031-55

ICS: A61K031-515; A61K031-445; A61K031-52

EXF 544/276; 544/272; 544/216; 544/257; 544/285; 544/286; 544/301; 544/311;  
544/335; 514/263; 514/183; 514/211; 514/228.8; 514/241; 514/242;  
514/249; 514/256; 514/259; 514/270; 514/274; 514/309; 514/312; 514/315;  
514/348; 514/357; 514/374; 514/400; 514/418; 514/425; 514/427; 540/467;  
540/544; 546/96; 546/141; 546/142; 546/157; 546/246; 546/296; 546/334;

RLI Division of Ser. No. US 1994-303842, filed on 8 Sep 1994, now patented,  
Pat. No. US 5641783 which is a continuation-in-part of Ser. No. US  
1993-152650, filed on 12 Nov 1993, now patented, Pat. No. US 5801181 And  
Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US  
5470878 , said Ser. No. US -152650 And Ser. No. US -164081 , each  
Ser. No. US - which is a continuation-in-part of Ser. No. US  
1993-40820, filed on 31 Mar 1993, now abandoned

DT Utility

FS Granted

LN.CNT 3136

. INCL INCLM: 514/222.500

INCLS: 514/223.500; 514/224.500; 514/226.800; 514/227.500; 514/228.800;  
514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/248.000;  
514/249.000; 514/255.000; 514/258.000; 514/274.000; 514/301.000;  
514/303.000; 514/311.000; 514/351.000; 514/360.000; 514/361.000;  
514/362.000; 514/363.000; 514/364.000; 514/365.000; 514/367.000;  
514/372.000; 514/373.000; 514/374.000; 514/375.000; 514/376.000;  
514/378.000; 514/379.000; 514/380.000; 514/387.000; 514/395.000;  
514/415.000; 514/418.000; 514/424.000; 514/425.000; 514/433.000;  
514/452.000; 514/432.000; 514/438.000; 346/113.000; 346/114.000;  
346/164.000; 346/300.000; 549/014.000; 549/050.000; 549/075.000;  
549/367.000; 549/368.000; 544/002.000; 544/003.000; 544/005.000;  
544/008.000; 544/053.000; 544/063.000; 544/065.000; 544/066.000;  
544/067.000; 544/090.000; 544/091.000; 544/127.000; 544/128.000;  
544/162.000; 544/215.000; 544/219.000; 544/229.000; 544/235.000;  
544/237.000; 544/255.000; 544/278.000; 544/311.000; 544/353.000;  
544/385.000; 548/123.000; 548/125.000; 548/131.000; 548/134.000;  
548/143.000; 548/146.000; 548/153.000; 548/174.000; 548/207.000;  
548/214.000; 548/215.000; 548/217.000; 548/221.000; 548/228.000;  
548/229.000; 548/237.000; 548/240.000; 548/241.000; 548/243.000;  
548/247.000; 548/267.200; 548/303.700; 548/307.100; 548/453.000;  
548/486.000; 548/543.000; 548/546.000

NCL NCLM: 514/222.500

NCLS: 514/223.500; 514/224.500; 514/226.800; 514/227.500; 514/228.800;  
514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/248.000;  
514/249.000; 514/255.020; 514/260.100; 514/274.000; 514/301.000;

L5 ANSWER 502 OF 549 USPATFULL on STN  
AN 1998:128232 USPATFULL  
TI Method of attenuating arterial stenosis  
IN Abendschein, Dana R., St. Louis, MO, United States  
PA G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)  
PI US 5824644 19981020 <--  
AI US 1996-675122 19960703 (8)  
RLI Continuation-in-part of Ser. No. US 1996-648777, filed on 16 May 1996,  
now abandoned which is a continuation-in-part of Ser. No. US  
1994-271930, filed on 7 Jul 1994, now abandoned  
DT Utility  
FS Granted  
LN.CNT 679  
INCL INCLM: 514/012.000  
INCLS: 514/002.000; 514/021.000; 530/324.000; 530/350.000; 530/380.000;  
424/422.000  
NCL NCLM: 514/012.000  
NCLS: 424/422.000; 514/002.000; 514/021.000; 530/324.000; 530/350.000;  
530/380.000  
IC [6]  
ICM: A61K038-00  
ICS: C07K014-00; A61F013-00  
EXF 514/12; 514/2; 514/21; 530/350; 530/324; 530/380; 424/422  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 503 OF 549 USPATFULL on STN  
AN 1998:122413 USPATFULL  
TI Substituted amino alkyl compounds  
IN Klein, J. Peter, Vashon Island, WA, United States  
Underiner, Gail E., Brier, WA, United States  
Leigh, Alistair J., Brier, WA, United States  
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 5817662 19981006 <--  
AI US 1995-468656 19950606 (8)  
RLI Division of Ser. No. US 1993-149681, filed on 9 Nov 1993, now abandoned

935/6; 935/8; 935/17; 935/77; 935/78

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 505 OF 549 USPATFULL on STN  
AN 1998:111942 USPATFULL  
TI Therapeutic compounds containing pyrimidinyl moieties  
IN Klein, J. Peter, Vashon, WA, United States  
Leigh, Alistair J., Brier, WA, United States  
Underiner, Gail E., Brier, WA, United States  
Kumar, Anil M., Seattle, WA, United States  
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 5807862 19980915 <--  
AI US 1995-478112 19950607 (8)  
RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 2190  
INCL INCLM: 514/269.000  
INCLS: 544/309.000; 544/310.000; 544/311.000; 544/312.000  
NCL NCLM: 514/269.000  
NCLS: 544/309.000; 544/310.000; 544/311.000; 544/312.000  
IC [6]  
ICM: A61K031-505  
ICS: C07D239-54  
EXF 514/269; 514/274; 544/309; 544/310; 544/311; 544/312  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 506 OF 549 USPATFULL on STN  
AN 1998:111941 USPATFULL  
TI Amine substituted xanthinyl compounds  
IN Klein, J. Peter, Vashon, WA, United States  
Underiner, Gail E., Brier, WA, United States  
Kumar, Anil M., Seattle, WA, United States  
Ridgers, Lance H., Bothell, WA, United States  
Rice, Glenn C., Seattle, WA, United States



ICM: A61K038-18

ICS: C07K014-50; A61N001-18

EXF 514/12; 514/56; 424/548; 424/198.1; 530/399; 536/21; 607/3; 607/50

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 508 OF 549 USPATFULL on STN

AN 1998:108415 USPATFULL

TI Therapeutic compounds containing a monocyclic five- to six- membered  
ring structure having one to two nitrogen atoms

IN Underiner, Gail E., Brier, WA, United States

Porubek, David, Seattle, WA, United States

Klein, J. Peter, Vashon Island, WA, United States

Woodson, Paul, Edmonds, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5804584 19980908 <--

AI US 1995-468659 19950606 (8)

RLI Division of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned  
which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16  
Nov 1992, now patented, Pat. No. US 5473070

DT Utility

FS Granted

LN.CNT 1554

INCL INCLM: 514/269.000

INCLS: 544/298.000; 544/242.000; 544/301.000; 544/302.000; 514/256.000

NCL NCLM: 514/269.000

NCLS: 514/256.000; 544/242.000; 544/298.000; 544/301.000; 544/302.000

IC [6]

ICM: C07D239-54

ICS: A61K031-52

EXF 514/242; 514/243; 514/269; 544/298; 544/299

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 509 OF 549 USPATFULL on STN

AN 1998:104752 USPATFULL

TI Amine substituted compounds

IN Klein, J. Peter, Vashon, WA, United States

LN.CNT 2822

INCL INCLM: 514/263.000

INCLS: 514/183.000; 514/249.000; 514/259.000; 514/274.000; 514/309.000;  
514/315.000; 514/418.000; 514/425.000; 514/617.000; 514/619.000;  
514/626.000; 514/668.000; 514/669.000

NCL NCLM: 514/263.350

NCLS: 514/183.000; 514/249.000; 514/266.300; 514/274.000; 514/309.000;  
514/315.000; 514/418.000; 514/425.000; 514/617.000; 514/619.000;  
514/626.000; 514/668.000; 514/669.000

IC [6]

ICM: A01N043-00

ICS: A01N043-90; A01N043-58; A01N043-42

EXF 514/263; 514/249; 514/259; 514/265; 514/274; 514/309; 514/315; 514/418;  
514/425; 514/617; 514/619; 514/626; 514/668; 514/669

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 511 OF 549 USPATFULL on STN

AN 1998:95545 USPATFULL

TI Enantiomerically pure hydroxylated xanthine compounds

IN Bianco, James A., Seattle, WA, United States

Woodson, Paul, Bothell, WA, United States

Porubek, David, Edmonds, WA, United States

Singer, Jack, Seattle, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5792772 19980811 <--

AI US 1995-458957 19950601 (8)

RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now patented,  
Pat. No. US 5652243 which is a division of Ser. No. US 1994-307554,  
filed on 16 Sep 1994, now patented, Pat. No. US 5648357 which is a  
continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now  
abandoned which is a continuation-in-part of Ser. No. US 1992-926665,  
filed on 7 Aug 1992, now abandoned which is a continuation-in-part of  
Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned

DT Utility

FS Granted

LN.CNT 1734

-  
IN Pratt, Richard E., Palo Alto, CA, United States  
Dzau, Victor J., Los Altos Hills, CA, United States  
PA The Board of Trustees of the Leland Stanford Junior Univ., Palo Alto,  
CA, United States (U.S. corporation)  
PI US 5785965 19980728 <--  
AI US 1996-647821 19960515 (8)  
DT Utility  
FS Granted  
LN.CNT 905  
INCL INCLM: 424/093.210  
INCLS: 424/093.100; 424/093.200; 435/172.300; 435/325.000  
NCL NCLM: 424/093.210  
NCLS: 424/093.100; 424/093.200; 435/325.000; 435/455.000; 435/456.000  
IC [6]  
ICM: A01N063-00  
ICS: C12N015-00  
EXF 600/36; 623/1; 623/11; 623/12; 435/172.3; 435/240.2; 435/320.1; 435/325;  
424/93.21; 424/93.1; 424/93.2; 514/44  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 514 OF 549 USPATFULL on STN  
AN 1998:82763 USPATFULL  
TI Hydroxyl-containing xanthine compounds  
IN Underiner, Gail E., Brier, WA, United States  
Porubek, David, Seattle, WA, United States  
Klein, J. Peter, Vashon Island, WA, United States  
Woodson, Paul, Edmonds, WA, United States -  
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 5780476 19980714 <--  
AI US 1995-468660 19950606 (8)  
RLI Division of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned  
which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16  
Nov 1992, now patented, Pat. No. US 5473070  
DT Utility  
FS Granted  
LN.CNT 1672

EXF 544/267; 544/257; 544/285; 544/286; 544/287; 544/311; 546/141; 546/243;  
546/246; 548/477; 548/546

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 516 OF 549 USPATFULL on STN

AN 1998:79342 USPATFULL

TI Acetal-and ketal-substituted pyrimidine compounds

IN Leigh, Alistair, Brier, WA, United States

Underiner, Gail, Brier, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5777115 19980707 <--

AI US 1994-193331 19940207 (8)

RLI Continuation-in-part of Ser. No. US 1993-4353, filed on 14 Jan 1993, now  
abandoned

DT Utility

FS Granted

LN.CNT 1632

INCL INCLM: 544/242.000

INCLS: 544/267.000; 514/269.000; 514/270.000; 514/256.000

NCL NCLM: 544/242.000

NCLS: 544/267.000

IC [6]

ICM: C07D239-26

ICS: A61K031-505

EXF 544/267; 544/242; 546/242; 546/243; 514/256; 514/269; 514/270

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 517 OF 549 USPATFULL on STN

AN 1998:72634 USPATFULL

TI Prevention and treatment of cardiovascular pathologies

IN Grainger, David J., Cambridge, England

Metcalfe, James C., Cambridge, England

Kunz, Lawrence L., Redmond, WA, United States

Schroff, Robert W., Edmonds, WA, United States

Weissberg, Peter L., Cambridge, England

PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

LN.CNT 2183

INCL INCLM: 514/263.000

INCLS: 544/271.000; 544/273.000

NCL NCLM: 514/263.350

NCLS: 514/151.000; 544/271.000; 544/273.000

IC [6]

ICM: M61K031-52

EXF 514/263; 544/271; 544/273

L5 ANSWER 519 OF 549 USPATFULL on STN

AN 1998:51651 USPATFULL

TI Substituted amino alcohol compounds

IN Klein, J. Peter, Vashon, WA, United States

Underiner, Gail E., Brier, WA, United States

Kumar, Anil M., Seattle, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5750575 19980512 <--

AI US 1995-475721 19950607 (8)

RLI Division of Ser. No. US 1994-303842, filed on 8 Sep 1994, now patented,  
Pat. No. US 5641783 which is a continuation-in-part of Ser. No. US  
1993-152650, filed on 12 Nov 1993 And a continuation-in-part of Ser. No.  
US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878  
which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31  
Mar 1993, now abandoned

DT Utility

FS Granted

LN.CNT 3115

INCL INCLM: 514/617.000

INCLS: 514/653.000; 564/182.000; 564/355.000; 564/361.000

NCL NCLM: 514/617.000

NCLS: 514/653.000; 564/182.000; 564/355.000; 564/361.000

IC [6]

ICM: A61K031-165

ICS: A61K031-135; C07C233-35; C07C215-20

EXF 564/355; 564/182; 564/361; 514/617; 514/653

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PA New England Medical Center Hospitals, Inc., Boston, MA, United States  
(U.S. corporation)

PI US 5728534 19980317 <--

AI US 1996-684704 19960719 (8)

DT Utility

FS Granted

LN.CNT 1298

INCL INCLM: 435/007.100  
INCLS: 435/007.800; 435/007.720; 435/244.000; 435/325.000; 435/375.000;  
435/069.100

NCL NCLM: 435/007.100  
NCLS: 435/007.720; 435/007.800; 435/069.100; 435/244.000; 435/325.000;  
435/375.000

IC [6]  
ICM: G01N033-53  
ICS: G01N033-566; C12N015-09

EXF 435/325; 435/375; 435/7.1; 435/7.8; 435/244; 435/7.72; 435/7.2; 435/69.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 522 OF 549 USPATFULL on STN

AN 97:86614 USPATFULL

TI Halogen, isothiocyanate or azide substituted xanthines

IN Leigh, Alistair, Brier, WA, United States  
Michnick, John, Seattle, WA, United States  
Kumar, Anil, Seattle, WA, United States  
Underiner, Gail, Brier, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5670506 19970923 <--

AI US 1993-42946 19930405 (8)

DT Utility

FS Granted

LN.CNT 1994

INCL INCLM: 514/258.000  
INCLS: 514/263.000; 544/267.000; 544/272.000; 544/277.000

NCL NCLM: 514/141.000  
NCLS: 544/267.000; 544/272.000; 544/277.000

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 524 OF 549 USPATFULL on STN

AN 97:66130 USPATFULL

TI Methods of using enantiomerically pure hydroxylated xanthine compounds

IN Bianco, James A., Seattle, WA, United States

Singer, Jack, Seattle, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5652243 19970729 <--

AI US 1994-343810 19941122 (8)

RLI Division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a  
continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992,  
now abandoned which is a continuation-in-part of Ser. No. US  
1992-846354, filed on 4 Mar 1992, now abandoned

DT Utility

FS Granted

LN.CNT 1731

INCL INCLM: 514/263.000

INCLS: 514/262.000; 514/265.000; 514/814.000

NCL NCLM: 514/263.360

NCLS: 514/814.000

IC [6]

ICM: A61K031-52

EXF 514/262; 514/263; 514/265

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 525 OF 549 USPATFULL on STN

AN 97:61689 USPATFULL

TI Enatiomerically pure hydroxylated xanthine compounds

IN Bianco, James A., Seattle, WA, United States

Woodson, Paul, Bothell, WA, United States

Porubek, David, Edmonds, WA, United States

Singer, Jack, Seattle, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5648357 19970715 <--

AI US 1994-307554 19940916 (8)

514/258.000; 514/259.000; 514/261.000; 514/262.000; 514/263.000;  
514/270.000; 514/274.000; 514/297.000; 514/300.000; 514/301.000;  
514/302.000; 514/303.000; 514/306.000; 514/307.000; 514/311.000;  
514/312.000; 514/315.000; 514/345.000; 514/351.000; 514/357.000;  
514/359.000; 514/360.000; 514/361.000; 514/362.000; 514/363.000;  
514/364.000; 514/365.000; 514/367.000; 514/369.000; 514/372.000;  
514/373.000; 514/374.000; 514/375.000; 514/376.000; 514/378.000;  
514/379.000; 514/380.000; 514/381.000; 514/383.000; 514/389.000;  
514/394.000; 514/395.000; 514/398.000; 514/399.000; 514/401.000;  
514/404.000; 514/406.000; 514/413.000; 514/415.000; 514/416.000;  
514/418.000; 514/423.000; 514/424.000; 514/425.000; 514/427.000;  
514/428.000; 544/001.000; 544/002.000; 544/003.000; 544/008.000;  
544/053.000; 544/063.000; 544/065.000; 544/066.000; 544/067.000;  
544/090.000; 544/091.000; 544/162.000; 544/215.000; 544/216.000;  
544/219.000; 544/220.000; 544/224.000; 544/235.000; 544/239.000;  
544/254.000; 544/255.000; 544/257.000; 544/262.000; 544/272.000;  
544/277.000; 544/278.000; 544/280.000; 544/283.000; 544/286.000;  
544/301.000; 544/311.000; 544/335.000; 544/336.000; 544/350.000;  
544/353.000; 544/385.000; 544/401.000; 546/102.000; 546/113.000;  
546/114.000; 546/115.000; 546/117.000; 546/118.000; 546/119.000;  
546/122.000; 546/138.000; 546/139.000; 546/150.000; 546/153.000;  
546/157.000; 546/164.000; 546/176.000; 546/178.000; 546/242.000;  
546/243.000; 546/246.000; 546/264.000; 546/300.000; 546/334.000;  
548/100.000; 548/123.000; 548/125.000; 548/127.000; 548/128.000;  
548/131.000; 548/134.000; 548/146.000; 548/153.000; 548/179.000;  
548/186.000; 548/207.000; 548/214.000; 548/215.000; 548/217.000;  
548/221.000; 548/225.000; 548/228.000; 548/229.000; 548/235.000;  
548/237.000; 548/240.000; 548/241.000; 548/243.000; 548/247.000;  
548/252.000; 548/267.200; 548/267.800; 548/303.700; 548/306.400;  
548/307.100; 548/309.700; 548/319.100; 548/323.500; 548/340.100;  
548/348.100; 548/349.100; 548/356.100; 548/370.100; 548/375.100;  
548/379.400; 548/452.000; 548/453.000; 548/470.000; 548/482.000;  
548/485.000; 548/486.000; 548/491.000; 548/503.000; 548/532.000;  
548/543.000; 548/546.000; 548/550.000; 548/565.000; 548/566.000

NCL NCLM: 514/263.350

NCLS: 514/183.000; 514/222.500; 514/223.500; 514/224.200; 514/226.800;



548/550.000; 548/565.000; 548/566.000

IC [6]

ICM: A61K031-415

ICS: A61K031-42; A61K031-425; A61K031-52

EXF 544/272; 514/263

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 527 OF 549 USPATFULL on STN

AN 97:51973 USPATFULL

TI Peptide mediated enhancement of thrombolysis methods and compositions

IN Lawrence, Daniel A., Ann Arbor, MI, United States

Ginsburg, David, Ann Arbor, MI, United States

Shore, Joseph D., Grosse Point Farms, MI, United States

Fay, William P., Ann Arbor, MI, United States

Olson, Steven T., Chicago, IL, United States

Francis-Chmura, Ann Marie, Warren, MI, United States

Eitzman, Daniel T., Ypsilanti, MI, United States

Paielli, Dell, Wyandotte, MI, United States

PA The Regents of the University of Michigan, Ann Arbor, MI, United States  
(U.S. corporation)

Henry Ford Health System, Detroit, MI, United States (U.S. corporation)

PI US 5639726 19970617 <--

AI US 1994-315461 19940930 (8)

DT Utility

FS Granted

LN.CNT 4817

INCL INCLM: 514/012.000 --

INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 530/324.000;  
530/325.000; 530/326.000; 530/327.000; 530/328.000

NCL NCLM: 514/012.000

NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 530/324.000;  
530/325.000; 530/326.000; 530/327.000; 530/328.000

IC [6]

ICM: A61K038-00

ICS: A61K038-02; C07K005-00; C07K007-00

EXF 530/324; 530/325; 530/326; 530/327; 530/328; 514/12; 514/13; 514/14;

IN Bianco, James A., Seattle, WA, United States  
Woodson, Paul, Bothell, WA, United States  
Porubek, David, Edmonds, WA, United States  
Singer, Jack, Seattle, WA, United States  
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 5621102 19970415 <--  
AI US 1995-456897 19950601 (8)  
RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned  
which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994,  
now abandoned which is a continuation of Ser. No. US 1993-13977, filed  
on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No.  
US 1992-926665, filed on 7 Aug 1992, now abandoned which is a  
continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 1763  
INCL INCLM: 544/267.000  
INCLS: 514/340.000  
NCL NCLM: 544/267.000  
IC [6]  
ICM: C07D473-06  
ICS: C07D473-08; C07D473-12  
EXF 544/267  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 530 OF 549 USPATFULL on STN  
AN 97:31706 USPATFULL  
TI Enantiomerically pure hydroxylated xanthine compounds to treat  
inflammatory diseases  
IN Bianco, James A., Seattle, WA, United States  
Woodson, Paul, Bothell, WA, United States  
Porubek, David, Edmonds, WA, United States  
Singer, Jack, Seattle, WA, United States  
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 5620984 19970415 <--



AI US 1995-456899 19950601 (8)

RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994 which is a  
division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a  
continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now  
abandoned which is a continuation-in-part of Ser. No. US 1992-926665,  
filed on 7 Aug 1992, now abandoned which is a continuation-in-part of  
Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned

DT Utility

FS Granted

LN.CNT 1728

INCL INCLM: 514/263.000

NCL NCLM: 514/263.360

IC [6]

ICM: A61K031-52

EXF 514/263

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 535 OF 549 USPATFULL on STN

AN 96:111313 USPATFULL

TI Methods of determining chemicals that modulate transcriptionally  
expression of genes associated with cardiovascular disease

IN Foulkes, J. Gordon, Huntington Station, NY, United States  
Liechtfried, Franz E., Vienna, Austria  
Pieler, Christian, Vienna, Austria  
Stephenson, John R., Santa Cruz, CA, United States  
Case, Casey C., Lynbrook, NY, United States

PA Oncogene Science, Inc., Uniondale, NY, United States (U.S. corporation)

PI US 5580722 19961203 <--

AI US 1992-832905 19920207 (7)

RLI Continuation-in-part of Ser. No. US 1990-555196, filed on 18 Jul 1990,  
now abandoned which is a continuation-in-part of Ser. No. US  
1989-382712, filed on 18 Jul 1989, now abandoned

DT Utility

FS Granted

LN.CNT 4011

INCL INCLM: 435/006.000

L5 ANSWER 537 OF 549 USPATFULL on STN  
AN 96:72817 USPATFULL  
TI Prevention and treatment of pathologies associated with abnormally  
proliferative smooth muscle cells  
IN Grainger, David J., Cambridge, United Kingdom  
Metcalf, James C., Cambridge, United Kingdom  
Weissberg, Peter L., Cambridge, United Kingdom  
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)  
PI US 5545569 19960813 <--  
AI US 1995-450520 19950525 (8)  
RLI Division of Ser. No. US 1994-242161, filed on 12 May 1994 which is a  
continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 2263  
INCL INCLM: 436/518.000  
NCL NCLM: 436/518.000  
IC [6]  
ICM: G01N033-543  
EXF 436/518; 424/178.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 538 OF 549 USPATFULL on STN  
AN 95:105868 USPATFULL  
TI Cell signaling inhibitors  
IN Michnick, John, Seattle, WA, United States  
Underiner, Gail E., Brier, WA, United States  
Klein, J. Peter, Vashon Island, WA, United States  
Rice, Glenn C., Seattle, WA, United States  
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 5470878 19951128 <--  
AI US 1993-164081 19931208 (8)  
RLI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,  
now abandoned

INCL INCLM: 514/396.000  
INCLS: 514/399.000; 514/824.000  
NCL NCLM: 514/396.000  
NCLS: 514/399.000; 514/824.000  
IC [5]  
ICM: A61K031-415  
EXF 514/396; 514/399; 514/824  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 540 OF 549 USPATFULL on STN  
AN 91:84437 USPATFULL  
TI Method for preventing tissue damage after an ischemic episode  
IN Sheffield, Warren D., Lebanon, NJ, United States  
PA Ethicon, Inc., Somerville, NJ, United States (U.S. corporation)  
PI US 5057494 19911015 <--  
AI US 1988-227579 19880803 (7)  
DT Utility  
FS Granted  
LN.CNT 487  
INCL INCLM: 514/012.000  
INCLS: 514/021.000  
NCL NCLM: 514/012.000  
NCLS: 514/021.000  
IC [5]  
ICM: A61K037-02  
ICS: A61K037-36  
EXF 514/12; 514/21  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 541 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN  
AN 2001-025162 [03] WPIDS  
CR 2001-041064 [05]  
DNC C2001-007775  
TI Enhancing biological activity of vascular endothelial growth factor by  
replacing a Cys residue, for producing variant useful for treating  
hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis,

AN 2000-619171 [59] WPIDS  
 CR 2000-619148 [58]  
 DNC C2000-185530  
 TI Enhancing collateral growth of collateral arteries and arteries from  
 pre-existing arteriolar connections, using monocytes loaded with  
 arteriogenic polypeptides, useful e.g. for treating cerebral occlusive and  
 peripheral occlusive disease.  
 DC B04 D16 J04  
 IN BUSCHMANN, I; SCHAPER, W  
 PA (PLAC) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN  
 CYC 90  
 PI WO 2000060054 A1 20001012 (200059)\* EN 30 C12N005-10 <--  
 RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ  
 EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK  
 LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI  
 SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
 AU 2000045446 A 20001023 (200107) C12N005-10 <--  
 EP 1165754 A1 20020102 (200209) EN C12N005-10  
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
 RO SE SI  
 ADT WO 2000060054 A1 WO 2000-EP3087 20000406; AU 2000045446 A AU 2000-45446  
 20000406; EP 1165754 A1 EP 2000-926832 20000406, WO 2000-EP3087 20000406  
 FDT AU 2000045446 A Based on WO 2000060054; EP 1165754 A1 Based on WO  
 2000060054  
 PRAI EP 1999-106800 19990406  
 IC ICM C12N005-10  
 ICS A61K048-00; C12N005-06  
  
 L5 ANSWER 543 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN  
 AN 2000-365394 [31] WPIDS  
 DNC C2000-110292  
 TI Viral vascular endothelial growth factor-like proteins useful for  
 stimulating cell proliferation, modulating vascular permeability while  
 antagonists of the proteins are useful for treating pustular dermatitis.  
 DC B04 D16

L5 ANSWER 544 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN  
 AN 2000-317840 [27] WPIDS  
 CR 2000-256860 [22]; 2002-608416 [65]; 2003-101732 [09]; 2003-174592 [17];  
 2003-746236 [70]  
 DNC C2000-096206  
 TI Novel unit dose comprising fibroblast growth factor, its angiogenically  
 active fragment or mutein for inducing cardiac angiogenesis, treating  
 \*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\* and reducing post  
 myocardial infarction injury.  
 DC B04  
 IN KAVANAUGH, W M  
 PA (CHIR) CHIRON CORP; (WHIT-I) WHITEHOUSE M J  
 CYC 87  
 PI WO 2000021548 A2 20000420 (200027)\* EN 66 A61K038-00 <--  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL  
 OA PT SD SE SL SZ TZ UG ZW  
 W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB  
 GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU  
 LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR  
 TT UA UG UZ VN YU ZA ZW  
 AU 9964111 A 20000501 (200036) <--  
 EP 1121141 A2 20010808 (200146) EN A61K038-18  
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
 RO SE SI  
 JP 2002527401 W 20020827 (200271) 72 A61K038-22  
 ADT WO 2000021548 A2 WO 1999-US22936 19991013; AU 9964111 A AU 1999-64111  
 19991013; EP 1121141 A2 EP 1999-951728 19991013, WO 1999-US22936 19991013;  
 JP 2002527401 W WO 1999-US22936 19991013, JP 2000-575522 19991013  
 FDT AU 9964111 A Based on WO 2000021548; EP 1121141 A2 Based on WO 2000021548;  
 JP 2002527401 W Based on WO 2000021548  
 PRAI US 1998-104103P 19981013  
 IC ICM A61K038-00; A61K038-18; A61K038-22  
 ICS A61K031-726; A61P009-10  
 ICA C07K014-50



L5 ANSWER 546 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2000-246641 [21] WPIDS

CR 2000-038600 [03]

DNN N2000-184459 DNC C2000-074681

TI Implantable device, carrying cells which produce and release therapeutic agent locally at site, and a monitor to detect unfavorable physiological change and signal the cells before damage occurs, use, e.g., in  
\*\*\*coronary\*\*\* \*\*\*artery\*\*\* \*\*\*disease\*\*\* .

DC A96 B07 D16 D22 P31 P32

IN DONOVAN, M G; SOYHAN, O; SOYKAN, O

PA (MEDT) MEDTRONIC INC

CYC 20

PI WO 2000012028 A1 20000309 (200021)\* EN 52 A61F002-06 <--

RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

EP 1027014 A1 20000816 (200040) EN A61F002-06 <--

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

US 6206914 B1 20010327 (200119) A61F002-06

US 2001000802 A1 20010503 (200126) A61F002-06

EP 1426021 A1 20040609 (200438) EN A61F002-06

R: CH DE FR LI NL SE

EP 1027014 B1 20041124 (200477) EN A61F002-06

R: CH DE FR LI NL SE

US 6824561 B2 20041130 (200479) A61F002-06

DE 69922143 E 20041230 (200502) A61F002-06

ADT WO 2000012028 A1 WO 1999-US18719 19990823; EP 1027014 A1 EP 1999-942261  
19990823, WO 1999-US18719 19990823; US 6206914 B1 CIP of US 1998-70480  
19980430, US 1998-144420 19980831; US 2001000802 A1 CIP of US 1998-70480  
19980430, Div ex US 1998-144420 19980831, US 2000-745144 20001220; EP  
1426021 A1 Div ex EP 1999-942261 19990823, EP 2004-6105 19990823; EP  
1027014 B1 EP 1999-942261 19990823, WO 1999-US18719 19990823, Related to  
EP 2004-6105 19990823; US 6824561 B2 CIP of US 1998-70480 19980430, Div ex  
US 1998-144420 19980831, US 2000-745144 20001220; DE 69922143 E DE  
1999-622143 19990823, EP 1999-942261 19990823, WO 1999-US18719 19990823

FDT EP 1027014 A1 Based on WO 2000012028; EP 1426021 A1 Div ex EP 1027014; EP  
1027014 B1 Related to EP 1426021, Based on WO 2000012028; US 6824561 B2  
Div ex US 6206914; DE 69922143 E Based on EP 1027014, Based on WO

US 6261587 B1 CIP of US 1998-113437 19980710, US 1999-337959 19990622; US  
 2001007658 A1 CIP of US 1992-841973 19920224, CIP of US 1994-300429  
 19940902, CIP of US 1995-568482 19951207, Div ex US 1998-113437 19980710,  
 US 2001-758676 20010111; US 2001010826 A1 CIP of US 1992-841973 19920224,  
 CIP of US 1994-300429 19940902, CIP of US 1995-568482 19951207, CIP of US  
 1998-113437 19980710, Div ex US 1999-337959 19990622, US 2001-766330  
 20010119; AU 757968 B AU 1999-50952 19990709; US 6713079 B2 CIP of US  
 1992-841973 19920224, CIP of US 1994-300429 19940902, CIP of US  
 1995-568482 19951207, CIP of US 1998-113437 19980710, Div ex US  
 1999-337959 19990622, US 2001-766330 20010119; US 6730315 B2 CIP of US  
 1992-841973 19920224, CIP of US 1994-300429 19940902, Div ex US  
 1998-113437 19980710, CIP of US 1998-568482 19981207, US 2001-758676  
 20010111

FDT AU 9950952 A Based on WO 2000002596; EP 1094849 A1 Based on WO 2000002596;  
 US 2001007658 A1 CIP of US 5834005, Div ex US 6231881; US 2001010826 A1  
 CIP of US 5834005, CIP of US 6231881; AU 757968 B Previous Publ. AU  
 9950952, Based on WO 2000002596; US 6713079 B2 CIP of US 5834005, CIP of  
 US 6231881, Div ex US 6261587; US 6730315 B2 CIP of US 5834005

PRAI US 1999-337959 19990622; US 1998-113437 19980710;  
 US 1992-841973 19920224; US 1994-300429 19940902;  
 US 1995-568482 19951207; US 2001-758676 20010111;  
 US 2001-766330 20010119

IC ICM A61F002-00; A61F002-02; A61K009-06; A61L015-32; C12N005-00  
 ICS A61F013-00; A61K031-715; A61L015-44; A61L031-00; A61L033-00;  
 C12N005-02

L5 ANSWER 548 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN  
 AN 2000-052684 [04] WPIDS  
 DNC C2000-013542

TI Use of angiogenic factors to stimulate angiogenesis for treatment of  
 cardiovascular diseases.

DC A96 B04 D16  
 IN COLLEY, K J  
 PA (ANGI-N) ANGIOGENIX INC; (COLL-I) COLLEY K J  
 CYC 87

PI WO 9953943 A2 19991028 (200004)\* EN 37 A61K038-18 <--

ICA A61K035-76

L5 ANSWER 549 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

AN 1998-179057 [16] WPIDS

DNC C1998-057496

TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders.

DC B04 D16

IN ACHEN, M G; ALITALO, K; STACKER, S A; WILKS, A F

PA (LUDW-N) LUDWIG INST CANCER RES; (UYHE-N) UNIV HELSINKI LICENSING LTD OY;  
(UYHE-N) UNIV HELSINKI LICENSING LTD

CYC 79

PI WO 9807832 A1 19980226 (199816)\* EN 90 C12N001-21 <--

RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT  
SD SE SZ UG ZW

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE  
GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW  
MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU  
ZW

AU 9740796 A 19980306 (199830) C12N001-21 <--

EP 956339 A1 19991117 (199953) EN C12N001-21 <--

R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AU 729880 B 20010215 (200115) C12N001-21

US 6235713 B1 20010522 (200130) A61K038-18

JP 2001517075 W 20011002 (200172) 112 C12N015-09

EP 1283268 A2 20030212 (200312) EN C12N015-85

R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

US 2003114658 A1 20030619 (200341) C07H021-04

US 2003125537 A1 20030703 (200345) A61K038-18

US 6689580 B1 20040210 (200413) C12N001-21

US 2004175730 A1 20040909 (200459) C12Q001-68

ADT WO 9807832 A1 WO 1997-US14696 19970821; AU 9740796 A AU 1997-40796  
19970821; EP 956339 A1 EP 1997-938486 19970821, WO 1997-US14696 19970821;  
AU 729880 B AU 1997-40796 19970821; US 6235713 B1 Provisional US  
1996-23751P 19960823, Provisional US 1996-31097P 19961114, Provisional US